



Contents lists available at ScienceDirect

## Bioorganic &amp; Medicinal Chemistry

journal homepage: [www.elsevier.com/locate/bmc](http://www.elsevier.com/locate/bmc)

## Design, synthesis and biological evaluation of *N*-methyl-*N*-[(1,2,3-triazol-4-yl)alkyl]propargylamines as novel monoamine oxidase B inhibitors

Ornella Di Pietro<sup>a</sup>, Nelson Alencar<sup>b</sup>, Gerard Esteban<sup>c</sup>, Elisabet Viayna<sup>a</sup>, Natalia Szałaj<sup>a</sup>, Javier Vázquez<sup>b</sup>, Jordi Juárez-Jiménez<sup>b</sup>, Irene Sola<sup>a</sup>, Belén Pérez<sup>d</sup>, Montse Solé<sup>c</sup>, Mercedes Unzeta<sup>c</sup>, Diego Muñoz-Torrero<sup>a,\*</sup>, F. Javier Luque<sup>b,\*</sup>

<sup>a</sup> Laboratori de Química Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia and Institut de Biomedicina (IBUB), Universitat de Barcelona, Av. Joan XXIII 27-31, E-08028 Barcelona, Spain

<sup>b</sup> Department of Nutrition, Food Science and Gastronomy, Faculty of Pharmacy and Institute of Biomedicine (IBUB), University of Barcelona, Av. Prat de la Riba 171, E-08921 Santa Coloma de Gramenet, Spain

<sup>c</sup> Departament de Bioquímica i Biologia Molecular, Facultat de Medicina and Institut de Neurociències, Universitat Autònoma de Barcelona, E-08193 Bellaterra, Spain

<sup>d</sup> Departament de Farmacologia, Terapèutica i Toxicologia, Universitat Autònoma de Barcelona, E-08193 Bellaterra, Spain

## ARTICLE INFO

## Article history:

Received 9 June 2016

Revised 22 June 2016

Accepted 23 June 2016

Available online xxx

## Keywords:

Click-chemistry

Monoamine oxidase B

Alzheimer's disease

Irreversible inhibition

## ABSTRACT

Different azides and alkynes have been coupled via Cu-catalyzed 1,3-dipolar Huisgen cycloaddition to afford a novel family of *N*<sub>1</sub>- and *C*<sub>5</sub>-substituted 1,2,3-triazole derivatives that feature the propargylamine group typical of irreversible MAO-B inhibitors at the C4-side chain of the triazole ring. All the synthesized compounds were evaluated against human MAO-A and MAO-B. Structure–activity relationships and molecular modeling were utilized to gain insight into the structural and chemical features that enhance the binding affinity and selectivity between the two enzyme isoforms. Several lead compounds, in terms of potency (submicromolar to low micromolar range), MAO-B selective recognition, and brain permeability, were identified. One of these leads (MAO-B IC<sub>50</sub> of 3.54 μM, selectivity MAO-A/MAO-B index of 27.7) was further subjected to reversibility and time-dependence inhibition studies, which disclosed a slow and irreversible inhibition of human MAO-B. Overall, the results support the suitability of the 4-triazolylalkyl propargylamine scaffold for exploring the design of multipotent anti-Alzheimer compounds endowed with irreversible MAO-B inhibitory activity.

© 2016 Elsevier Ltd. All rights reserved.

## 1. Introduction

Alzheimer's disease (AD) is one of the most relevant age-related neurodegenerative disorders currently representing the fourth leading cause of death and afflicting over 46.8 million people worldwide.<sup>1,2</sup> Its clinical manifestation is mainly reflected in a progressive loss of memory and cognitive functions, often in association with behavioral disturbances and depression.<sup>3</sup> Its complex and multifaceted etiology, which involves massive loss of cholinergic neurons,<sup>4</sup> oxidative stress,<sup>5–7</sup> metal dyshomeostasis,<sup>8</sup> excitotoxicity,<sup>9</sup> neurofibrillary tangles and β-amyloid aggregate deposition,<sup>10,11</sup> has precluded so far the discovery of effective disease-modifying drugs. Currently approved drugs, namely, three acetylcholinesterase (AChE) inhibitors (rivastigmine, galantamine,

and donepezil),<sup>12–14</sup> and an *N*-methyl-D-aspartate receptor antagonist (memantine),<sup>15</sup> primarily exert palliative effects. On the other hand, the failure in clinical trials of a number of drug candidates designed against targets mainly involved in β-amyloid biology has shifted drug discovery efforts toward the compounds hitting less explored biological targets alone or in combination with other key targets, i.e., the so-called multi-target-directed ligands (MTDLs).<sup>16–18</sup>

In this context, monoamine oxidase (MAO, E.C.1.4.3.4) has emerged as a promising target because of the neuroprotective properties exerted by their inhibitors.<sup>2,19–21</sup> MAO is a flavin adenine dinucleotide (FAD)-containing enzyme that catalyzes the degradation of biogenic and xenobiotic amines. Two isoforms, namely MAO-A and MAO-B, have been characterized by their amino acid sequence, tissue distribution, substrate specificity and inhibitor sensitivity.<sup>22–24</sup> MAO-A, preferentially degrading serotonin, adrenaline and noradrenaline, is irreversibly inhibited by

\* Corresponding authors.

E-mail addresses: [dmunoztorrero@ub.edu](mailto:dmunoztorrero@ub.edu) (D. Muñoz-Torrero), [fjluque@ub.edu](mailto:fjluque@ub.edu) (F.J. Luque).

clorgyline, whereas MAO-B, specifically responsible for the oxidative deamination of phenylethylamine and benzylamine, is irreversibly inhibited by (*R*)-(-)-deprenyl (selegiline) (Fig. 1). These trends reflect structural differences in the binding sites as revealed by high-resolution X-ray structures.<sup>25–29</sup> In particular, a key structural feature in shaping the substrate cavity is the replacement of the pair Phe208/Ile335 in MAO-A by Ile199/Tyr326 in MAO-B, leading to the distinction between ‘substrate’ and ‘entrance’ sites in MAO-B. The replacement of Ile180/Asn181 and Val210 in MAO-A by Leu17/Cys172 and Thr201 in MAO-B are additional differences in the binding sites, which may modulate the selective inhibition by certain MAO inhibitors.<sup>30</sup>

The neuroprotection exerted by MAO inhibitors may stem not only from the increased amine neurotransmission, but also from preventing the formation of neurotoxic species, which may lead to neuronal damage,<sup>31,32</sup> and from the anti-apoptotic properties of the propargylamine group present in some MAO inhibitors.<sup>33,34</sup> Interestingly, the levels of MAO-B increase with age and its activity is elevated in AD patients, which results in increased brain levels of neurotoxic free radicals.<sup>20</sup> In this context, the development of MAO-B-inhibitor-based MTDLs emerges as a promising strategy for the design of neuroprotective agents with potential disease-modifying activity towards AD and other neurodegenerative disorders, such as Parkinson disease.<sup>35,36</sup>

Most efforts have been addressed toward the design of MTDLs targeting AChE and/or butyrylcholinesterase (BuChE) and MAO. A successful example is ladostigil (Fig. 1), a dual inhibitor of MAO-B and AChE that combines the carbamate moiety of the AChE inhibitor rivastigmine with the indolamine moiety of the selective MAO-B inhibitor rasagiline, and shows neuroprotective and anti-apoptotic activities.<sup>37,38</sup> A novel series of MAO/ChE inhibitors that combine the *N*-benzylpiperidine moiety of the AChE inhibitor donepezil with the indolyl propargylamine of the potent MAO-B inhibitor PF9601N has been reported.<sup>39</sup> Within this series, the most promising MDTL compound (ASS234, **6** in Fig. 1) also showed anti-aggregating activity on  $\beta$ -amyloid, antioxidant and antiapoptotic behavior, and crossed easily the blood–brain barrier (BBB).<sup>40</sup> Other strategies have relied on the hybridization of coumarins with either *N*-benzyl-*N*-alkoxy groups<sup>41</sup> or tacrine,<sup>42</sup> leading to multipotent inhibitors of both MAO and ChEs, or alternatively have pursued the development of MTDLs targeting both MAO inhibition and additional activities, such as metal chelation.<sup>43,44</sup> Also, natural products endowed with MAO and ChEs inhibitory activities have been recently reported.<sup>45</sup>

Although the development of MAO-inhibitor-based MTDLs is very attractive, it is challenged by the need to keep a good balance among potencies against multiple targets and optimal ADME-T properties.<sup>46–50</sup> Furthermore, the success of this strategy depends

on the suitability of an efficient synthetic approach, which should afford the fusion or linkage of chemical scaffolds while minimizing drastic alterations in the activity against the multiple targets. In this context, the Cu(I)-catalyzed azide–alkyne cycloaddition (CuAAC) enables the synthesis of a virtually unlimited source of ligands containing the 1,4-disubstituted 1,2,3-triazole core.<sup>51–54</sup> The CuAAC reaction between libraries of azides and alkynes featuring different pharmacophoric moieties has been used for the synthesis of triazole-linked hybrid compounds as MTDLs.<sup>55–65</sup> Azide–alkyne cycloaddition reactions have also been used for the synthesis of high-affinity multisite enzyme inhibitors inside the biological target, in the absence of copper catalysis, i.e., the so-called *in situ* click chemistry.<sup>66–70</sup> In these compounds the triazole ring is used not only as a non-hydrolyzable, non-oxidizable, and non-reducible robust linker between the pharmacophoric moieties, but also provides favorable physicochemical properties and potential interactions with the biological target.<sup>71</sup>

In this context, as the first step of a program directed to the synthesis of MAO-B-inhibitor-based anti-Alzheimer MTDLs, here we have explored the CuAAC-mediated synthesis of a series of 1,2,3-triazole derivatives, featuring the propargylamine group of typical irreversible MAO-B inhibitors in the side chain at position 4, while the overall hydrophobicity has been modulated through different lipophilic substituents at positions 1 and 5 (Scheme 1). To determine the therapeutic potential of the target compounds and their usefulness as the MAO-B pharmacophoric moiety of novel families of MTDLs, we have assessed the *in vitro* inhibitory activity of the novel compounds against human MAO-B and MAO-A. Molecular modeling studies have been performed to rationalize the differences in inhibitory potency and selectivity between the MAO isoforms, and the mechanism of action of these compounds has been studied by reversibility and time-dependence inhibition studies. Finally, the brain penetration of the novel compounds has been examined through the widely used parallel artificial membrane permeability assay (PAMPA-BBB).

## 2. Results and discussion

### 2.1. Design and synthesis of the target *N*-methyl-*N*-[(1,2,3-triazol-4-yl)alkyl]propargylamines

We initially planned the synthesis of the 1-ethyltriazolylmethyl and 1-ethyltriazolylethyl propargylamines **31** and **32** (Scheme 2), unsubstituted at position 5 of the triazole ring, and their 5-methyl-substituted analogues **51** and **52**, as the early simple prototypes to validate the suitability of the CuAAC-assisted synthetic methodology to deliver 1,4-disubstituted and 1,4,5-trisubstituted 1,2,3-triazole scaffolds featuring the propargylamine group of






Figure 1. Chemical structures of MAO inhibitors.



**Scheme 1.** General structure of the target *N*-methyl-*N*-[(1,2,3-triazol-4-yl)alkyl]propargylamines.




**Scheme 2.** Reagents and conditions: (i)  $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ , ascorbic acid,  $\text{Na}_2\text{CO}_3$ ,  $\text{H}_2\text{O}/\text{DMF}$ , rt, overnight, 49–78% yield; (ii) MeI, NaH, THF, rt, 1.5–15 h, 81–97% yield; (iii)  $\text{H}_3\text{PO}_4$ ,  $\text{CH}_2\text{Cl}_2$ , rt, 1.5–4 h, 38–98% (**25–30**), 67–100% (**44–50**); (iv) propargyl bromide,  $\text{Cs}_2\text{CO}_3$ , acetone, rt for 2–15 h, or 0 °C for 2–2.5 h, or 0 °C for 30 min and then rt for 3 h, 22–89% (**31–36**), 53–95% (**51–57**); (v)  $\text{R}^5\text{-Hal}$ ,  $n\text{-BuLi}$ , THF,  $-78$  °C, 1 h, then  $-78$  °C  $\rightarrow$  rt, and rt, 2 h, 43–98%.

irreversible MAO inhibitors. These compounds are quite polar ( $\text{Log}P$  of 0.43, 0.84, 0.65, and 1.06, respectively)<sup>72</sup> due to the presence of the triazole ring. However, the substrate cavity of MAO is highly hydrophobic, and accordingly MAO inhibitors are usually more lipophilic molecules ( $\text{Log}P$  in the range 2–4 for compounds depicted in Fig. 1). Thus, to counterbalance the high polarity conferred by the triazole ring, we envisaged a second generation of derivatives that featured more lipophilic benzyl or phenethyl substituents at position 1 (i.e., compounds **33** and **34**, respectively, Scheme 2) or at position 5 of the triazole ring (i.e., the 1-methyl-5-butyl-substituted compound **54**). We also planned the synthesis of derivatives of the 1-benzyl-substituted compound **33** bearing different alkyl groups at position 5. However, the moderate acidity of the  $\alpha$ -nitrogen benzylic protons of the substituent at position 1 of the triazole ring interfered with the alkylation of the position 5 (see below). To avoid these synthetic issues, we envisaged the synthesis of compounds **55**, **56**, and **57** (Scheme 2), bearing a phenyl group instead of a benzyl group at position 1 of the triazole ring

and ethyl, propyl, or butyl substituents at position 5. Finally, we also explored the isomerization of the benzene ring of compound **33** from the substituent at position 1 of the triazole ring to the side chain at position 4, i.e., between the triazole ring and the propargylamine moiety (compounds **82** and **83**, Scheme 3).

After evaluation of MAO-A and MAO-B inhibitory activity of the first and second generation compounds, **33** emerged as the most selective MAO-B inhibitor, with a one-digit micromolar potency against MAO-B, 27-fold higher than against MAO-A, whereas compound **83** turned out to be the most potent inhibitor of both MAO isoforms, with submicromolar potencies but essentially without any selectivity (see below). In light of these results and on the basis of molecular modeling studies, we inferred that a total number of three methylenes might afford the optimal length between the terminal aromatic ring and the propargylamine nitrogen atom to confer selectivity towards MAO-B. To check this hypothesis, as a third generation we planned the synthesis of compound **36** (Scheme 2), an isomeric derivative of **33**, and compound **84** (Scheme 3), with a



**Scheme 3.** Reagents and conditions: (i) trimethylsilylacetylene, THF, *n*-BuLi,  $-78\text{ }^{\circ}\text{C}$ , 30 min, then, ZnBr<sub>2</sub>, THF,  $-78\text{ }^{\circ}\text{C} \rightarrow 0\text{ }^{\circ}\text{C}$ , then, **58**, **59**, or **60**, Cl<sub>2</sub>Pd(PPh<sub>3</sub>)<sub>2</sub>, rt, overnight, 44–83% yield; (ii) AgOTf, CH<sub>2</sub>Cl<sub>2</sub>/MeOH/H<sub>2</sub>O, rt, overnight, 63–77% yield; (iii) methyl azide, CuSO<sub>4</sub>·5H<sub>2</sub>O, ascorbic acid, Na<sub>2</sub>CO<sub>3</sub>, H<sub>2</sub>O/DMF, rt, overnight, 89–95% yield; (iv) LiAlH<sub>4</sub>, THF, reflux, 2 h: **70** (49%), **71** (80%), or H<sub>2</sub>, Raney-Ni, 7 N NH<sub>3</sub> in MeOH: **72** (quantitative); (v) (Boc)<sub>2</sub>O, THF, rt, 3 h, quantitative yield; (vi) MeI, NaH, THF, 60 °C, 4 h: **76** (84%), **77** (80%); (vii) LiAlH<sub>4</sub>, THF, 0 °C, then **75**, reflux, 72 h: **81** (44% yield); (viii) H<sub>3</sub>PO<sub>4</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt, 1.5–3 h: **79** (quantitative), **80** (96%); (ix) propargyl bromide, Cs<sub>2</sub>CO<sub>3</sub>, acetone, 0 °C for 3.5 h or 0 °C for 30 min and then rt for 3 h, 31–65% yield.

total number of three methylenes from the terminal aromatic ring (phenyl in **36**, triazole in **84**) to the propargylamine nitrogen atom. For comparison purposes, we also envisaged the synthesis of compound **35** (Scheme 2), the shorter homologue of **33** with a total number of two methylenes in the tether.

The synthesis of the target compounds was undertaken through synthetic sequences involving as the key step a CuAAC reaction<sup>73–76</sup> between alkyl or phenyl azides and alkynes bearing an amino or a cyano group to enable the subsequent installation of the propargylamine moiety (Scheme 1). The synthesis of the 5-unsubstituted triazolylmethyl and triazolylethyl propargylamines **31–36** was carried out through a four-step synthetic sequence, starting from the copper-catalyzed Huisgen 1,3-dipolar cycloaddition of the known *N*-Boc-protected amines **7** and **8** with ethyl, benzyl, and phenethyl azide, generated in situ by reaction of NaN<sub>3</sub> with the corresponding alkyl halide,<sup>77</sup> which afforded the 1-substituted triazole derivatives **9–16** in moderate to good yields (49–78%, Scheme 2). Subsequent methylation of the *N*-Boc-protected aliphatic nitrogen atom of compounds **9–16** with MeI in anhydrous THF, in the presence of NaH, followed by acidic deprotection of the resulting compounds **17–24** afforded the secondary amines **25–30** in general in excellent yields. The final propargylation of amines **25–30** on reaction with propargyl bromide in acetone in the presence of Cs<sub>2</sub>CO<sub>3</sub> led to propargylamines **31–36** in 22–89% yield (Scheme 2). Thus, the target compounds **31–36** were obtained in 5–58% overall yield without the need of any column chromatography purification, with the sole exception of the last step for **31**, **35** and **36**.

For the synthesis of the 5-alkyl-substituted triazolylmethyl and triazolylethyl propargylamines **51**, **52**, and **54**, apart from the intermediates **17** and **18**, the triazole derivative **21** was also prepared in good yield using the same CuAAC-*N*-methylation protocol (Scheme 2). Alkylation of compounds **17**, **18**, and **21** with the appropriate alkyl halide using *n*-BuLi as the base afforded the corresponding 5-alkylated compounds **37**, **38**, and **40**, respectively, in

excellent yields (90–97%). However, when we subjected the 1-benzyl-substituted intermediate **19** to the same alkylation reaction conditions with methyl iodide as the alkylating agent, we did not obtain the expected 1-benzyl-5-methyl-substituted derivative but the 1-( $\alpha$ -methylbenzyl)-5-methyl-substituted derivative **39** in 79% yield, resulting from the double alkylation at the position 5 of the triazole ring and at the moderately acidic  $\alpha$ -nitrogen benzylic position of the substituent at position 1 (Scheme 2). Treatment of intermediate **19** with ethyl bromide or *n*-butyl bromide as the alkylating agents and *n*-BuLi or the more hindered *t*-BuLi as the base yielded inseparable mixtures of 5-monoalkylated and  $\alpha$ ,5-dialkylated products. To avoid double alkylation, we prepared the 1-phenyl-substituted intermediate **22**, which was alkylated with ethyl bromide, *n*-propyl bromide, and *n*-butyl bromide using *n*-BuLi as the base, to afford the expected 5-alkyl-substituted derivatives **41**, **42**, and **43** in 98%, 96%, and 43% yield, respectively (Scheme 2). The acidic *N*-Boc deprotection of 5-alkyl-substituted compounds **37–43** afforded the secondary amines **44–50** in good yields (67% to quantitative yield). Propargylation of amines **44–50** had to be performed by monitoring the reaction course at different reaction temperatures and times to avoid the formation of dipropargylated products. For example, reaction of amine **44** with propargyl bromide in the presence of Cs<sub>2</sub>CO<sub>3</sub> at rt overnight yielded the dipropargylated derivative as the major reaction product (92% yield), whereas on reaction at 0 °C for 2 h only the desired monopropargylated product, **51**, was obtained, in 62% yield. Thus, by selecting the most appropriate reaction temperature and time, the target 5-alkyl-substituted triazolylmethyl and triazolylethyl propargylamines **51–57** were synthesized (19–44% overall yield over the five-step sequence).

The synthesis of the triazolyl-*m*-xylyl and triazolyl-*p*-xylyl propargylamines **82** and **83** and the triazolyl-*p*-methylphenethyl propargylamine **84** was carried out through the seven–eight-step sequences depicted in Scheme 3. First, the alkynes **64–66**,

necessary for the CuAAC, were prepared by an initial Negishi coupling<sup>77</sup> between benzyl bromides **58–60** and trimethylsilylacetylene in the presence of *n*-BuLi and ZnBr<sub>2</sub>, under Pd(0) catalysis, followed by desilylation of the protected alkyne derivatives **61–63** with AgOTf in a mixture of CH<sub>2</sub>Cl<sub>2</sub>/MeOH/H<sub>2</sub>O,<sup>78</sup> and silica gel column chromatography purification. The CuAAC of methyl azide to alkynes **64–66** afforded the corresponding triazole derivatives **67–69** in excellent yield (89–95%). LiAlH<sub>4</sub> reduction of the nitrile group of **67** and **68** afforded the corresponding amines **70** and **71** in 49% and 80% yield, respectively. However, the same reaction conditions failed to provide the amine derived from nitrile **69**, which could be efficiently reduced to amine **72** by hydrogenation using Raney-Ni as the catalyst. *N*-Boc protection of the primary amino group of **70–72** afforded the intermediates **73–75**. The *N*-Boc-protected amines **73** and **74** were converted into the target propargylamines **82** and **83** in good yields through the standard *N*-methylation–acidic deprotection–propargylation protocol, without the need of any additional column chromatography purification (Scheme 3). Because different attempts to methylate the *N*-Boc-protected amine **75** were fruitless, this compound was alternatively converted into the target propargylamine **84** by direct conversion into the secondary amine **81** upon LiAlH<sub>4</sub> reduction followed by propargylation (Scheme 3).

All the compounds to be subjected to biological evaluation were transformed into the corresponding hydrochloride salts and were chemically characterized through IR, <sup>1</sup>H and <sup>13</sup>C NMR spectra, and HRMS.

## 2.2. MAO inhibitory activity of the target compounds

The novel *N*-methyl-*N*-[(1,2,3-triazol-4-yl)alkyl]propargylamines **31–36**, **51–57**, and **82–84** were evaluated in vitro against human recombinant MAO-A and MAO-B (*hr*MAO-A and *hr*MAO-B). Selegiline and clorgyline were also used as reference compounds. The corresponding IC<sub>50</sub> values and selectivity indices (SI; defined as the ratio IC<sub>50</sub>(MAO-A)/IC<sub>50</sub>(MAO-B)) are shown in Table 1. The novel compounds turned out to be in most cases moderate to weak MAO inhibitors, with 2–3-digit micromolar IC<sub>50</sub> values, with the exceptions of compounds **33**, **55**, **82** and **83**, which exhibited submicromolar or low micromolar potencies against one or both MAO isoforms.

The first generation compounds **31**, **32**, **51**, and **52** were weak inhibitors and showed no selectivity. These trends were not unexpected due to the large polarity of the triazole ring and the small size of these fragment-like compounds. Furthermore, molecular modeling studies pointed out the feasibility of these compounds to adopt an arrangement compatible with the formation of the covalent linkage with the cofactor, but also revealed their inability to fill the substrate cavity, allowing for distinct orientations in the pocket, and the lack of complementarity between the polar triazole moiety and the hydrophobic environment of the cavity. Accordingly, several strategies were explored to modulate both the molecular size and hydrophobicity of the triazole derivatives.

The first approach involved the substitution of the ethyl group at position 1 of the triazole ring of the initial prototypes by benzyl and phenethyl groups, which led to increased inhibitory potencies. Thus, the 1-phenethyl-derivative **34** was 2- and 10-fold more potent MAO-A inhibitor than the 1-benzyl- and 1-ethyl-analogues **33** and **32**, respectively. In contrast, for MAO-B inhibition, the optimal substitution pattern involved the presence of a 1-benzyl group, with compound **33** being 49- and 106-fold more potent than the 1-phenethyl- and 1-ethyl-analogues **34** and **32**, respectively.

This latter finding suggests that the size of compound **33** is better suited to fill the binding cavity in MAO-B, as confirmed by the results obtained from restrained docking calculations. Thus,

**Table 1**  
MAO-A and MAO-B inhibitory activities, selectivity indices, and BBB permeability

Compound	<i>hr</i> MAO-A <sup>a</sup> IC <sub>50</sub> (μM)	<i>hr</i> MAO-B <sup>a</sup> IC <sub>50</sub> (μM)	SI <sup>b</sup>	<i>P</i> <sub>e</sub> (10 <sup>-6</sup> cm s <sup>-1</sup> ) <sup>c</sup>
<i>1st generation</i>				
<b>31</b>	134.7 ± 21.8	248.6 ± 94.5	0.5	nd <sup>d</sup>
<b>32</b>	553.5 ± 83.6	373.9 ± 119	1.5	nd <sup>d</sup>
<b>51</b>	267.4 ± 30.8	104.7 ± 27.1	2.6	nd <sup>d</sup>
<b>52</b>	91.2 ± 13.6	237.6 ± 51.8	0.4	nd <sup>d</sup>
<i>2nd generation</i>				
<b>33</b>	97.1 ± 30.1	3.5 ± 0.4	27.7	15.6 ± 1.5 (CNS+)
<b>34</b>	56.1 ± 8.7	172.8 ± 47.8	0.3	14.8 ± 0.9 (CNS+)
<b>53</b>	47.0 ± 6.9	134.2 ± 25.5	0.4	20.0 ± 0.7 (CNS+)
<b>54</b>	<300	94.7 ± 16.3	<3.2	29.9 ± 0.8 (CNS+)
<b>55</b>	7.5 ± 1.1	213.4 ± 54.0	0.04	17.0 ± 1.9 (CNS+)
<b>56</b>	26.1 ± 4.0	156.8 ± 31.9	0.2	17.2 ± 0.6 (CNS+)
<b>57</b>	17.3 ± 4.5	155.5 ± 25.0	0.1	21.4 ± 1.3 (CNS+)
<b>82</b>	2.1 ± 0.3	65.0 ± 15.4	0.03	15.6 ± 1.5 (CNS+)
<b>83</b>	0.5 ± 0.1	0.6 ± 0.1	0.9	14.8 ± 0.9 (CNS+)
<i>3rd generation</i>				
<b>35</b>	>500	129 ± 42.6	>3.9	2.3 ± 0.7 (CNS±)
<b>36</b>	>500	11.2 ± 2.1	>44.6	0.6 ± 0.1 (CNS–)
<b>84</b>	27.4 ± 0.1	5.2 ± 0.5	5.3	4.5 ± 0.5 (CNS±)
Selegiline	2 ± 0.1	0.018 ± 0.003	111.1	
Clorgyline	0.020 ± 0.003	65.5 ± 7.1	0.0003	


<sup>a</sup> In vitro inhibitory activities against *hr*-MAO-A and *hr*-MAO-B. Experiments performed with Amplex Red fluorimetric method in 96-well plates. Data are the mean of duplicate experiments ± SEM.

<sup>b</sup> SI = IC<sub>50</sub> (MAO-A)/IC<sub>50</sub> (MAO-B).

<sup>c</sup> Permeability values from the PAMPA-BBB assay. Values are expressed as the mean ± SD of three independent experiments.

<sup>d</sup> Not determined.

following the strategy used in our previous studies,<sup>39</sup> the propargylamine nitrogen atom was imposed to overly the position of the corresponding atom in the X-ray structures of covalently-bound selegiline and rasagiline (PDB entries 2BYB and 2BK4).<sup>28,79</sup> By imposing this restraint, we may explore the arrangement of the compound after covalent linkage of the propargylamine unit to the FAD cofactor. Figure 2 shows that **33** superposes well with the structures of the irreversible inhibitor **6** (PDB entry 4CRT),<sup>80</sup> and the reversible ligand 1,4-diphenyl-2-butene (PDB entry 1OJ9),<sup>26</sup> which spans the substrate binding cavity. In particular, it



**Figure 2.** Representation of the docked pose of compound **33** (shown as green-colored sticks) in the binding cavity of MAO-B (shown as gray cartoon). The surface of the binding cavity is depicted as a gray isocontour. The structures of inhibitor **6** (PDB entry 4CRT; covalently-bound to FAD, also shown as gray-colored sticks) and the reversible ligand 1,4-diphenyl-2-butene (PDB entry 1OJ9) are shown as white-colored and yellow sticks, respectively.

is worth noting that the benzene ring of **33** matches well the position filled by the benzene unit in 1,4-diphenyl-2-butene. In turn, docking of the phenethyl derivative **34** made it necessary to adopt a folded conformation, reflecting some degree of internal strain due to clashes within the cavity (data not shown).

An alternative strategy explored to modulate the hydrophobicity distribution of triazole derivatives relied on the alkylation of position 5 of the triazole ring (compounds **53–57**). However, alkylation did not seem to have a clear effect on MAO inhibitory potency, although this chemical modification was generally beneficial for MAO-A selectivity for compounds bearing large substituents at position 1 (Ph-CH(Me)- or Ph), with selectivity indices in the range 0.04–0.4 (compounds **53, 55–57** in Table 1).

Finally, we also envisaged the isomerization of the benzene ring of compound **33** from the substituent at position 1 of the triazole ring to the side chain at position 4. This approach led to increased MAO-A inhibitory potencies, with compounds **82** and **83** being 46- and 183-fold more potent than **33**, and also to increased MAO-B inhibitory activity in the case of **83** (6-fold more potent than **33**), bearing a *para*-disubstituted benzene ring in the side chain at position 4. Docking calculations of compound **83** also led to a binding pose that filled the binding cavity of MAO-B (Fig. 3), while docking of the derivative with a *meta*-disubstituted benzene (compound **82**) revealed steric clashes in the substrate binding cavity (data not shown), in agreement with the 100-fold ratio in the IC<sub>50</sub> values determined for these compounds against *hr*MAO-B (Table 1).

In agreement with the hypothesis that a total number of three methylenes separating the terminal aromatic ring and the propargylamine nitrogen atom afforded the optimal length to confer selectivity towards MAO-B, third generation compounds **36** and **84** turned out to be selective for MAO-B versus MAO-A inhibition, with IC<sub>50</sub> values for MAO-B inhibition in the low micromolar range. Compound **36** was found to be more selective MAO-B inhibitor than its shorter homologue **35**, and even more selective than its isomer **33** with the same total number of methylenes in the tether (27-fold more potent for MAO-B than for MAO-A inhibition; Table 1). Also, in contrast with compounds **82** and **83**, with the inverse selectivity or with no selectivity, compound **84** was found to be 5-fold more potent for MAO-B than for MAO-A inhibition, albeit with a 9-fold lower potency than its shorter homologue **83**.

Overall, compound **83** emerges as the most potent MAO inhibitor of the series, with submicromolar potencies against both MAO-A and MAO-B, and hence, essentially without selectivity, whereas compounds **33**, **36**, and **84**, with a total number of three methylene groups in the tethers that connect their phenyl and triazole rings with the propargylamine nitrogen atom, emerge as low micromolar selective MAO-B inhibitors of interest as novel leads for AD drug discovery.

### 2.3. Reversibility and time-dependent inhibition studies


The triazole derivative **33**, one the most promising compounds of the series by virtue of its one-digit micromolar inhibitory potency and MAO-B selectivity, was subjected to further studies to gain insight into the type of inhibition of MAO-B. First, we investigated whether the propargylamino group present in **33** led to the irreversible inhibition of the enzyme. As shown in Figure 4, the reversibility assays confirmed that **33** irreversibly inhibited MAO-B, since the inhibition was not reverted after various cycles of consecutive centrifugations and washings with buffer. Furthermore, this finding is in agreement with the time-dependent inhibition of MAO-B resulting from incubation with **33**, as shown in Figure 4. Thus, after pre-incubation of *hr*MAO-B with a 10 μM concentration of **33** for different times ranging from 5 to 360 min, the enzymatic activity showed a slow time-dependent inhibition of MAO-B. These findings mimic the behavior reported for the MTDL inhibitor **6**,<sup>39</sup> and for the structurally related MAO-B inhibitor PFN9601.<sup>81</sup> As previously noted for **6**,<sup>39</sup> these results suggest that the proper accommodation of **33** in a conformation suitable for covalent attachment to the FAD cofactor may require an a priori conformational rearrangement for the structural adaptation to the peculiar shape of the MAO-B binding pocket.

### 2.4. Blood–brain barrier permeation assay


Because an essential feature of anti-neurodegenerative drug candidates is the ability to cross the BBB, all the novel compounds were subjected to the well-established PAMPA-BBB assay, as an in vitro model of passive permeation.<sup>82</sup> The in vitro permeability ( $P_e$ ) of the novel compounds through a lipid extract of porcine brain was determined using a mixture of phosphate-buffered saline (PBS)/EtOH 70:30. Assay validation was carried out by comparison of the experimental and reported permeability values of 14 commercial drugs (see Section 4), which provided a good linear correlation:  $P_e(\text{exp}) = 1.003 P_e(\text{lit}) - 0.783$  ( $R^2 = 0.93$ ). Using this equation and the limits established by Di et al. for BBB permeation,<sup>82</sup> the following ranges of permeability were established:  $P_e(10^{-6} \text{ cm s}^{-1}) > 5.18$  for compounds with high BBB permeation (CNS+);  $P_e(10^{-6} \text{ cm s}^{-1}) < 2.06$  for compounds with low BBB permeation (CNS-); and  $5.18 > P_e(10^{-6} \text{ cm s}^{-1}) > 2.06$  for compounds with uncertain BBB permeation (CNS±). As shown in Table 1, the tested compounds had generally  $P_e$  values well above the threshold for high BBB permeation, so that they were predicted to be able to cross the BBB and reach their biological target in the CNS, although unexpectedly the third generation compounds showed lower permeabilities than the rest of compounds, maybe as a consequence of solubility issues.

### 3. Conclusion

The results reported in this study support the feasibility of the CuAAC-mediated synthesis of 1,2,3-triazole derivatives featuring the propargylamine group typical of irreversible MAO-A and MAO-B inhibitors, leading to suitable templates for the design of MAO-B inhibitor-based MTDLs. The synthetic procedures of the



**Figure 3.** Representation of the docked pose of compound **83** (shown as green-colored sticks) in the binding cavity of MAO-B (shown as gray cartoon). The surface of the binding cavity is depicted as a gray isocontour. The structures of inhibitor **6** (PDB entry 4CRT; covalently-bound to FAD, also shown as gray-colored sticks) and the reversible ligand 1,4-diphenyl-2-butene (PDB entry 1OJ9) are shown as white-colored and yellow sticks, respectively.



**Figure 4.** Plot of the enzymatic activity (mFU/min) versus pre-incubation time (min) (left) and plot of the remaining enzymatic activity (as % of control sample) versus pre-incubation time (right) in the study of reversibility of *hr*MAO-B inhibition by **33**.

1,4-disubstituted or 1,4,5-trisubstituted 1,2,3-triazole scaffolds involve 4–6-step sequences from the CuAAC of alkyl or phenyl azides with an alkyne bearing an *N*-Boc-protected primary amino or a cyano group as precursors of the propargylamine warhead. Nevertheless, introduction of lipophilic substituents were necessary to counterbalance the high polarity conferred by the triazole ring and to modulate the inhibitory activity against the two MAO isoforms. The triazolyl-*p*-xylyl propargylamine **83** has been found to be a moderately potent nonselective MAO inhibitor, with submicromolar potencies against both human MAO-A and MAO-B. On the other hand, the isomeric 1-benzyltriazolyethyl propargylamine **33** and 1-phenethyltriazolymethyl propargylamine **36**, and the triazolyl-*p*-methylphenethyl propargylamine **84** have emerged as moderately potent and selective MAO-B inhibitor with low micromolar potencies and large selectivity indices, with an appropriate hydrophilic–lipophilic balance (Log*P* values of 2.1, 1.9, and 2.4, respectively, i.e., in the range of classical MAO inhibitors) and relatively low molecular weight (254–268). Further work will be focused on refining the MAO-B inhibitory potency of these scaffolds by enabling the linkage to a second pharmacophoric moiety to derive novel MTDLs, as well as to develop small-molecule probes for MAO-B imaging in models of neurodegenerative diseases.<sup>83</sup>

## 4. Experimental part

### 4.1. Chemistry. General methods

Melting points were determined in open capillary tubes with a MFB 595010M Gallenkamp melting point apparatus. 400 MHz <sup>1</sup>H/100.6 MHz <sup>13</sup>C NMR spectra were recorded on a Varian Mercury 400 spectrometer at the Centres Científics i Tecnològics of the University of Barcelona (CCiTUB). The chemical shifts are reported in ppm ( $\delta$  scale) relative to solvent signals (CD<sub>3</sub>OD at 3.31 and 49.0 ppm in the <sup>1</sup>H and <sup>13</sup>C NMR spectra, respectively; CDCl<sub>3</sub> at 7.26 and 77.16 ppm in the <sup>1</sup>H and <sup>13</sup>C NMR spectra, respectively), and coupling constants are reported in Hertz (Hz). Assignments given for the NMR spectra of the new compounds have been carried out by comparison with the NMR data of compounds **10**, **25**, **34**, **37**, **52**, and **82**, which in turn, were assigned on the basis of DEPT, COSY <sup>1</sup>H/<sup>1</sup>H (standard procedures), and COSY <sup>1</sup>H/<sup>13</sup>C (gHSQC or gHMBC sequences) experiments. IR spectra were run on a Perkin–Elmer Spectrum RX I spectrophotometer. Absorption values are expressed as wavenumbers (cm<sup>-1</sup>); only significant absorption bands are given. Column chromatography was performed on silica gel 60 AC.C (40–60 mesh, SDS, ref 2000027). Thin-layer chromatography was performed with aluminum-backed sheets with

silica gel 60 F<sub>254</sub> (Merck, ref 1.05554), and spots were visualized with UV light and 1% aqueous solution of KMnO<sub>4</sub>. High resolution mass spectra were carried out at the CCiTUB with a LC/MSD TOF Agilent Technologies spectrometer. The analytical samples of all of the compounds that were subjected to pharmacological evaluation were dried at 65 °C/2 Torr (standard conditions).

#### 4.1.1. *N*-(*tert*-Butoxycarbonyl)-*N*-[(1-ethyl-1*H*-1,2,3-triazol-4-yl)methyl]amine **9**

To a solution of bromoethane (0.53 mL, 774 mg, 7.10 mmol) in H<sub>2</sub>O/DMF 1:4 (50 mL), NaN<sub>3</sub> (502 mg, 7.72 mmol), Na<sub>2</sub>CO<sub>3</sub> (2.05 g, 19.3 mmol), ascorbic acid (907 mg, 5.15 mmol), CuSO<sub>4</sub>·5H<sub>2</sub>O (641 mg, 2.57 mmol) and *N*-Boc-propargylamine, **7** (1.00 g, 6.44 mmol) were added. The reaction mixture was stirred at rt overnight, diluted with 20% aq NH<sub>4</sub>OH (200 mL), treated with solid EDTA (ca 5 g) and extracted with EtOAc (2 × 150 mL). The combined organic extracts were washed with H<sub>2</sub>O (3 × 100 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The resulting residue was washed with pentane (3 × 10 mL) and dried under vacuum, to give compound **9** (1.14 g, 78% yield) as a white solid; *R*<sub>f</sub> 0.57 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 9:1); mp 77–78 °C; IR (ATR)  $\nu$  3318 (N–H), 1685, 1675 (C=O) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  1.40 [s, 9H, C(CH<sub>3</sub>)<sub>3</sub>], 1.51 (t, *J* = 7.2 Hz, 3H, 1-CH<sub>2</sub>-CH<sub>3</sub>), 4.35 (q, *J* = 7.2 Hz, 2H, 1-CH<sub>2</sub>-CH<sub>3</sub>), 4.36 (s, 2H, 4-CH<sub>2</sub>-NH), 5.21 (broad s, 1H, *NH*Boc), 7.50 (s, 1H, 5-H); <sup>13</sup>C NMR (100.6 MHz, CDCl<sub>3</sub>)  $\delta$  15.5 (CH<sub>3</sub>, 1-CH<sub>2</sub>-CH<sub>3</sub>), 28.4 [3CH<sub>3</sub>, C(CH<sub>3</sub>)<sub>3</sub>], 36.2 (CH<sub>2</sub>, 4-CH<sub>2</sub>-N), 45.3 (CH<sub>2</sub>, 1-CH<sub>2</sub>-CH<sub>3</sub>), 79.7 [C, C(CH<sub>3</sub>)<sub>3</sub>], 121.3 (CH, C5), 145.6 (C, C4), 156.0 (C, NCOO); HRMS (ESI), calcd for (C<sub>10</sub>H<sub>18</sub>N<sub>4</sub>O<sub>2</sub> + H<sup>+</sup>) 227.1503, found 227.1493.

#### 4.1.2. *N*-(*tert*-Butoxycarbonyl)-*N*-[2-(1-ethyl-1*H*-1,2,3-triazol-4-yl)ethyl]amine **10**

It was prepared as described for **9**. From bromoethane (0.65 mL, 949 mg, 8.71 mmol), NaN<sub>3</sub> (618 mg, 9.51 mmol), Na<sub>2</sub>CO<sub>3</sub> (2.52 g, 23.8 mmol), ascorbic acid (1.12 g, 6.36 mmol), CuSO<sub>4</sub>·5H<sub>2</sub>O (790 mg, 3.16 mmol), and *N*-Boc-3-butynylamine, **8** (1.34 g, 7.92 mmol), compound **10** (1.48 g, 78% yield) was obtained as a white solid; *R*<sub>f</sub> 0.50 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 9:1); mp 78–80 °C; IR (ATR)  $\nu$  3341 (N–H), 1692 (C=O) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  1.40 [s, 9H, C(CH<sub>3</sub>)<sub>3</sub>], 1.51 (t, *J* = 7.6 Hz, 3H, 1-CH<sub>2</sub>-CH<sub>3</sub>), 2.87 (t, *J* = 6.4 Hz, 2H, 4-CH<sub>2</sub>-CH<sub>2</sub>-NH), 3.44 (dt, *J* = *J*' = 6.4 Hz, 2H, 4-CH<sub>2</sub>-CH<sub>2</sub>-NH), 4.35 (q, *J* = 7.6 Hz, 2H, 1-CH<sub>2</sub>-CH<sub>3</sub>), 5.04 (broad s, 1H, *NH*Boc), 7.35 (s, 1H, 5-H); <sup>13</sup>C NMR (100.6 MHz, CDCl<sub>3</sub>)  $\delta$  15.6 (CH<sub>3</sub>, 1-CH<sub>2</sub>-CH<sub>3</sub>), 26.3 (CH<sub>2</sub>, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 28.5 [3CH<sub>3</sub>, C(CH<sub>3</sub>)<sub>3</sub>], 39.9 (CH<sub>2</sub>, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 45.2 (CH<sub>2</sub>, 1-CH<sub>2</sub>-CH<sub>3</sub>), 79.2 [C, C(CH<sub>3</sub>)<sub>3</sub>], 120.8 (CH, C5), 145.5 (C, C4), 156.1 (C, NCOO); HRMS (ESI), calcd for (C<sub>11</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub> + H<sup>+</sup>) 241.1659, found 241.1654.

#### 4.1.3. *N*-(*tert*-Butoxycarbonyl)-*N*-[2-(1-benzyl-1*H*-1,2,3-triazol-4-yl)ethyl]amine **11**

It was prepared as described for **9**. From benzyl bromide (0.75 mL, 1.08 g, 6.31 mmol), NaN<sub>3</sub> (462 mg, 7.11 mmol), Na<sub>2</sub>CO<sub>3</sub> (1.88 g, 17.7 mmol), ascorbic acid (834 mg, 4.74 mmol), CuSO<sub>4</sub>·5H<sub>2</sub>O (590 mg, 2.36 mmol), and *N*-Boc-3-butynylamine, **8** (1.00 g, 5.91 mmol), compound **11** (1.27 g, 71% yield) was obtained as a white solid; *R*<sub>f</sub> 0.58 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 9.5:0.5:0.05); mp 103–105 °C; IR (ATR)  $\nu$  3407 (N–H), 1688 (C=O) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  1.38 [s, 9H, C(CH<sub>3</sub>)<sub>3</sub>], 2.84 (t, *J* = 6.8 Hz, 2H, 4-CH<sub>2</sub>-CH<sub>2</sub>-NH), 3.41 (td, *J* = 6.8 Hz, *J'* = 6.0 Hz, 2H, 4-CH<sub>2</sub>-CH<sub>2</sub>-NH), 5.04 (broad s, 1H, *NH*Boc), 5.46 (s, 2H, 1-CH<sub>2</sub>-Ph), 7.22 [ddm, *J* = 7.6 Hz, *J'* = 2.0 Hz, 2H, Ph-C2(6)-H], 7.29–7.37 [complex signal, 4H, 5-H, Ph-C3(5)-H, Ph-C4-H]; <sup>13</sup>C NMR (100.6 MHz, CDCl<sub>3</sub>)  $\delta$  26.3 (CH<sub>2</sub>, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 28.4 [3CH<sub>3</sub>, C(CH<sub>3</sub>)<sub>3</sub>], 39.8 (CH<sub>2</sub>, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 54.1 (CH<sub>2</sub>, 1-CH<sub>2</sub>-Ph), 79.2 [C, C(CH<sub>3</sub>)<sub>3</sub>], 121.4 (CH, C5), 128.1 (2CH), 128.8 (CH), 129.2 (2CH) (Ph-CH), 134.8 (C, Ph-C1), 145.9 (C, C4), 156.0 (C, NCOO); HRMS (ESI), calcd for (C<sub>16</sub>H<sub>22</sub>N<sub>4</sub>O<sub>2</sub> + H<sup>+</sup>) 303.1816, found 303.1813.

#### 4.1.4. *N*-(*tert*-Butoxycarbonyl)-*N*-[2-(1-phenethyl-1*H*-1,2,3-triazol-4-yl)ethyl]amine **12**

It was prepared as described for **9**. From phenethyl bromide (0.89 mL, 1.21 g, 6.52 mmol), NaN<sub>3</sub> (462 mg, 7.11 mmol), Na<sub>2</sub>CO<sub>3</sub> (1.88 g, 17.7 mmol), ascorbic acid (834 mg, 4.74 mmol), CuSO<sub>4</sub>·5H<sub>2</sub>O (590 mg, 2.36 mmol), and *N*-Boc-3-butynylamine, **8** (1.00 g, 5.91 mmol), compound **12** (908 mg, 49% yield) was obtained as a white solid; *R*<sub>f</sub> 0.52 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 9.5:0.5:0.05); mp 123–125 °C; IR (ATR)  $\nu$  3392 (N–H), 1688 (C=O) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  1.43 [s, 9H, C(CH<sub>3</sub>)<sub>3</sub>], 2.85 (t, *J* = 6.8 Hz, 2H, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 3.19 (t, *J* = 7.2 Hz, 2H, 1-CH<sub>2</sub>-CH<sub>2</sub>-Ph), 3.42 (m, 2H, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 4.55 (t, *J* = 7.2 Hz, 2H, 1-CH<sub>2</sub>-CH<sub>2</sub>-Ph), 4.95 (br s, 1H, *NH*Boc), 7.09 [dm, *J* = 6.8 Hz, 2H, Ph-C2(6)-H], 7.22–7.32 [complex signal, 4H, 5-H, Ph-C3(5)-H, Ph-C4-H]; <sup>13</sup>C NMR (100.6 MHz, CDCl<sub>3</sub>)  $\delta$  26.2 (CH<sub>2</sub>, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 28.5 [3CH<sub>3</sub>, C(CH<sub>3</sub>)<sub>3</sub>], 36.9 (CH<sub>2</sub>, 1-CH<sub>2</sub>-CH<sub>2</sub>-Ph), 40.0 (CH<sub>2</sub>, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 51.6 (CH<sub>2</sub>, 1-CH<sub>2</sub>-CH<sub>2</sub>-Ph), 79.3 [C, C(CH<sub>3</sub>)<sub>3</sub>], 121.9 (CH, C5), 127.2 (CH), 128.8 (2CH), 128.9 (2CH) (Ph-CH), 137.2 (C, Ph-C1), 145.2 (C, C4), 156.1 (C, NCOO); HRMS (ESI), calcd for (C<sub>17</sub>H<sub>24</sub>N<sub>4</sub>O<sub>2</sub> + H<sup>+</sup>) 317.1972, found 317.1968.

#### 4.1.5. *N*-(*tert*-Butoxycarbonyl)-*N*-[(1-methyl-1*H*-1,2,3-triazol-4-yl)methyl]amine **13**

It was prepared as described for **9**. From iodomethane (0.44 mL, 1.00 g, 7.07 mmol), NaN<sub>3</sub> (502 mg, 7.72 mmol), Na<sub>2</sub>CO<sub>3</sub> (2.05 g, 19.3 mmol), ascorbic acid (907 mg, 5.15 mmol), CuSO<sub>4</sub>·5H<sub>2</sub>O (641 mg, 2.57 mmol), and *N*-Boc-propargylamine, **7** (1.00 g, 6.44 mmol), compound **13** (938 mg, 69% yield) was obtained as a white solid; *R*<sub>f</sub> 0.87 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 9.5:0.5:0.05); mp 102–104 °C; IR (ATR)  $\nu$  3379 (N–H), 1679 (C=O) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  1.41 [s, 9H, C(CH<sub>3</sub>)<sub>3</sub>], 4.05 (s, 3H, 1-CH<sub>3</sub>), 4.35 (d, *J* = 6.0 Hz, 2H, 4-CH<sub>2</sub>-N), 5.17 (br s, 1H, *NH*Boc), 7.48 (s, 1H, 5-H); <sup>13</sup>C NMR (100.6 MHz, CDCl<sub>3</sub>)  $\delta$ : 28.5 [3CH<sub>3</sub>, C(CH<sub>3</sub>)<sub>3</sub>], 36.2 (CH<sub>2</sub>, 4-CH<sub>2</sub>-N), 36.7 (CH<sub>3</sub>, 1-CH<sub>3</sub>), 79.7 [C, C(CH<sub>3</sub>)<sub>3</sub>], 122.9 (CH, C5), 145.9 (C, C4), 156.0 (C, NCOO); HRMS (ESI), calcd for (C<sub>9</sub>H<sub>16</sub>N<sub>4</sub>O<sub>2</sub> + H<sup>+</sup>) 213.1346, found 213.1336.

#### 4.1.6. *N*-(*tert*-Butoxycarbonyl)-*N*-[2-(1-phenyl-1*H*-1,2,3-triazol-4-yl)ethyl]amine **14**

It was prepared as described for **9**. From phenyl azide (0.5 M solution in *tert*-butyl methyl ether, 26.2 mL, 13.1 mmol), Na<sub>2</sub>CO<sub>3</sub> (3.47 g, 32.7 mmol), ascorbic acid (1.54 g, 8.74 mmol), CuSO<sub>4</sub>·5H<sub>2</sub>O (1.09 mg, 4.36 mmol), and *N*-Boc-3-butynylamine, **8** (2.00 g, 11.8 mmol), compound **14** (1.89 g, 56% yield) was obtained as a yellow solid; *R*<sub>f</sub> 0.90 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 9:1:0.05); mp 127–129 °C; IR (ATR)  $\nu$  3297 (N–H), 1712 (C=O) cm<sup>-1</sup>; <sup>1</sup>H NMR

(400 MHz, CDCl<sub>3</sub>)  $\delta$  1.43 [s, 9H, C(CH<sub>3</sub>)<sub>3</sub>], 3.00 (t, *J* = 6.8 Hz, 2H, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 3.55 (td, *J* = 6.8 Hz, *J'* = 6.0 Hz, 2H, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 5.02 (br s, 1H, *NH*Boc), 7.43 (tt, *J* = 7.4 Hz, *J'* = 1.2 Hz, 1H, Ph-C4-H), 7.52 [m, 2H, Ph-C3(5)-H], 7.71 [ddd, *J* = 8.8 Hz, *J'* = 2.4 Hz, *J''* = 1.2 Hz, 2H, Ph-C2(6)-H], 7.81 (s, 1H, 5-H); <sup>13</sup>C NMR (100.6 MHz, CDCl<sub>3</sub>)  $\delta$  26.4 (CH<sub>2</sub>, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 28.5 [3CH<sub>3</sub>, C(CH<sub>3</sub>)<sub>3</sub>], 39.9 (CH<sub>2</sub>, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 79.4 [C, C(CH<sub>3</sub>)<sub>3</sub>], 119.8 (CH, Ph-C4), 120.5 (CH, C5), 128.7 (2CH), 129.9 (2CH) [Ph-C2(6), Ph-C3(5)], 137.2 (C, Ph-C1), 146.3 (C, C4), 156.1 (C, NCOO); HRMS (ESI), calcd for (C<sub>15</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub> + Na<sup>+</sup>) 311.1478, found 311.1476.

#### 4.1.7. *N*-[(1-Benzyl-1*H*-1,2,3-triazol-4-yl)methyl]-*N*-(*tert*-butoxycarbonyl)amine **15**

It was prepared as described for **9**. From benzyl bromide (1.04 mL, 1.50 g, 8.74 mmol), NaN<sub>3</sub> (622 mg, 9.57 mmol), Na<sub>2</sub>CO<sub>3</sub> (2.53 g, 23.9 mmol), ascorbic acid (1.12 g, 6.36 mmol), CuSO<sub>4</sub>·5H<sub>2</sub>O (796 mg, 3.19 mmol), and *N*-Boc-propargylamine, **7** (1.24 g, 7.99 mmol), compound **15** (1.68 g, 68% yield) was obtained as a white solid; *R*<sub>f</sub> 0.62 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>4</sub>OH 9.75:0.25:0.05); mp 97–99 °C; IR (ATR)  $\nu$  3400, 3302, 3105, 3059 (N–H), 1684, 1679 (C=O) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  1.32 [s, 9H, C(CH<sub>3</sub>)<sub>3</sub>], 4.27 (d, *J* = 6.0 Hz, 2H, 4-CH<sub>2</sub>-N), 5.06 (br s, 1H, *NH*Boc), 5.40 (s, 2H, 1-CH<sub>2</sub>-Ph), 7.26 [m, 2H, Ph-C2(6)-H], 7.30–7.40 [complex signal, 3H, Ph-C3(5)-H, Ph-C4-H], 7.43 (s, 1H, 5-H); <sup>13</sup>C NMR (100.6 MHz, CDCl<sub>3</sub>)  $\delta$  28.4 [3CH<sub>3</sub>, C(CH<sub>3</sub>)<sub>3</sub>], 36.2 (CH<sub>2</sub>, 4-CH<sub>2</sub>-N), 54.2 (CH<sub>2</sub>, 1-CH<sub>2</sub>-Ph), 79.8 [C, C(CH<sub>3</sub>)<sub>3</sub>], 121.9 (CH, C5), 128.2 (2CH), 128.8 (CH), 129.2 (2CH) (Ph-CH), 134.7 (C, Ph-C1), 146.0 (C, C4), 155.9 (C, NCOO); HRMS (ESI), calcd for (C<sub>15</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub> + Na<sup>+</sup>) 311.1478, found 311.1487.

#### 4.1.8. *N*-(*tert*-Butoxycarbonyl)-*N*-[(1-phenethyl-1*H*-1,2,3-triazol-4-yl)methyl]amine **16**

It was prepared as described for **9**. From phenethyl bromide (1.11 mL, 1.50 g, 8.13 mmol), NaN<sub>3</sub> (574 mg, 8.83 mmol), Na<sub>2</sub>CO<sub>3</sub> (2.34 g, 22.1 mmol), ascorbic acid (1.04 g, 5.91 mmol), CuSO<sub>4</sub>·5H<sub>2</sub>O (735 mg, 2.94 mmol), and *N*-Boc-propargylamine, **7** (1.00 g, 6.44 mmol), compound **16** (1.43 g, 73% yield) was obtained as a white solid; *R*<sub>f</sub> 0.57 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>4</sub>OH 9.75:0.25:0.05); mp 98–100 °C; IR (ATR)  $\nu$  3410, 3111, 3069, 3054 (N–H), 1684 (C=O) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  1.43 [s, 9H, C(CH<sub>3</sub>)<sub>3</sub>], 3.19 (t, *J* = 7.2 Hz, 2H, 1-CH<sub>2</sub>-CH<sub>2</sub>-Ph), 4.34 (d, *J* = 6.0 Hz, 2H, 4-CH<sub>2</sub>-N), 4.56 (t, *J* = 7.2 Hz, 2H, 1-CH<sub>2</sub>-CH<sub>2</sub>-Ph), 5.14 (br s, 1H, *NH*Boc), 7.10 [dm, *J* = 8.4 Hz, 2H, Ph-C2(6)-H], 7.21–7.32 [complex signal, 4H, 5-H, Ph-C3(5)-H, Ph-C4-H]; <sup>13</sup>C NMR (100.6 MHz, CDCl<sub>3</sub>)  $\delta$  28.5 [3CH<sub>3</sub>, C(CH<sub>3</sub>)<sub>3</sub>], 36.2 (CH<sub>2</sub>, 4-CH<sub>2</sub>-N), 36.8 (CH<sub>2</sub>, 1-CH<sub>2</sub>-CH<sub>2</sub>-Ph), 51.7 (CH<sub>2</sub>, 1-CH<sub>2</sub>-CH<sub>2</sub>-Ph), 79.7 [C, C(CH<sub>3</sub>)<sub>3</sub>], 122.2 (CH, C5), 127.2 (CH), 128.7 (2CH), 128.9 (2CH) (Ph-CH), 137.0 (C, Ph-C1), 145.3 (C, C4), 155.9 (C, NCOO); HRMS (ESI), calcd for (C<sub>16</sub>H<sub>22</sub>N<sub>4</sub>O<sub>2</sub> + H<sup>+</sup>) 303.1816, found 303.1827.

#### 4.1.9. *N*-(*tert*-Butoxycarbonyl)-*N*-[(1-ethyl-1*H*-1,2,3-triazol-4-yl)methyl]-*N*-methylamine **17**

A solution of **9** (634 mg, 2.80 mmol) in anhydrous THF (6.5 mL) was cooled to 0 °C and treated with NaH (60% suspension in mineral oil, 246 mg, 6.15 mmol) and iodomethane (0.19 mL, 433 mg, 3.05 mmol). The reaction mixture was stirred at rt for 3 h, cooled to 0 °C, diluted dropwise with satd aq NH<sub>4</sub>Cl (40 mL), and extracted with EtOAc (3 × 40 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and evaporated under reduced pressure. The resulting residue was washed with pentane (3 × 10 mL) and dried under vacuum, to give **17** (654 mg, 97% yield) as a colorless oil; *R*<sub>f</sub> 0.64 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 9:1); IR (ATR)  $\nu$  1688, 1677 (C=O) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  1.40 [s, C(CH<sub>3</sub>)<sub>3</sub> minor rotamer], 1.42 [s, C(CH<sub>3</sub>)<sub>3</sub> major rotamer], 1.50 (t, *J* = 7.2 Hz, 1-CH<sub>2</sub>-CH<sub>3</sub> minor rotamer), 1.51 (t, *J* = 7.2 Hz, 1-CH<sub>2</sub>-CH<sub>3</sub> major rotamer), 2.87 (s, 3H, N-CH<sub>3</sub>), 4.39 (q, *J* = 7.2 Hz, 1-CH<sub>2</sub>-CH<sub>3</sub> minor rotamer),

4.40 (q,  $J = 7.2$  Hz, 1-CH<sub>2</sub>-CH<sub>3</sub> major rotamer), 4.49 (s, 4-CH<sub>2</sub>-N), 7.37 (br s, 5-H minor rotamer), 7.49 (s, 5-H major rotamer); HRMS (ESI), calcd for (C<sub>11</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub> + H<sup>+</sup>) 241.1659, found 241.1654.

#### 4.1.10. *N*-(*tert*-Butoxycarbonyl)-*N*-[2-(1-ethyl-1*H*-1,2,3-triazol-4-yl)ethyl]-*N*-methylamine **18**

It was prepared as described for **17**. From compound **10** (1.70 g, 7.08 mmol), NaH (60% suspension in mineral oil, 424 mg, 10.6 mmol), and iodomethane (0.48 mL, 1.09 g, 7.71 mmol), stirring at rt for 2 h, compound **18** (1.71 mg, 95% yield) was obtained as a colorless oil;  $R_f$  0.58 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 9:1); IR (ATR)  $\nu$  1690 (C=O) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  1.41 [s, 9H, C(CH<sub>3</sub>)<sub>3</sub>], 1.51 (t,  $J = 7.2$  Hz, 3H, 1-CH<sub>2</sub>-CH<sub>3</sub>), 2.82 (s, 3H, N-CH<sub>3</sub>), 2.93 (m, 2H, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 3.52 (br t,  $J = 6.8$  Hz, 2H, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 4.35 (q,  $J = 7.2$  Hz, 2H, 1-CH<sub>2</sub>-CH<sub>3</sub>), 7.28 (br s), 7.40 (br s) (5-H); <sup>13</sup>C NMR (100.6 MHz, CDCl<sub>3</sub>)  $\delta$  15.6 (CH<sub>3</sub>, 1-CH<sub>2</sub>-CH<sub>3</sub>), 24.3 (CH<sub>2</sub>), 24.7 (CH<sub>2</sub>) (4-CH<sub>2</sub>-CH<sub>2</sub>-N), 28.5 [3CH<sub>3</sub>, C(CH<sub>3</sub>)<sub>3</sub>], 34.4 (CH<sub>3</sub>, N-CH<sub>3</sub>), 45.2 (CH<sub>2</sub>, 1-CH<sub>2</sub>-CH<sub>3</sub>), 48.0 (CH<sub>2</sub>), 48.9 (CH<sub>2</sub>) (4-CH<sub>2</sub>-CH<sub>2</sub>-N), 79.5 [C, C(CH<sub>3</sub>)<sub>3</sub>], 120.8 (CH, C5), 145.2 (br C, C4), 155.8 (br C, NCOO); HRMS (ESI), calcd for (C<sub>12</sub>H<sub>22</sub>N<sub>4</sub>O<sub>2</sub> + H<sup>+</sup>) 255.1816, found 255.1815.

#### 4.1.11. *N*-(*tert*-Butoxycarbonyl)-*N*-[2-(1-benzyl-1*H*-1,2,3-triazol-4-yl)ethyl]-*N*-methylamine **19**

It was prepared as described for **17**. From compound **11** (3.67 g, 12.1 mmol), NaH (60% suspension in mineral oil, 0.73 g, 18.2 mmol), and iodomethane (0.83 mL, 1.89 g, 13.3 mmol), stirring at rt for 3 h, compound **19** (3.64 g, 95% yield) was obtained as a yellowish oil;  $R_f$  0.60 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 9.5:0.5:0.05); IR (ATR)  $\nu$  1687 (C=O) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  1.37 [s, 9H, C(CH<sub>3</sub>)<sub>3</sub>], 2.78 (s, 3H, N-CH<sub>3</sub>), 2.90 (m, 2H, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 3.48 (t,  $J = 6.8$  Hz, 2H, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 5.45 (s, 2H, 1-CH<sub>2</sub>-Ph), 7.20–7.37 (complex signal, 6H, 5-H, Ph-CH); <sup>13</sup>C NMR (100.6 MHz, CDCl<sub>3</sub>)  $\delta$  24.2 (CH<sub>2</sub>), 24.7 (CH<sub>2</sub>) (4-CH<sub>2</sub>-CH<sub>2</sub>-N), 28.4 [3CH<sub>3</sub>, C(CH<sub>3</sub>)<sub>3</sub>], 34.4 [CH<sub>3</sub>, N-CH<sub>3</sub>], 48.0 (CH<sub>2</sub>), 48.7 (CH<sub>2</sub>) (4-CH<sub>2</sub>-CH<sub>2</sub>-N), 54.1 (CH<sub>2</sub>, 1-CH<sub>2</sub>-Ph), 79.5 [C, C(CH<sub>3</sub>)<sub>3</sub>], 121.4 (br CH, C5), 128.1 (2CH), 128.7 (CH), 129.1 (2CH) (Ph-CH), 134.9 (C, Ph-C1), 145.6 (br C, C4), 155.7 (C, NCOO); HRMS (ESI), calcd for (C<sub>17</sub>H<sub>24</sub>N<sub>4</sub>O<sub>2</sub> + H<sup>+</sup>) 317.1972, found 317.1964.

#### 4.1.12. *N*-(*tert*-Butoxycarbonyl)-*N*-methyl-*N*-[2-(1-phenethyl-1*H*-1,2,3-triazol-4-yl)ethyl]amine **20**

It was prepared as described for **17**. From compound **12** (876 mg, 2.77 mmol), NaH (60% suspension in mineral oil, 167 mg, 4.17 mmol), and iodomethane (0.19 mL, 433 mg, 3.05 mmol), stirring at rt for 1.5 h, compound **20** (738 mg, 81% yield) was obtained as a yellowish oil;  $R_f$  0.57 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 9.5:0.5:0.05); mp 58–60 °C; IR (ATR)  $\nu$  1686 (C=O) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  1.42 [s, 9H, C(CH<sub>3</sub>)<sub>3</sub>], 2.80 (s, 3H, N-CH<sub>3</sub>), 2.90 (m, 2H, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 3.18 (t,  $J = 7.2$  Hz, 2H, 1-CH<sub>2</sub>-CH<sub>2</sub>-Ph), 3.48 (m, 2H, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 4.54 (t,  $J = 7.2$  Hz, 2H, 1-CH<sub>2</sub>-CH<sub>2</sub>-Ph), 7.03 (br s), 7.19 (br s) (5-H), 7.10 [dm,  $J = 8.0$  Hz, 2H, Ph-C2(6)-H], 7.21–7.32 (complex signal, 3H, Ph-C3(5)-H, Ph-C4-H); <sup>13</sup>C NMR (100.6 MHz, CDCl<sub>3</sub>)  $\delta$  24.2 (CH<sub>2</sub>), 24.6 (CH<sub>2</sub>) (4-CH<sub>2</sub>-CH<sub>2</sub>-N), 28.5 [3CH<sub>3</sub>, C(CH<sub>3</sub>)<sub>3</sub>], 34.5 (CH<sub>3</sub>, N-CH<sub>3</sub>), 36.9 (CH<sub>2</sub>, 1-CH<sub>2</sub>-CH<sub>2</sub>-Ph), 48.1 (CH<sub>2</sub>), 48.9 (CH<sub>2</sub>) (4-CH<sub>2</sub>-CH<sub>2</sub>-N), 51.6 (CH<sub>2</sub>, 1-CH<sub>2</sub>-CH<sub>2</sub>-Ph), 79.5 [C, C(CH<sub>3</sub>)<sub>3</sub>], 121.8 (CH, C5), 127.1 (CH), 128.7 (2CH), 128.9 (2CH) (Ph-CH), 137.2 (C, Ph-C1), 144.8 (br C, C4), 155.8 (C, NCOO); HRMS (ESI), calcd for (C<sub>18</sub>H<sub>26</sub>N<sub>4</sub>O<sub>2</sub> + H<sup>+</sup>) 331.2129, found 331.2122.

#### 4.1.13. *N*-(*tert*-Butoxycarbonyl)-*N*-methyl-*N*-[(1-methyl-1*H*-1,2,3-triazol-4-yl)methyl]amine **21**

It was prepared as described for **17**. From compound **13** (928 mg, 4.38 mmol), NaH (60% suspension in mineral oil, 263 mg, 6.57 mmol), and iodomethane (0.30 mL, 684 mg,

4.82 mmol), stirring at rt for 1.5 h, compound **21** (945 mg, 95% yield) was obtained as a yellowish oil;  $R_f$  0.31 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 9.5:0.5:0.05); IR (ATR)  $\nu$  1686 (C=O) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  1.45 [s, 9H, C(CH<sub>3</sub>)<sub>3</sub>], 2.89 (s, 3H, N-CH<sub>3</sub>), 4.07 (s, 3H, 1-CH<sub>3</sub>), 4.47 (s, 2H, 4-CH<sub>2</sub>-N), 7.37 (br s), 7.49 (broad s) (5-H); <sup>13</sup>C NMR (100.6 MHz, CDCl<sub>3</sub>)  $\delta$  28.6 [3CH<sub>3</sub>, C(CH<sub>3</sub>)<sub>3</sub>], 34.2 (br CH<sub>3</sub>), 34.6 (br CH<sub>3</sub>) (N-CH<sub>3</sub>), 36.8 (CH<sub>3</sub>, 1-CH<sub>3</sub>), 43.8 (br CH<sub>2</sub>), 44.5 (br CH<sub>2</sub>) (4-CH<sub>2</sub>-N), 79.9 [br C, C(CH<sub>3</sub>)<sub>3</sub>], 122.6 (br CH), 123.5 (br CH) (C5), 145.3 (br C), 145.8 (br C) (C4), 155.3 (br C), 155.9 (br C) (NCOO); HRMS (ESI), calcd for (C<sub>10</sub>H<sub>18</sub>N<sub>4</sub>O<sub>2</sub> + Na<sup>+</sup>) 249.1322; found 249.1323.

#### 4.1.14. *N*-(*tert*-Butoxycarbonyl)-*N*-methyl-*N*-[2-(1-phenyl-1*H*-1,2,3-triazol-4-yl)ethyl]amine **22**

It was prepared as described for **17**. From compound **14** (1.82 g, 6.32 mmol), NaH (60% suspension in mineral oil, 0.76 g, 19.0 mmol), and iodomethane (1.96 mL, 4.47 g, 31.5 mmol), stirring at rt overnight, compound **22** (1.82 g, 95% yield) was obtained as a yellowish oil;  $R_f$  0.86 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 9:1:0.05); IR (ATR)  $\nu$  1689, 1681 (C=O) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  1.42 [s, 9H, C(CH<sub>3</sub>)<sub>3</sub>], 2.88 (s, 3H, N-CH<sub>3</sub>), 3.04 (m, 2H, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 3.61 (m, 2H, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 7.43 (m, 1H, Ph-C4-H), 7.51 [m, 2H, Ph-C3(5)-H], 7.71 [dm,  $J = 8.8$  Hz, 2H, Ph-C2(6)-H], 7.89 (br s, 1H, 5-H); <sup>13</sup>C NMR (100.6 MHz, CDCl<sub>3</sub>)  $\delta$  24.3 (br CH<sub>2</sub>), 24.6 (br CH<sub>2</sub>) (4-CH<sub>2</sub>-CH<sub>2</sub>-N), 28.5 [3CH<sub>3</sub>, C(CH<sub>3</sub>)<sub>3</sub>], 34.4 (CH<sub>3</sub>, N-CH<sub>3</sub>), 47.8 (br CH<sub>2</sub>), 48.7 (br CH<sub>2</sub>) (4-CH<sub>2</sub>-CH<sub>2</sub>-N), 79.6 [C, C(CH<sub>3</sub>)<sub>3</sub>], 119.8 (CH, Ph-C4), 120.5 (CH, C5), 128.6 (2CH), 129.8 (2CH) [Ph-C2(6), Ph-C3(5)], 137.2 (C, Ph-C1), 145.9 (br C, C4), 155.8 (br C, NCOO); HRMS (ESI), calcd for (C<sub>16</sub>H<sub>22</sub>N<sub>4</sub>O<sub>2</sub> + H<sup>+</sup>) 303.1816, found 303.1809.

#### 4.1.15. *N*-[(1-benzyl-1*H*-1,2,3-triazol-4-yl)methyl]-*N*-(*tert*-butoxycarbonyl)-*N*-methylamine **23**

It was prepared as described for **17**. From compound **15** (1.60 g, 5.16 mmol), NaH (60% suspension in mineral oil, 670 mg, 16.7 mmol), and iodomethane (1.73 mL, 3.94 g, 27.8 mmol), stirring at rt overnight, compound **23** (1.30 g, 83% yield) was obtained as a brown solid;  $R_f$  0.68 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>4</sub>OH 9.75:0.25:0.05); mp 79–81 °C; IR (ATR)  $\nu$  1679 (C=O) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  1.41 [br s, 9H, C(CH<sub>3</sub>)<sub>3</sub>], 2.89 (s, 3H, N-CH<sub>3</sub>), 4.45 (s, 2H, 4-CH<sub>2</sub>-N), 5.50 (s, 2H, 1-CH<sub>2</sub>-Ph), 7.26 [br dd,  $J = 8.0$  Hz,  $J' = 1.6$  Hz, 2H, Ph-C2(6)-H], 7.34–7.40 [complex signal, 3H, Ph-C3(5)-H, Ph-C4-H], 7.44 (br s, 1H, 5-H); <sup>13</sup>C NMR (100.6 MHz, CDCl<sub>3</sub>)  $\delta$  28.4 [3CH<sub>3</sub>, C(CH<sub>3</sub>)<sub>3</sub>], 34.5 (CH<sub>3</sub>, N-CH<sub>3</sub>), 43.8 (CH<sub>2</sub>), 44.6 (CH<sub>2</sub>) (4-CH<sub>2</sub>-N), 54.2 (CH<sub>2</sub>, 1-CH<sub>2</sub>-Ph), 79.8 [C, C(CH<sub>3</sub>)<sub>3</sub>], 121.6 (CH), 122.4 (CH) (C5), 128.1 (2CH), 128.8 (CH), 129.2 (2CH) (Ph-CH), 134.7 (C, Ph-C1), 145.4 (C), 145.6 (C) (C4), 155.4 (C), 155.8 (C) (NCOO); HRMS (ESI), calcd for (C<sub>16</sub>H<sub>22</sub>N<sub>4</sub>O<sub>2</sub> + Na<sup>+</sup>) 325.1635, found 325.1638.

#### 4.1.16. *N*-(*tert*-Butoxycarbonyl)-*N*-methyl-*N*-[(1-phenethyl-1*H*-1,2,3-triazol-4-yl)methyl]amine **24**

It was prepared as described for **17**. From compound **16** (1.27 g, 4.20 mmol), NaH (60% suspension in mineral oil, 505 mg, 12.6 mmol), and iodomethane (1.31 mL, 2.99 g, 21.0 mmol), stirring at rt overnight, compound **24** (1.07 g, 81% yield) was obtained as a brown oil;  $R_f$  0.59 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>4</sub>OH 9.75:0.25:0.05); IR (ATR)  $\nu$  1687 (C=O) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  1.43 [s, 9H, C(CH<sub>3</sub>)<sub>3</sub>], 2.84 (s, 3H, N-CH<sub>3</sub>), 3.19 (t,  $J = 7.2$  Hz, 2H, 1-CH<sub>2</sub>-CH<sub>2</sub>-Ph), 4.43 (s, 2H, 4-CH<sub>2</sub>-N), 4.56 (m, 2H, 1-CH<sub>2</sub>-CH<sub>2</sub>-Ph), 7.08 [dm,  $J = 8.4$  Hz, 2H, Ph-C2(6)-H], 7.20–7.32 [complex signal, 4H, 5-H, Ph-C3(5)-H, Ph-C4-H]; <sup>13</sup>C NMR (100.6 MHz, CDCl<sub>3</sub>)  $\delta$  28.2 [CH<sub>3</sub>, C(CH<sub>3</sub>)<sub>3</sub> minor rotamer], 28.3 [CH<sub>3</sub>, C(CH<sub>3</sub>)<sub>3</sub> major rotamer], 33.9 (CH<sub>3</sub>, N-CH<sub>3</sub> minor rotamer), 34.2 (CH<sub>3</sub>, N-CH<sub>3</sub> major rotamer), 36.5 (CH<sub>2</sub>, 1-CH<sub>2</sub>-CH<sub>2</sub>-Ph minor rotamer), 36.6 (CH<sub>2</sub>, 1-CH<sub>2</sub>-CH<sub>2</sub>-Ph major rotamer), 43.5 (CH<sub>2</sub>, 4-CH<sub>2</sub>-N major rotamer),

44.2 (CH<sub>2</sub>, 4-CH<sub>2</sub>-N minor rotamer), 51.4 (CH<sub>2</sub>, 1-CH<sub>2</sub>-CH<sub>2</sub>-Ph minor rotamer), 51.5 (CH<sub>2</sub>, 1-CH<sub>2</sub>-CH<sub>2</sub>-Ph major rotamer), 79.6 [br C, C(CH<sub>3</sub>)<sub>3</sub>], 121.9 (CH, C5 minor rotamer), 122.6 (CH, C5 major rotamer), 126.8 (CH, Ph-C4 minor rotamer), 127.0 (CH, Ph-C4 major rotamer), 128.4 (CH), 128.5 (CH), 128.7 (CH) [Ph-C2(6), Ph-C3(5)], 136.8 (C, Ph-C1 minor rotamer), 136.9 (C, Ph-C1 major rotamer), 144.4 (br C, C4), 155.2 (C, NCOO minor rotamer), 155.7 (C, NCOO major rotamer); HRMS (ESI), calcd for (C<sub>17</sub>H<sub>24</sub>N<sub>4</sub>O<sub>2</sub> + H<sup>+</sup>) 317.1972, found 317.1979.

#### 4.1.17. N-[(1-Ethyl-1H-1,2,3-triazol-4-yl)methyl]-N-methylamine 25

To a solution of **17** (411 mg, 1.71 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (6 mL), H<sub>3</sub>PO<sub>4</sub> (85% purity, 2.96 mL, 25.7 mmol) was added. The reaction mixture was stirred at rt for 2 h, cooled to 0 °C, diluted with H<sub>2</sub>O (15 mL), alkalinized dropwise to pH = 14 with 5 N NaOH, and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 × 30 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and evaporated under reduced pressure to give amine **25** (205 mg, 86% yield) as a colorless oil; R<sub>f</sub> 0.07 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 9:1:0.05).

A solution of amine **25** (25 mg, 0.18 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (4 mL) was filtered through a PTFE filter (0.2 μm), treated with a HCl/MeOH solution (0.75 N, 0.71 mL, 0.53 mmol), and evaporated under reduced pressure. The resulting residue was washed with pentane (3 × 2 mL) to give, after drying under standard conditions, **25**·HCl (28 mg) as a beige sticky solid; IR (ATR) ν 3500–2500 (max at 3386, 3126, 3080, 3028, 2981, 2935, 2756, 2695, <sup>+</sup>N–H and C–H) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 1.55 (t, J = 7.2 Hz, 3H, 1-CH<sub>2</sub>-CH<sub>3</sub>), 2.76 (s, 3H, N-CH<sub>3</sub>), 4.35 (s, 2H, 4-CH<sub>2</sub>-N), 4.50 (q, J = 7.2 Hz, 2H, 1-CH<sub>2</sub>-CH<sub>3</sub>), 4.96 (s, <sup>+</sup>NH<sub>2</sub>), 8.22 (s, 1H, 5-H); <sup>13</sup>C NMR (100.6 MHz, CD<sub>3</sub>OD) δ 15.8 (CH<sub>3</sub>, 1-CH<sub>2</sub>-CH<sub>3</sub>), 33.1 (CH<sub>3</sub>, N-CH<sub>3</sub>), 44.2 (CH<sub>2</sub>, 4-CH<sub>2</sub>-N), 46.8 (CH<sub>2</sub>, 1-CH<sub>2</sub>-CH<sub>3</sub>), 126.2 (CH, C5), 139.3 (C, C4); HRMS (ESI), calcd for (C<sub>6</sub>H<sub>12</sub>N<sub>4</sub> + H<sup>+</sup>) 141.1135, found 141.1133.

#### 4.1.18. N-[2-(1-Ethyl-1H-1,2,3-triazol-4-yl)ethyl]-N-methylamine 26

It was prepared as described for **25**. From **18** (263 mg, 1.03 mmol) and H<sub>3</sub>PO<sub>4</sub> (85% purity, 1.80 mL, 15.6 mmol), and stirring at rt for 4 h, amine **26** (143 mg, 90% yield) was obtained as a colorless oil; R<sub>f</sub> 0.07 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 9:1:0.05).

**26**·HCl: beige sticky solid, IR (ATR) ν 3500–2400 (max at 3395, 3116, 3064, 2976, 2936, 2752, 2691, 2446, <sup>+</sup>N–H and C–H) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 1.54 (t, J = 7.2 Hz, 3H, 1-CH<sub>2</sub>-CH<sub>3</sub>), 2.76 (s, 3H, N-CH<sub>3</sub>), 3.17 (t, J = 7.2 Hz, 2H, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 3.37 (t, J = 7.2 Hz, 2H, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 4.48 (q, J = 7.2 Hz, 2H, 1-CH<sub>2</sub>-CH<sub>3</sub>), 4.87 (s, <sup>+</sup>NH<sub>2</sub>), 8.07 (s, 1H, 5-H); <sup>13</sup>C NMR (100.6 MHz, CD<sub>3</sub>OD) δ 15.6 (CH<sub>3</sub>, 1-CH<sub>2</sub>-CH<sub>3</sub>), 22.9 (CH<sub>2</sub>, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 33.7 (CH<sub>3</sub>, N-CH<sub>3</sub>), 47.1 (CH<sub>2</sub>, 1-CH<sub>2</sub>-CH<sub>3</sub>), 49.3 (CH<sub>2</sub>, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 124.6 (CH, C5), 143.3 (C, C4); HRMS (ESI), calcd for (C<sub>7</sub>H<sub>14</sub>N<sub>4</sub> + H<sup>+</sup>) 155.1291, found 155.1297.

#### 4.1.19. N-[2-(1-Benzyl-1H-1,2,3-triazol-4-yl)ethyl]-N-methylamine 27

It was prepared as described for **25**. From **19** (1.12 g, 3.54 mmol) and H<sub>3</sub>PO<sub>4</sub> (85% purity, 6.08 mL, 52.7 mmol), amine **27** (721 mg, 94% yield) was obtained as a yellow oil; R<sub>f</sub> 0.23 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 9.5:0.5:0.05).

**27**·HCl: beige solid, mp 189–190 °C; IR (ATR) ν 3600–2400 (max at 3554, 3064, 3013, 2927, 2868, 2735, 2685, 2447, C–H, <sup>+</sup>N–H and C–H) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 2.75 (s, 3H, N-CH<sub>3</sub>), 3.24 (t, J = 7.2 Hz, 2H, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 3.38 (t, J = 7.2 Hz, 2H, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 4.98 (s, <sup>+</sup>NH<sub>2</sub>), 5.72 (s, 2H, 1-CH<sub>2</sub>-Ph), 7.35–7.46 (complex signal, 5H, Ph-CH), 8.30 (s, 1H, 5-H); <sup>13</sup>C NMR (100.6 MHz, CD<sub>3</sub>OD) δ 22.4 (CH<sub>2</sub>, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 33.7 (CH<sub>3</sub>, N-CH<sub>3</sub>), 48.6 (CH<sub>2</sub>, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 56.5 (CH<sub>2</sub>, 1-CH<sub>2</sub>-Ph), 126.6 (CH, C5), 129.8 (2CH),

130.15 (CH), 130.20 (2CH) (Ph-CH), 135.3 (C, Ph-C1), 142.6 (C, C4); HRMS (ESI), calcd for (C<sub>12</sub>H<sub>16</sub>N<sub>4</sub> + H<sup>+</sup>) 217.1448, found 217.1442.

#### 4.1.20. N-Methyl-N-[2-(1-phenethyl-1H-1,2,3-triazol-4-yl)ethyl]amine 28

It was prepared as described for **25**. From **20** (693 mg, 2.10 mmol) and H<sub>3</sub>PO<sub>4</sub> (85% purity, 3.61 mL, 31.3 mmol), amine **28** (472 mg, 98% yield) was obtained as a yellow oil; R<sub>f</sub> 0.26 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 9.5:0.5:0.05).

**28**·HCl: beige solid, mp 160–162 °C; IR (ATR) ν 3500–2400 (max at 3413, 3354, 3126, 3092, 2954, 2783, 2703, 2444, <sup>+</sup>N–H and C–H) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 2.75 (s, 3H, N-CH<sub>3</sub>), 3.25 (t, J = 7.2 Hz, 2H, 1-CH<sub>2</sub>-CH<sub>2</sub>-Ph), overlapped in part 3.29 (t, J = 7.2 Hz, 2H, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 3.37 (t, J = 7.2 Hz, 2H, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 4.80 (t, J = 7.2 Hz, 2H, 1-CH<sub>2</sub>-CH<sub>2</sub>-Ph), 4.99 (s, <sup>+</sup>NH<sub>2</sub>), 7.18–7.30 (complex signal, 5H, Ph-CH), 8.30 (s, 1H, 5-H); <sup>13</sup>C NMR (100.6 MHz, CD<sub>3</sub>OD) δ 22.1 (CH<sub>2</sub>, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 33.8 (CH<sub>3</sub>, N-CH<sub>3</sub>), 36.7 (CH<sub>2</sub>, 1-CH<sub>2</sub>-CH<sub>2</sub>-Ph), 48.4 (CH<sub>2</sub>, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 54.6 (CH<sub>2</sub>, 1-CH<sub>2</sub>-CH<sub>2</sub>-Ph), 127.5 (CH, C5), 128.2 (CH), 129.8 (4CH) (Ph-CH), 137.9 (C, Ph-C1), 141.6 (C, C4); HRMS (ESI), calcd for (C<sub>13</sub>H<sub>18</sub>N<sub>4</sub> + H<sup>+</sup>) 231.1604; found 231.1604.

#### 4.1.21. N-[(1-Benzyl-1H-1,2,3-triazol-4-yl)methyl]-N-methylamine 29

It was prepared as described for **25**. From **23** (723 mg, 2.39 mmol) and H<sub>3</sub>PO<sub>4</sub> (85% purity, 4.14 mL, 35.9 mmol), amine **29** (420 mg, 87% yield) was obtained as a brown oil; R<sub>f</sub> 0.14 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 9.75:0.25:0.05).

**29**·HCl: yellow solid, mp 218–219 °C; IR (ATR) ν 3500–2400 (max at 3126, 3059, 3018, 2981, 2940, 2852, 2770, 2697, <sup>+</sup>N–H and C–H) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 2.74 (s, 3H, N-CH<sub>3</sub>), 4.33 (s, 2H, 4-CH<sub>2</sub>-N), 4.87 (s, <sup>+</sup>NH<sub>2</sub>), 5.64 (s, 2H, 1-CH<sub>2</sub>-Ph), 7.31–7.40 (complex signal, 5H, Ph-CH), 8.19 (s, 1H, 5-H); <sup>13</sup>C NMR (100.6 MHz, CD<sub>3</sub>OD) δ 33.1 (CH<sub>3</sub>, N-CH<sub>3</sub>), 44.2 (CH<sub>2</sub>, 4-CH<sub>2</sub>-N), 55.0 (CH<sub>2</sub>, 1-CH<sub>2</sub>-Ph), 126.5 (CH, C5), 129.3 (2CH), 129.7 (CH), 130.0 (2CH) (Ph-CH), 136.6 (C, Ph-C1), 139.8 (C, C4); HRMS (ESI), calcd for (C<sub>11</sub>H<sub>14</sub>N<sub>4</sub> + H<sup>+</sup>) 203.1291, found 203.1284.

#### 4.1.22. N-Methyl-N-[(1-phenethyl-1H-1,2,3-triazol-4-yl)methyl]amine 30

It was prepared as described for **25**. From **24** (983 mg, 3.11 mmol) and H<sub>3</sub>PO<sub>4</sub> (85% purity, 5.37 mL, 46.6 mmol), amine **30** (258 mg, 38% yield) was obtained as a colorless oil; R<sub>f</sub> 0.16 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 9.75:0.25:0.05).

**30**·HCl: yellow solid, mp 173–175 °C; IR (ATR) ν 3500–2400 (max at 3111, 3069, 3023, 2981, 2925, 2764, 2749, 2692, 2599, 2542, <sup>+</sup>N–H and C–H) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 2.67 (s, 3H, N-CH<sub>3</sub>), 3.24 (t, J = 7.2 Hz, 2H, 1CH<sub>2</sub>-CH<sub>2</sub>-Ph), 4.26 (s, 2H, 4-CH<sub>2</sub>-N), 4.71 (t, J = 7.2 Hz, 2H, 1-CH<sub>2</sub>-CH<sub>2</sub>-Ph), 4.87 (s, <sup>+</sup>NH<sub>2</sub>), 7.15 [dm, J = 8.4 Hz, 2H, Ph-C2(6)-H], 7.16–7.29 [complex signal, 3H, Ph-C3(5)-H, Ph-C4-H], 7.94 (s, 1H, 5-H); <sup>13</sup>C NMR (100.6 MHz, CD<sub>3</sub>OD) δ 32.9 (CH<sub>3</sub>, N-CH<sub>3</sub>), 37.3 (CH<sub>2</sub>, 1-CH<sub>2</sub>-CH<sub>2</sub>-Ph), 44.1 (CH<sub>2</sub>, 4-CH<sub>2</sub>-N), 52.7 (CH<sub>2</sub>, 1-CH<sub>2</sub>-CH<sub>2</sub>-Ph), 126.8 (CH, C5), 128.0 (CH), 129.7 (2CH), 129.8 (2CH) (Ph-CH), 138.6 (C, Ph-C1), 139.0 (C, C4); HRMS (ESI), calcd for (C<sub>12</sub>H<sub>16</sub>N<sub>4</sub> + H<sup>+</sup>) 217.1448, found 217.1443.

#### 4.1.23. N-[(1-Ethyl-1H-1,2,3-triazol-4-yl)methyl]-N-methyl-N-propargylamine 31

A solution of amine **25** (85 mg, 0.61 mmol) in anhydrous acetone (20 mL) was cooled to 0 °C and treated with Cs<sub>2</sub>CO<sub>3</sub> (199 mg, 0.61 mmol) and propargyl bromide (80% solution in toluene, 0.09 mL, 0.61 mmol). The reaction mixture was stirred at rt overnight, then filtered, and evaporated under reduced pressure to give an oily residue (161 mg), which was purified through

column chromatography (40–60  $\mu\text{m}$  silica gel,  $\text{CH}_2\text{Cl}_2/\text{MeOH}/50\%$  aq  $\text{NH}_4\text{OH}$  mixtures, gradient elution). On elution with  $\text{CH}_2\text{Cl}_2/\text{MeOH}/50\%$  aq  $\text{NH}_4\text{OH}$  98:2:0.2, propargylamine **31** (97 mg, 89% yield) was isolated as a colorless oil;  $R_f$  0.33 ( $\text{CH}_2\text{Cl}_2/\text{MeOH}/50\%$  aq  $\text{NH}_4\text{OH}$  9:1:0.05).

**31**·HCl: beige sticky solid, IR (ATR)  $\nu$  3500–2300 (max at 3412, 3205, 3126, 2987, 2941, 2568, 2477, 2381,  $^*\text{N}-\text{H}$ ,  $\equiv\text{C}-\text{H}$ , and  $\text{C}-\text{H}$ ), 2125 ( $\text{C}\equiv\text{C}$ )  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  1.56 (t,  $J = 7.6$  Hz, 3H, 1- $\text{CH}_2-\text{CH}_3$ ), 2.94 (s, 3H, N- $\text{CH}_3$ ), 3.39 (t,  $J = 2.4$  Hz, 1H, propargyl CH), 4.12 (d,  $J = 2.4$  Hz, 2H, propargyl  $\text{CH}_2$ ), 4.50 (q,  $J = 7.6$  Hz, 2H, 1- $\text{CH}_2-\text{CH}_3$ ), 4.54 (s, 2H, 4- $\text{CH}_2-\text{N}$ ), 4.87 (s,  $^*\text{NH}$ ), 8.26 (s, 1H, 5-H);  $^{13}\text{C}$  NMR (100.6 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  15.7 ( $\text{CH}_3$ , 1- $\text{CH}_2-\text{CH}_3$ ), 40.3 ( $\text{CH}_3$ , N- $\text{CH}_3$ ), 45.6 ( $\text{CH}_2$ , propargyl  $\text{CH}_2$ ), 46.8 ( $\text{CH}_2$ , 1- $\text{CH}_2-\text{CH}_3$ ), 50.4 ( $\text{CH}_2$ , 4- $\text{CH}_2-\text{N}$ ), 73.3 (C, propargyl C), 81.2 (CH, propargyl CH), 127.4 (CH, C5), 137.8 (C, C4); HRMS (ESI), calcd for ( $\text{C}_9\text{H}_{14}\text{N}_4 + \text{H}^+$ ) 179.1291, found 179.1289.

#### 4.1.24. *N*-[2-(1-Ethyl-1*H*-1,2,3-triazol-4-yl)ethyl]-*N*-methyl-*N*-propargylamine **32**

It was prepared as described for **31**. From amine **26** (299 mg, 1.94 mmol),  $\text{Cs}_2\text{CO}_3$  (630 mg, 1.93 mmol), and propargyl bromide (80% solution in toluene, 0.29 mL, 1.95 mmol), and stirring at 0  $^\circ\text{C}$  for 2.5 h, propargylamine **32** (220 mg, 59% yield) was obtained as a yellow oil, without the need of chromatographic purification;  $R_f$  0.55 ( $\text{CH}_2\text{Cl}_2/\text{MeOH}/50\%$  aq  $\text{NH}_4\text{OH}$  9:1:0.05).

**32**·HCl: yellow sticky solid, IR (ATR)  $\nu$  3500–2300 (max at 3417, 3191, 2937, 2521, 2434, 2359,  $^*\text{NH}$ ,  $\equiv\text{C}-\text{H}$ , and  $\text{C}-\text{H}$ ), 2121 ( $\text{C}\equiv\text{C}$ )  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  1.53 (t,  $J = 7.2$  Hz, 3H, 1- $\text{CH}_2-\text{CH}_3$ ), 3.05 (s, 3H, N- $\text{CH}_3$ ), 3.24 (t,  $J = 7.2$  Hz, 2H, 4- $\text{CH}_2-\text{CH}_2-\text{N}$ ), 3.41 (t,  $J = 2.8$  Hz, 1H, propargyl CH), 3.62 (br t,  $J = 7.2$  Hz, 2H, 4- $\text{CH}_2-\text{CH}_2-\text{N}$ ), 4.24 (d,  $J = 2.8$  Hz, 2H, propargyl  $\text{CH}_2$ ), 4.46 (q,  $J = 7.2$  Hz, 2H, 1- $\text{CH}_2-\text{CH}_3$ ), 4.86 (s,  $^*\text{NH}$ ), 8.01 (s, 1H, 5-H);  $^{13}\text{C}$  NMR (100.6 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  15.7 ( $\text{CH}_3$ , 1- $\text{CH}_2-\text{CH}_3$ ), 21.6 ( $\text{CH}_2$ , 4- $\text{CH}_2-\text{CH}_2-\text{N}$ ), 40.7 ( $\text{CH}_3$ , N- $\text{CH}_3$ ), 46.3 ( $\text{CH}_2$ , propargyl  $\text{CH}_2$ ), 46.8 ( $\text{CH}_2$ , 1- $\text{CH}_2-\text{CH}_3$ ), 55.4 ( $\text{CH}_2$ , 4- $\text{CH}_2-\text{CH}_2-\text{N}$ ), 72.6 (C, propargyl C), 81.6 (CH, propargyl CH), 124.2 (CH, C5), 143.1 (C, C4); HRMS (ESI), calcd for ( $\text{C}_{10}\text{H}_{16}\text{N}_4 + \text{H}^+$ ) 193.1448, found 193.1440.

#### 4.1.25. *N*-[2-(1-Benzyl-1*H*-1,2,3-triazol-4-yl)ethyl]-*N*-methyl-*N*-propargylamine **33**

It was prepared as described for **31**. From amine **27** (690 mg, 3.19 mmol),  $\text{Cs}_2\text{CO}_3$  (1.04 g, 3.19 mmol), and propargyl bromide (80% solution in toluene, 0.47 mL, 3.16 mmol), and stirring at rt for 2 h, propargylamine **33** (577 mg, 71% yield) was obtained as a yellow oil, without the need of chromatographic purification;  $R_f$  0.48 ( $\text{CH}_2\text{Cl}_2/\text{MeOH}/50\%$  aq  $\text{NH}_4\text{OH}$  9.5:0.5:0.05).

**33**·HCl: brown solid, mp 97–99  $^\circ\text{C}$ ; IR (ATR)  $\nu$  3500–2300 (max at 3413, 3194, 2948, 2522,  $^*\text{N}-\text{H}$ ,  $\equiv\text{C}-\text{H}$ , and  $\text{C}-\text{H}$ ), 2124 ( $\text{C}\equiv\text{C}$ )  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  3.03 (s, 3H, N- $\text{CH}_3$ ), 3.31 (t,  $J = 7.2$  Hz, 2H, 4- $\text{CH}_2-\text{CH}_2-\text{N}$ ), 3.39 (t,  $J = 2.4$  Hz, 1H, propargyl CH), 3.62 (m, 2H, 4- $\text{CH}_2-\text{CH}_2-\text{N}$ ), 4.23 (d,  $J = 2.4$  Hz, 2H, propargyl  $\text{CH}_2$ ), 5.00 (s,  $^*\text{NH}$ ), 5.68 (s, 2H, 1- $\text{CH}_2-\text{Ph}$ ), 7.33–7.43 (complex signal, 5H, Ph-CH), 8.23 (s, 1H, 5-H);  $^{13}\text{C}$  NMR (100.6 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  21.2 ( $\text{CH}_2$ , 4- $\text{CH}_2-\text{CH}_2-\text{N}$ ), 40.7 ( $\text{CH}_3$ , N- $\text{CH}_3$ ), 46.4 ( $\text{CH}_2$ , propargyl  $\text{CH}_2$ ), 54.8 ( $\text{CH}_2$ , 4- $\text{CH}_2-\text{CH}_2-\text{N}$ ), 56.1 ( $\text{CH}_2$ , 1- $\text{CH}_2-\text{Ph}$ ), 72.6 (C, propargyl C), 81.7 (CH, propargyl CH), 126.1 (CH, C5), 129.6 (2CH), 130.0 (CH), 130.1 (2CH) (Ph-CH), 135.6 (C, Ph-C1), 142.6 (C, C4); HRMS (ESI), calcd for ( $\text{C}_{15}\text{H}_{18}\text{N}_4 + \text{H}^+$ ) 255.1604, found 255.1607.

#### 4.1.26. *N*-Methyl-*N*-[2-(1-phenethyl-1*H*-1,2,3-triazol-4-yl)ethyl]-*N*-propargylamine **34**

It was prepared as described for **31**. From amine **28** (384 mg, 1.67 mmol),  $\text{Cs}_2\text{CO}_3$  (543 mg, 1.67 mmol), and propargyl bromide (80% solution in toluene, 0.25 mL, 1.68 mmol), and stirring at rt for 2 h, propargylamine **34** (295 mg, 66% yield) was obtained as a

yellow oil, without the need of chromatographic purification;  $R_f$  0.75 ( $\text{CH}_2\text{Cl}_2/\text{MeOH}/50\%$  aq  $\text{NH}_4\text{OH}$  9.5:0.5:0.05).

**34**·HCl: brown solid, mp 157–159  $^\circ\text{C}$ ; IR (ATR)  $\nu$  3500–2300 (max at 3471, 3369, 3203, 3094, 3059, 3023, 2925, 2842, 2584, 2532,  $^*\text{N}-\text{H}$ ,  $\equiv\text{C}-\text{H}$ , and  $\text{C}-\text{H}$ ), 2126 ( $\text{C}\equiv\text{C}$ )  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  3.03 (s, 3H, N- $\text{CH}_3$ ), 3.27 (t,  $J = 7.2$  Hz, 2H, 1- $\text{CH}_2-\text{CH}_2-\text{Ph}$ ), 3.32 (t,  $J = 7.2$  Hz, 2H, 4- $\text{CH}_2-\text{CH}_2-\text{N}$ ), 3.42 (t,  $J = 2.4$  Hz, 1H, propargyl CH), 3.61 (m, 2H, 4- $\text{CH}_2-\text{CH}_2-\text{N}$ ), 4.23 (d,  $J = 2.4$  Hz, 2H, propargyl  $\text{CH}_2$ ), 4.78 (t,  $J = 7.2$  Hz, 2H, 1- $\text{CH}_2-\text{CH}_2-\text{Ph}$ ), 4.98 (s,  $^*\text{NH}$ ), 7.16–7.30 (complex signal, 5H, Ph-CH), 8.22 (s, 1H, 5-H);  $^{13}\text{C}$  NMR (100.6 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  20.8 ( $\text{CH}_2$ , 4- $\text{CH}_2-\text{CH}_2-\text{N}$ ), 36.8 ( $\text{CH}_2$ , 1- $\text{CH}_2-\text{CH}_2-\text{Ph}$ ), 40.7 ( $\text{CH}_3$ , N- $\text{CH}_3$ ), 46.4 ( $\text{CH}_2$ , propargyl  $\text{CH}_2$ ), 54.3 ( $\text{CH}_2$ , 1- $\text{CH}_2-\text{CH}_2-\text{Ph}$ ), 54.6 ( $\text{CH}_2$ , 4- $\text{CH}_2-\text{CH}_2-\text{N}$ ), 72.6 (C, propargyl C), 81.8 (CH, propargyl CH), 127.1 (CH, C5), 128.2 (CH), 129.8 (4CH) (Ph-CH), 138.0 (C, Ph-C1), 141.5 (C, C4); HRMS (ESI), calcd for ( $\text{C}_{16}\text{H}_{20}\text{N}_4 + \text{H}^+$ ) 269.1761; found 269.1758.

#### 4.1.27. *N*-[(1-Benzyl-1*H*-1,2,3-triazol-4-yl)methyl]-*N*-methyl-*N*-propargylamine **35**

It was prepared as described for **31**. From amine **29** (420 mg, 2.08 mmol),  $\text{Cs}_2\text{CO}_3$  (676 mg, 2.07 mmol), and propargyl bromide (80% solution in toluene, 0.31 mL, 2.08 mmol), and stirring at rt for 3 h, an oily residue (451 mg) was obtained and subjected to purification through column chromatography (40–60  $\mu\text{m}$  silica gel,  $\text{CH}_2\text{Cl}_2/\text{MeOH}$  mixtures, gradient elution). On elution with  $\text{CH}_2\text{Cl}_2/\text{MeOH}$  98:2, propargylamine **35** (195 mg, 39% yield) was isolated as a colorless oil;  $R_f$  0.48 ( $\text{CH}_2\text{Cl}_2/\text{MeOH}$  9.75:0.25).

**35**·HCl: pale brown solid, mp 121–123  $^\circ\text{C}$ ; IR (ATR)  $\nu$  3500–2300 (max at 3193, 3126, 2976, 2961, 2692, 2578,  $^*\text{N}-\text{H}$ ,  $\equiv\text{C}-\text{H}$ , and  $\text{C}-\text{H}$ ), 2118 ( $\text{C}\equiv\text{C}$ )  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  2.96 (s, 3H, N- $\text{CH}_3$ ), 3.40 (t,  $J = 2.8$  Hz, 1H, propargyl CH), 4.15 (d,  $J = 2.8$  Hz, 2H, propargyl  $\text{CH}_2$ ), 4.57 (s, 2H, 4- $\text{CH}_2-\text{N}$ ), 4.86 (s,  $^*\text{NH}$ ), 5.66 (s, 2H, 1- $\text{CH}_2-\text{Ph}$ ), 7.32–7.41 (complex signal, 5H, Ph-CH), 8.27 (s, 1H, 5-H);  $^{13}\text{C}$  NMR (100.6 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  40.2 ( $\text{CH}_3$ , N- $\text{CH}_3$ ), 45.7 ( $\text{CH}_2$ , propargyl  $\text{CH}_2$ ), 50.3 ( $\text{CH}_2$ , 4- $\text{CH}_2-\text{N}$ ), 55.1 ( $\text{CH}_2$ , 1- $\text{CH}_2-\text{Ph}$ ), 72.9 (C, propargyl C), 81.6 (CH, propargyl CH), 128.1 (CH, C5), 129.3 (2CH), 129.7 (CH), 130.1 (2CH) (Ph-CH), 136.5 (C, Ph-C1), 137.9 (C, C4); HRMS (ESI), calcd for ( $\text{C}_{14}\text{H}_{16}\text{N}_4 + \text{H}^+$ ) 241.1448, found 241.1444.

#### 4.1.28. *N*-Methyl-*N*-[(1-phenethyl-1*H*-1,2,3-triazol-4-yl)methyl]-*N*-propargylamine **36**

It was prepared as described for **31**. From amine **30** (258 mg, 1.19 mmol),  $\text{Cs}_2\text{CO}_3$  (199 mg, 0.61 mmol), and propargyl bromide (80% solution in toluene, 0.17 mL, 1.14 mmol), and stirring at rt for 3 h, an oily residue (204 mg) was obtained and subjected to purification through column chromatography (40–60  $\mu\text{m}$  silica gel,  $\text{CH}_2\text{Cl}_2/\text{EtOAc}$  mixtures, gradient elution). On elution with  $\text{CH}_2\text{Cl}_2/\text{EtOAc}$  0:100, propargylamine **36** (63 mg, 22% yield) was isolated as a colorless oil;  $R_f$  0.26 (EtOAc).

**36**·HCl: beige sticky solid, IR (ATR)  $\nu$  3500–2300 (max at 3400, 3271, 3209, 3023, 2945, 2501,  $^*\text{N}-\text{H}$ ,  $\equiv\text{C}-\text{H}$ , and  $\text{C}-\text{H}$ ), 2124 ( $\text{C}\equiv\text{C}$ )  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  2.88 (s, 3H, N- $\text{CH}_3$ ), 3.25 (t,  $J = 7.2$  Hz, 2H, 1- $\text{CH}_2-\text{CH}_2-\text{Ph}$ ), 3.42 (t,  $J = 2.4$  Hz, 1H, propargyl CH), 4.02 (br s, 2H, propargyl  $\text{CH}_2$ ), 4.51 (s, 2H, 4- $\text{CH}_2-\text{N}$ ), 4.73 (t,  $J = 7.2$  Hz, 2H, 1- $\text{CH}_2-\text{CH}_2-\text{Ph}$ ), 4.90 (s,  $^*\text{NH}$ ), 7.14 [dm,  $J = 8.4$  Hz, 2H, Ph-C2(6)-H], 7.17–7.29 [complex signal, 3H, Ph-C3(5)-H, Ph-C4-H], 8.02 (s, 1H, 5-H);  $^{13}\text{C}$  NMR (100.6 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  37.3 ( $\text{CH}_2$ , 1- $\text{CH}_2-\text{CH}_2-\text{Ph}$ ), 40.1 ( $\text{CH}_3$ , N- $\text{CH}_3$ ), 45.5 ( $\text{CH}_2$ , propargyl  $\text{CH}_2$ ), 50.2 ( $\text{CH}_2$ , 4- $\text{CH}_2-\text{N}$ ), 52.8 ( $\text{CH}_2$ , 1- $\text{CH}_2-\text{CH}_2-\text{Ph}$ ), 72.8 (C, propargyl C), 81.7 (CH, propargyl CH), 128.0 (CH), 128.4 (CH) (C5, Ph-C4), 129.7 (2CH), 129.9 (2CH) [Ph-C2(6), Ph-C3(5)], 137.0 (C, Ph-C1), 138.6 (C, C4); HRMS (ESI), calcd for ( $\text{C}_{15}\text{H}_{18}\text{N}_4 + \text{H}^+$ ) 255.1604, found 255.1601.

**4.1.29. *N*-(*tert*-Butoxycarbonyl)-*N*-[(1-ethyl-5-methyl-1*H*-1,2,3-triazol-4-yl)methyl]-*N*-methylamine 37**

A solution of **17** (420 mg, 1.75 mmol) in anhydrous THF (30 mL) was cooled to  $-78^{\circ}\text{C}$  and then treated with *n*-BuLi (2.5 M solution in hexanes, 1.05 mL, 2.62 mmol) and iodomethane (0.43 mL, 980 mg, 6.91 mmol). The reaction mixture was stirred at  $-78^{\circ}\text{C}$  for 1 h, then warmed to rt and stirred an additional 2 h. The resulting solution was diluted with  $\text{H}_2\text{O}$  (20 mL) and extracted with  $\text{CH}_2\text{Cl}_2$  ( $2 \times 40$  mL). The combined organic extracts were dried over anhydrous  $\text{Na}_2\text{SO}_4$  and evaporated under reduced pressure. The resulting residue was washed with pentane ( $3 \times 10$  mL) and dried under vacuum, to give compound **37** (427 mg, 96% yield) as a colorless oil;  $R_f$  0.57 ( $\text{CH}_2\text{Cl}_2/\text{MeOH}$  9:1); IR (ATR)  $\nu$  1686 ( $\text{C}=\text{O}$ )  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  1.46 [s, 9H,  $\text{C}(\text{CH}_3)_3$ ], superimposed in part 1.47 (t,  $J = 7.6$  Hz, 3H, 1- $\text{CH}_2\text{-CH}_3$ ), 2.31 (s, 3H, 5- $\text{CH}_3$ ), 2.85 (s, 3H,  $\text{N-CH}_3$ ), 4.26 (q,  $J = 7.6$  Hz, 2H, 1- $\text{CH}_2\text{-CH}_3$ ), 4.48 (s, 2H, 4- $\text{CH}_2\text{-N}$ );  $^{13}\text{C}$  NMR (100.6 MHz,  $\text{CDCl}_3$ )  $\delta$  7.8 ( $\text{CH}_3$ , 5- $\text{CH}_3$ ), 15.2 ( $\text{CH}_3$ , 1- $\text{CH}_2\text{-CH}_3$ ), 28.5 [ $3\text{CH}_3$ ,  $\text{C}(\text{CH}_3)_3$ ], 34.0 ( $\text{CH}_3$ ,  $\text{N-CH}_3$ ), 42.7 ( $\text{CH}_2$ , 4- $\text{CH}_2\text{-N}$ ), 43.1 ( $\text{CH}_2$ , 1- $\text{CH}_2\text{-CH}_3$ ), 79.8 [C,  $\text{C}(\text{CH}_3)_3$ ], 130.5 (C, C5), 142.0 (C, C4), 156.0 (C, NCOO); HRMS (ESI), calcd for ( $\text{C}_{12}\text{H}_{22}\text{N}_4\text{O}_2 + \text{H}^+$ ) 255.1816, found 255.1811.

**4.1.30. *N*-(*tert*-Butoxycarbonyl)-*N*-[2-(1-ethyl-5-methyl-1*H*-1,2,3-triazol-4-yl)ethyl]-*N*-methylamine 38**

It was prepared as described for **37**. From **18** (942 mg, 3.71 mmol), *n*-BuLi (2.5 M solution in hexanes, 2.97 mL, 7.42 mmol) and iodomethane (0.92 mL, 2.10 g, 14.8 mmol), compound **38** (895 mg, 90% yield) was obtained as a colorless oil;  $R_f$  0.57 ( $\text{CH}_2\text{Cl}_2/\text{MeOH}$  9:1); IR (ATR)  $\nu$  1685 ( $\text{C}=\text{O}$ )  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  1.40 [s, 9H,  $\text{C}(\text{CH}_3)_3$ ], 1.44 (t,  $J = 7.6$  Hz, 3H, 1- $\text{CH}_2\text{-CH}_3$ ), 2.20 (s, 3H, 5- $\text{CH}_3$ ), 2.77 (s, 3H,  $\text{N-CH}_3$ ), 2.82 (m, 2H, 4- $\text{CH}_2\text{-CH}_2\text{-N}$ ), 3.43 (t,  $J = 7.2$  Hz, 4- $\text{CH}_2\text{-CH}_2\text{-N}$ ), 4.23 (q,  $J = 7.6$  Hz, 2H, 1- $\text{CH}_2\text{-CH}_3$ );  $^{13}\text{C}$  NMR (100.6 MHz,  $\text{CDCl}_3$ )  $\delta$  7.7 ( $\text{CH}_3$ , 5- $\text{CH}_3$ ), 15.3 ( $\text{CH}_3$ , 1- $\text{CH}_2\text{-CH}_3$ ), 23.7 (br  $\text{CH}_2$ ), 24.1 (br  $\text{CH}_2$ ) (4- $\text{CH}_2\text{-CH}_2\text{-N}$ ), 28.5 [ $3\text{CH}_3$ ,  $\text{C}(\text{CH}_3)_3$ ], 34.7 (br  $\text{CH}_3$ ), 35.0 (br  $\text{CH}_3$ ) ( $\text{N-CH}_3$ ), 43.0 ( $\text{CH}_2$ , 1- $\text{CH}_2\text{-CH}_3$ ), 48.7 (br  $\text{CH}_2$ ), 49.2 (br  $\text{CH}_2$ ) (4- $\text{CH}_2\text{-CH}_2\text{-N}$ ), 79.4 [C,  $\text{C}(\text{CH}_3)_3$ ], 129.2 (br C), 129.4 (br C) (C5), 142.2 (C, C4), 155.7 (C, NCOO); HRMS (ESI), calcd for ( $\text{C}_{13}\text{H}_{24}\text{N}_4\text{O}_2 + \text{H}^+$ ) 269.1972, found 269.1974.

**4.1.31. *N*-(*tert*-Butoxycarbonyl)-*N*-methyl-*N*-[2-[5-methyl-1-( $\alpha$ -methyl)benzyl-1*H*-1,2,3-triazol-4-yl]ethyl]amine 39**

It was prepared as described for **37**. From **19** (356 mg, 1.13 mmol), *n*-BuLi (2.5 M solution in hexanes, 0.90 mL, 2.25 mmol) and iodomethane (0.28 mL, 638 mg, 4.50 mmol), compound **39** (306 mg, 79% yield) was obtained as a yellowish oil; IR (ATR)  $\nu$  1686, 1681 ( $\text{C}=\text{O}$ )  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  1.41 [s, 9H,  $\text{C}(\text{CH}_3)_3$ ], 2.019 [d,  $J = 7.2$  Hz, 3H, 1- $\text{CH}(\text{CH}_3)\text{-Ph}$ ], 2.023 (s, 3H, 5- $\text{CH}_3$ ), 2.76 (s, 3H,  $\text{N-CH}_3$ ), 2.81 (m, 2H, 4- $\text{CH}_2\text{-CH}_2\text{-N}$ ), 3.47 (m, 2H, 4- $\text{CH}_2\text{-CH}_2\text{-N}$ ), 5.49 [q,  $J = 7.2$  Hz, 1H, 1- $\text{CH}(\text{CH}_3)\text{-Ph}$ ], 7.14 [br d,  $J = 7.2$  Hz,  $\text{Ph-C2(6)-H}$ ], 7.24–7.34 [complex signal, 3H,  $\text{Ph-C3(5)-H}$ ,  $\text{Ph-C4-H}$ ]; HRMS (ESI), calcd for ( $\text{C}_{19}\text{H}_{28}\text{N}_4\text{O}_2 + \text{H}^+$ ) 345.2285, found 345.2285.

**4.1.32. *N*-(*tert*-Butoxycarbonyl)-*N*-[(5-butyl-1-methyl-1*H*-1,2,3-triazol-4-yl)methyl]-*N*-methylamine 40**

It was prepared as described for **37**. From **21** (945 mg, 4.18 mmol), *n*-BuLi (2.5 M solution in hexanes, 3.36 mL, 8.40 mmol) and 1-bromobutane (1.81 mL, 2.31 g, 16.9 mmol), compound **40** (1.14 g, 97% yield) was obtained as a yellowish oil;  $R_f$  0.87 ( $\text{CH}_2\text{Cl}_2/\text{MeOH}/50\%$  aq  $\text{NH}_4\text{OH}$  9.5:0.5:0.05); IR (ATR)  $\nu$  1689 ( $\text{C}=\text{O}$ )  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  0.92 (t,  $J = 7.2$  Hz, 3H, 5- $\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-CH}_3$ ), 1.35 (tq,  $J = 7.2$  Hz, 2H, 5- $\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-CH}_3$ ), superimposed 1.40–1.52 (2H, 5- $\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-CH}_3$ ), 1.44 [s, 9H,  $\text{C}(\text{CH}_3)_3$ ], 2.69 (m, 2H, 5- $\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-CH}_3$ ),

2.81 (s, 3H,  $\text{N-CH}_3$ ), 3.93 (s, 3H, 1- $\text{CH}_3$ ), 4.49 (s, 2H, 4- $\text{CH}_2\text{-N}$ ); HRMS (ESI), calcd for ( $\text{C}_{14}\text{H}_{26}\text{N}_4\text{O}_2 + \text{H}^+$ ) 283.2129; found 283.2123.

**4.1.33. *N*-(*tert*-Butoxycarbonyl)-*N*-methyl-*N*-[2-(5-ethyl-1-phenyl-1*H*-1,2,3-triazol-4-yl)ethyl]amine 41**

It was prepared as described for **37**. From **22** (542 mg, 1.79 mmol), *n*-BuLi (2.5 M solution in hexanes, 1.43 mL, 3.57 mmol) and bromoethane (0.53 mL, 774 mg, 7.10 mmol), compound **41** (578 mg, 98% yield) was obtained as a yellowish oil;  $R_f$  0.86 ( $\text{CH}_2\text{Cl}_2/\text{MeOH}/50\%$  aq  $\text{NH}_4\text{OH}$  9:1:0.05); IR (ATR)  $\nu$  1688, 1683 ( $\text{C}=\text{O}$ )  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  1.05 (t,  $J = 7.6$  Hz, 3H, 5- $\text{CH}_2\text{-CH}_3$ ), 1.45 [s, 9H,  $\text{C}(\text{CH}_3)_3$ ], 2.70 (m, 2H, 5- $\text{CH}_2\text{-CH}_3$ ), 2.88 (s, 3H,  $\text{N-CH}_3$ ), 2.93 (m, 2H, 4- $\text{CH}_2\text{-CH}_2\text{-N}$ ), 3.58 (t,  $J = 7.6$  Hz, 2H, 4- $\text{CH}_2\text{-CH}_2\text{-N}$ ), 7.42 [ddm,  $J = 8.0$  Hz,  $J' = 2.4$  Hz, 2H,  $\text{Ph-C2(6)-H}$ ], 7.48–7.57 [complex signal, 3H,  $\text{Ph-C3(5)-H}$ ,  $\text{Ph-C4-H}$ ]; HRMS (ESI), calcd for ( $\text{C}_{18}\text{H}_{26}\text{N}_4\text{O}_2 + \text{H}^+$ ) 331.2129; found 331.2128.

**4.1.34. *N*-(*tert*-Butoxycarbonyl)-*N*-methyl-*N*-[2-(1-phenyl-5-propyl-1*H*-1,2,3-triazol-4-yl)ethyl]amine 42**

It was prepared as described for **37**. From **22** (577 mg, 1.91 mmol), *n*-BuLi (2.5 M solution in hexanes, 1.53 mL, 3.82 mmol) and 1-bromopropane (0.69 mL, 934 mg, 7.60 mmol), compound **42** (634 mg, 96% yield) was obtained as an orange oil;  $R_f$  0.84 ( $\text{CH}_2\text{Cl}_2/\text{MeOH}/50\%$  aq  $\text{NH}_4\text{OH}$  9:1:0.05); IR (ATR)  $\nu$  1692, 1682 ( $\text{C}=\text{O}$ )  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  0.82 (t,  $J = 7.6$  Hz, 3H, 5- $\text{CH}_2\text{-CH}_2\text{-CH}_3$ ), superimposed in part 1.42 (tt,  $J = J' = 7.6$  Hz, 2H, 5- $\text{CH}_2\text{-CH}_2\text{-CH}_3$ ), 1.46 [s, 9H,  $\text{C}(\text{CH}_3)_3$ ], 2.63 (m, 2H, 5- $\text{CH}_2\text{-CH}_2\text{-CH}_3$ ), 2.88 (s, 3H,  $\text{N-CH}_3$ ), 2.93 (m, 2H, 4- $\text{CH}_2\text{-CH}_2\text{-N}$ ), 3.59 (t,  $J = 7.2$  Hz, 2H, 4- $\text{CH}_2\text{-CH}_2\text{-N}$ ), 7.41 [ddm,  $J = 8.0$  Hz,  $J' = 2.4$  Hz, 2H,  $\text{Ph-C2(6)-H}$ ], 7.48–7.56 [complex signal, 3H,  $\text{Ph-C3(5)-H}$ ,  $\text{Ph-C4-H}$ ]; HRMS (ESI), calcd for ( $\text{C}_{19}\text{H}_{28}\text{N}_4\text{O}_2 + \text{H}^+$ ) 345.2285, found 345.2286.

**4.1.35. *N*-(*tert*-Butoxycarbonyl)-*N*-methyl-*N*-[2-(5-butyl-1-phenyl-1*H*-1,2,3-triazol-4-yl)ethyl]amine 43**

It was prepared as described for **37**. From **22** (590 mg, 1.95 mmol), *n*-BuLi (2.5 M solution in hexanes, 1.56 mL, 3.90 mmol) and 1-bromobutane (0.84 mL, 1.07 g, 7.82 mmol), an oily residue (678 mg) was obtained. After column chromatography purification of the residue (40–60  $\mu\text{m}$  silica gel,  $\text{CH}_2\text{Cl}_2/50\%$  aq  $\text{NH}_4\text{OH}$  100:0.2), compound **43** (300 mg, 43% yield) was isolated as a yellow oil;  $R_f$  0.82 ( $\text{CH}_2\text{Cl}_2/\text{MeOH}/50\%$  aq  $\text{NH}_4\text{OH}$  9:1:0.05); IR (ATR)  $\nu$  1692 ( $\text{C}=\text{O}$ )  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  0.79 (t,  $J = 7.2$  Hz, 3H, 5- $\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-CH}_3$ ), 1.21 (tq,  $J = J' = 7.2$  Hz, 2H, 5- $\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-CH}_3$ ), 1.35 (m, 2H, 5- $\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-CH}_3$ ), 1.45 [s, 9H,  $\text{C}(\text{CH}_3)_3$ ], 2.65 (m, 2H, 5- $\text{CH}_2\text{-CH}_2\text{-CH}_2\text{-CH}_3$ ), 2.87 (s, 3H,  $\text{N-CH}_3$ ), 2.91 (m, 2H, 4- $\text{CH}_2\text{-CH}_2\text{-N}$ ), 3.59 (t,  $J = 7.6$  Hz, 2H, 4- $\text{CH}_2\text{-CH}_2\text{-N}$ ), 7.41 [ddm,  $J = 8.0$  Hz,  $J' = 2.4$  Hz, 2H,  $\text{Ph-C2(6)-H}$ ], 7.47–7.56 [complex signal, 3H,  $\text{Ph-C3(5)-H}$ ,  $\text{Ph-C4-H}$ ]; HRMS (ESI), calcd for ( $\text{C}_{20}\text{H}_{30}\text{N}_4\text{O}_2 + \text{H}^+$ ) 359.2442, found 359.2438.

**4.1.36. *N*-[(1-Ethyl-5-methyl-1*H*-1,2,3-triazol-4-yl)methyl]-*N*-methylamine 44**

It was prepared as described for **25**. From **37** (370 mg, 1.46 mmol) and  $\text{H}_3\text{PO}_4$  (85% purity, 2.52 mL, 21.9 mmol), and stirring at rt for 4 h, amine **44** (205 mg, 91% yield) was obtained as a colorless oil;  $R_f$  0.11 ( $\text{CH}_2\text{Cl}_2/\text{MeOH}/50\%$  aq  $\text{NH}_4\text{OH}$  9:1:0.05).

**44-HCl**: beige sticky solid, IR (ATR)  $\nu$  3500–2400 (max at 3390, 2925, 2868, 2837, 2757, 2697, 2546, 2440, \* $\text{N-H}$  and  $\text{C-H}$ )  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  1.48 (t,  $J = 7.2$  Hz, 3H, 1- $\text{CH}_2\text{-CH}_3$ ), 2.41 (s, 3H, 5- $\text{CH}_3$ ), 2.76 (s, 3H,  $\text{N-CH}_3$ ), 4.28 (s, 2H, 4- $\text{CH}_2\text{-N}$ ), 4.38 (q,  $J = 7.2$  Hz, 2H, 1- $\text{CH}_2\text{-CH}_3$ ), 4.87 (s, \* $\text{NH}_2$ );  $^{13}\text{C}$  NMR (100.6 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  7.7 ( $\text{CH}_3$ , 5- $\text{CH}_3$ ), 15.2 ( $\text{CH}_3$ , 1- $\text{CH}_2\text{-CH}_3$ ), 33.1 ( $\text{CH}_3$ ,  $\text{N-CH}_3$ ), 43.6 ( $\text{CH}_2$ ), 44.4 ( $\text{CH}_2$ ) (1- $\text{CH}_2\text{-CH}_3$ , 4- $\text{CH}_2\text{-N}$ ),

134.7 (C, C5), 136.8 (C, C4); HRMS (ESI), calcd for (C<sub>7</sub>H<sub>14</sub>N<sub>4</sub> + H<sup>+</sup>) 155.1291, found 155.1288.

#### 4.1.37. N-[2-(1-Ethyl-5-methyl-1H-1,2,3-triazol-4-yl)ethyl]-N-methylamine 45

It was prepared as described for **25**. From **38** (890 mg, 3.32 mmol) and H<sub>3</sub>PO<sub>4</sub> (85% purity, 5.70 mL, 49.4 mmol), and stirring at rt for 1.5 h, amine **45** (495 mg, 89% yield) was obtained as a colorless oil; R<sub>f</sub> 0.10 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 9:1:0.05).

**45**-HCl: beige sticky solid, IR (ATR) ν 3500–2300 (max at 3374, 2981, 2937, 2746, 2692, 2449, 2359, <sup>+</sup>N–H and C–H) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 1.49 (t, J = 7.2 Hz, 3H, 1-CH<sub>2</sub>-CH<sub>3</sub>), 2.38 (s, 3H, 5-CH<sub>3</sub>), 2.76 (s, 3H, N-CH<sub>3</sub>), 3.09 (t, J = 7.2 Hz, 2H, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 3.34 (t, J = 7.2 Hz, 2H, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 4.40 (q, J = 7.2 Hz, 2H, 1-CH<sub>2</sub>-CH<sub>3</sub>), 4.86 (s, <sup>+</sup>NH<sub>2</sub>); <sup>13</sup>C NMR (100.6 MHz, CD<sub>3</sub>OD) δ 7.6 (CH<sub>3</sub>, 5-CH<sub>3</sub>), 15.0 (CH<sub>3</sub>, 1-CH<sub>2</sub>-CH<sub>3</sub>), 22.2 (CH<sub>2</sub>, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 33.7 (CH<sub>3</sub>, N-CH<sub>3</sub>), 44.9 (CH<sub>2</sub>, 1-CH<sub>2</sub>-CH<sub>3</sub>), 49.0 (4-CH<sub>2</sub>-CH<sub>2</sub>-N), 133.4 (C, C5), 140.1 (C, C4); HRMS (ESI), calcd for (C<sub>8</sub>H<sub>16</sub>N<sub>4</sub> + H<sup>+</sup>) 169.1448, found 169.1452.

#### 4.1.38. N-Methyl-N-[2-[5-methyl-1-(α-methyl)benzyl-1H-1,2,3-triazol-4-yl]ethyl]amine 46

It was prepared as described for **25**. From **39** (306 mg, 0.89 mmol) and H<sub>3</sub>PO<sub>4</sub> (85% purity, 1.60 mL, 13.9 mmol), amine **46** (215 mg, quantitative yield) was obtained as a yellow oil; R<sub>f</sub> 0.33 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 9:1:0.05).

**46**-HCl: yellow sticky solid, IR (ATR) ν 3400–2400 (max at 3373, 2950, 2709, 2434, <sup>+</sup>N–H and C–H) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 2.01 [d, J = 7.2 Hz, 3H, 1-CH(CH<sub>3</sub>)-Ph], 2.30 (s, 3H, 5-CH<sub>3</sub>), 2.76 (s, 3H, N-CH<sub>3</sub>), 3.19 (t, J = 7.2 Hz, 2H, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 3.36 (t, J = 7.2 Hz, 2H, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 4.94 (s, <sup>+</sup>NH<sub>2</sub>), 5.93 (q, J = 7.2 Hz, 1H, 1-CH(CH<sub>3</sub>)-Ph), 7.30 [dm, J = 8.4 Hz, 2H, Ph-C2(6)-H], 7.36–7.42 [complex signal, 3H, Ph-C3(5)-H, Ph-C4-H]; <sup>13</sup>C NMR (100.6 MHz, CD<sub>3</sub>OD) δ 8.2 (CH<sub>3</sub>, 5-CH<sub>3</sub>), 21.7 [CH<sub>3</sub>, 1-CH(CH<sub>3</sub>)-Ph], 21.9 (CH<sub>2</sub>, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 33.7 (CH<sub>3</sub>, N-CH<sub>3</sub>), 53.8 (CH<sub>2</sub>, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 61.5 [CH, 1-CH(CH<sub>3</sub>)-Ph], 127.5 (2CH), 129.7 (CH), 130.2 (2CH) (Ph-CH), 135.6 (C, Ph-C1), 139.3 (C, C5), 140.5 (C, C4); HRMS (ESI), calcd for (C<sub>14</sub>H<sub>20</sub>N<sub>4</sub> + H<sup>+</sup>) 245.1761, found 245.1762.

#### 4.1.39. N-[(5-Butyl-1-methyl-1H-1,2,3-triazol-4-yl)methyl]-N-methylamine 47

It was prepared as described for **25**. From **40** (954 mg, 3.38 mmol) and H<sub>3</sub>PO<sub>4</sub> (85% purity, 5.84 mL, 50.7 mmol), amine **47** (620 mg, quantitative yield) was obtained as a yellow oil; R<sub>f</sub> 0.06 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 9.5:0.5:0.05).

**47**-HCl: beige sticky solid, IR (ATR) ν 3400–2500 (max at 3372, 2957, 2930, 2863, 2711, <sup>+</sup>N–H and C–H) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 0.97 (t, J = 7.2 Hz, 3H, 5-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>3</sub>), 1.42 (tq, J = J' = 7.2 Hz, 2H, 5-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>3</sub>), 1.58 (tt, J = 7.6 Hz, J' = 7.2 Hz, 2H, 5-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>3</sub>), 2.79 (s, 3H, N-CH<sub>3</sub>), 2.87 (t, J = 7.6 Hz, 2H, 5-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>3</sub>), 4.05 (s, 3H, 1-CH<sub>3</sub>), 4.31 (s, 2H, 4-CH<sub>2</sub>-N), 5.06 (s, <sup>+</sup>NH<sub>2</sub>); <sup>13</sup>C NMR (100.6 MHz, CD<sub>3</sub>OD) δ 14.0 (CH<sub>3</sub>, 5-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>3</sub>), 22.9 (CH<sub>2</sub>), 23.4 (CH<sub>2</sub>) (5-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>3</sub>), 31.6 (CH<sub>2</sub>, 5-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>3</sub>), 33.3 (CH<sub>3</sub>, N-CH<sub>3</sub>), 35.5 (CH<sub>3</sub>, 1-CH<sub>3</sub>), 43.5 (CH<sub>2</sub>, 4-CH<sub>2</sub>-N), 136.5 (C, C5), 139.3 (C, C4); HRMS (ESI), calcd for (C<sub>9</sub>H<sub>18</sub>N<sub>4</sub> + H<sup>+</sup>) 183.1604, found 183.1599.

#### 4.1.40. N-Methyl-N-[2-(5-ethyl-1-phenyl-1H-1,2,3-triazol-4-yl)ethyl]amine 48

It was prepared as described for **25**. From **41** (517 mg, 1.57 mmol) and H<sub>3</sub>PO<sub>4</sub> (85% purity, 2.68 mL, 23.2 mmol), and stirring at rt for 3 h, an orange oil (435 mg) was obtained and purified

through column chromatography (40–60 μm silica gel, CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH mixtures, gradient elution). On elution with CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 98:2:0.2 to 96:4:0.2, amine **48** (322 mg, 89% yield) was obtained as a yellowish oil; R<sub>f</sub> 0.51 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 9:1:0.05).

**48**-HCl: yellow sticky solid, IR (ATR) ν 3400–2300 (max at 3380, 2964, 2930, 2873, 2741, 2434, 2351, <sup>+</sup>N–H and C–H) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 1.05 (t, J = 7.6 Hz, 3H, 5-CH<sub>2</sub>-CH<sub>3</sub>), superimposed in part 2.80 (q, J = 7.6 Hz, 2H, 5-CH<sub>2</sub>-CH<sub>3</sub>), 2.81 (s, 3H, N-CH<sub>3</sub>), 3.20 (t, J = 7.2 Hz, 2H, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 3.45 (t, J = 7.2 Hz, 2H, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 4.89 (s, <sup>+</sup>NH<sub>2</sub>), 7.53 [ddm, J = 7.6 Hz, J' = 2.0 Hz, 2H, Ph-C2(6)-H], 7.62–7.67 [complex signal, 3H, Ph-C3(5)-H, Ph-C4-H]; <sup>13</sup>C NMR (100.6 MHz, CD<sub>3</sub>OD) δ 13.4 (CH<sub>3</sub>, 5-CH<sub>2</sub>-CH<sub>3</sub>), 16.9 (CH<sub>2</sub>, 5-CH<sub>2</sub>-CH<sub>3</sub>), 22.5 (CH<sub>2</sub>, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 33.9 (CH<sub>3</sub>, N-CH<sub>3</sub>), 49.3 (CH<sub>2</sub>, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 126.8 (2CH), 130.9 (2CH), 131.4 (CH) (Ph-CH), 137.5 (C, Ph-C1), 139.1 (C, C5), 140.5 (C, C4); HRMS (ESI), calcd for (C<sub>13</sub>H<sub>18</sub>N<sub>4</sub> + H<sup>+</sup>) 231.1604; found 231.1607.

#### 4.1.41. N-Methyl-N-[2-(1-phenyl-5-propyl-1H-1,2,3-triazol-4-yl)ethyl]amine 49

It was prepared as described for **25**. From **42** (573 mg, 1.66 mmol) and H<sub>3</sub>PO<sub>4</sub> (85% purity, 2.85 mL, 24.7 mmol), and stirring at rt for 3 h, an orange oil (564 mg) was obtained and purified through column chromatography (40–60 μm silica gel, CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH mixtures, gradient elution). On elution with CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 99:1:0.2 to 95:5:0.2, amine **49** (270 mg, 67% yield) was obtained as a yellowish oil; R<sub>f</sub> 0.52 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 9:1:0.05).

**49**-HCl: yellow sticky solid, IR (ATR) ν 3400–2400 (max at 3350, 2960, 2935, 2863, 2721, 2430, <sup>+</sup>N–H and C–H) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 0.81 (t, J = 7.6 Hz, 3H, 5-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>3</sub>), 1.42 (tq, J = J' = 7.6 Hz, 2H 5-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>3</sub>), 2.74 (t, J = 7.6 Hz, 2H, 5-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>3</sub>), 2.80 (s, 3H, N-CH<sub>3</sub>), 3.16 (t, J = 7.2 Hz, 2H, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 3.43 (t, J = 7.2 Hz, 2H, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 4.85 (s, <sup>+</sup>NH<sub>2</sub>), 7.48–7.65 (complex signal, 5H, Ph-CH); <sup>13</sup>C NMR (100.6 MHz, CD<sub>3</sub>OD) δ 13.9 (CH<sub>3</sub>, 5-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>3</sub>), 22.6 (CH<sub>2</sub>, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 22.9 (CH<sub>2</sub>, 5-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>3</sub>), 25.2 (CH<sub>2</sub>, 5-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>3</sub>), 33.8 (CH<sub>3</sub>, N-CH<sub>3</sub>), 49.4 (CH<sub>2</sub>, 4-CH<sub>2</sub>-CH<sub>2</sub>-N) 126.8 (2CH), 130.9 (2CH), 131.3 (CH) (Ph-CH), 137.4 (C, Ph-C1), 137.7 (C, C5), 141.3 (C, C4); HRMS (ESI), calcd for (C<sub>14</sub>H<sub>20</sub>N<sub>4</sub> + H<sup>+</sup>) 245.1761, found 245.1761.

#### 4.1.42. N-Methyl-N-[2-(5-butyl-1-phenyl-1H-1,2,3-triazol-4-yl)ethyl]amine 50

It was prepared as described for **25**. From **43** (265 mg, 0.74 mmol) and H<sub>3</sub>PO<sub>4</sub> (85% purity, 1.27 mL, 11.0 mmol), and stirring at rt for 3 h, amine **50** (175 mg, 92% yield) was obtained as a yellowish oil; R<sub>f</sub> 0.54 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 9:1:0.05).

**50**-HCl: yellow oil, IR (ATR) ν 3400–2400 (max at 3389, 2954, 2919, 2868, 2755, 2444, <sup>+</sup>N–H and C–H) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 0.80 (t, J = 7.6 Hz, 3H, 5-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>3</sub>), 1.22 (tq, J = J' = 7.6 Hz, 2H, 5-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>3</sub>), 1.38 (tt, J = J' = 7.6 Hz, 2H, 5-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>3</sub>), 2.77 (t, J = 7.6 Hz, 2H, 5-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>3</sub>), 2.81 (s, 3H, N-CH<sub>3</sub>), 3.15 (t, J = 7.2 Hz, 2H, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 3.44 (t, J = 7.2 Hz, 2H, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 4.85 (s, <sup>+</sup>NH<sub>2</sub>), 7.51 [dm, J = 8.0 Hz, 2H, Ph-C2(6)-H], 7.61–7.66 [complex signal, 3H, Ph-C3(5)-H, Ph-C4-H]; <sup>13</sup>C NMR (100.6 MHz, CD<sub>3</sub>OD) δ 13.8 (CH<sub>3</sub>, 5-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>3</sub>), 22.6 (CH<sub>2</sub>, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 23.0 (CH<sub>2</sub>), 23.2 (CH<sub>2</sub>) (5-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>3</sub>), 31.6 (CH<sub>2</sub>, 5-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>3</sub>), 33.8 (CH<sub>3</sub>, N-CH<sub>3</sub>), 49.4 (CH<sub>2</sub>, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 126.8 (2CH), 130.9 (2CH), 131.3 (CH) (Ph-CH), 137.5 (C, Ph-C1), 137.7 (C, C5), 141.2 (C, C4); HRMS (ESI), calcd for (C<sub>15</sub>H<sub>22</sub>N<sub>4</sub> + H<sup>+</sup>) 259.1917, found 259.1922.

#### 4.1.43. *N*-[(1-Ethyl-5-methyl-1*H*-1,2,3-triazol-4-yl)methyl]-*N*-methyl-*N*-propargylamine **51**

It was prepared as described for **31**. From amine **44** (128 mg, 0.83 mmol), Cs<sub>2</sub>CO<sub>3</sub> (270 mg, 0.83 mmol), and propargyl bromide (80% solution in toluene, 0.12 mL, 0.81 mmol), and stirring at 0 °C for 2 h, propargylamine **51** (96 mg, 62% yield) was obtained as a yellow oil, without the need of chromatographic purification; *R*<sub>f</sub> 0.43 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 9:1:0.05).

**51**·HCl: yellow sticky solid, IR (ATR)  $\nu$  3500–2300 (max at 3386, 3197, 2938, 2496, 2352, \*N–H,  $\equiv$ C–H, and C–H), 2123 (C $\equiv$ C) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD)  $\delta$  1.50 (t, *J* = 7.2 Hz, 3H, 1-CH<sub>2</sub>-CH<sub>3</sub>), 2.45 (s, 3H, 5-CH<sub>3</sub>), 3.00 (s, 3H, N-CH<sub>3</sub>), 3.44 (t, *J* = 2.4 Hz, 1H, propargyl CH), 4.17 (d, *J* = 2.4 Hz, 2H, propargyl CH<sub>2</sub>), 4.39 (q, *J* = 7.2 Hz, 2H, 1-CH<sub>2</sub>-CH<sub>3</sub>), 4.52 (s, 2H, 4-CH<sub>2</sub>-N), 4.84 (s, \*NH); <sup>13</sup>C NMR (100.6 MHz, CD<sub>3</sub>OD)  $\delta$  8.0 (CH<sub>3</sub>, 5-CH<sub>3</sub>), 15.2 (CH<sub>3</sub>, 1-CH<sub>2</sub>-CH<sub>3</sub>), 40.3 (CH<sub>3</sub>, N-CH<sub>3</sub>), 44.5 (CH<sub>2</sub>, 1-CH<sub>2</sub>-CH<sub>3</sub>), 45.6 (CH<sub>2</sub>, propargyl CH<sub>2</sub>), 49.8 (CH<sub>2</sub>, 4-CH<sub>2</sub>-N), 73.1 (C, propargyl C), 81.5 (CH, propargyl CH), 135.1 (C, C5), 136.3 (C, C4); HRMS (ESI), calcd for (C<sub>10</sub>H<sub>16</sub>N<sub>4</sub> + H<sup>+</sup>) 193.1448, found 193.1450.

Note: From amine **44** (117 mg, 0.76 mmol), Cs<sub>2</sub>CO<sub>3</sub> (362 mg, 1.11 mmol), and propargyl bromide (80% solution in toluene, 0.16 mL, 1.08 mmol), and stirring at rt overnight, an oily residue was obtained and purified through column chromatography (40–60  $\mu$ m silica gel, CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH mixtures, gradient elution). On elution with CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 99:1:0.2 to 98:2:0.2, propargylamine **51** (15 mg, 10% yield) was isolated as a colorless oil. On elution with CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 98:2:0.2, slightly impure *N*-[(1-ethyl-5-methyl-1*H*-1,2,3-triazol-4-yl)methyl]-*N*-methyl-*N,N*-dipropargylammonium bromide (223 mg) was isolated as a brown oil; *R*<sub>f</sub> 0.04 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 9:1:0.05).

A solution of the dipropargylated byproduct (223 mg) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) was filtered through a PTFE filter (0.2  $\mu$ m) and evaporated under reduced pressure. The resulting residue was washed with pentane (3  $\times$  2 mL) to give, after drying under standard conditions, the analytical sample of the dipropargylated byproduct (213 mg) as a brownish oil; IR (ATR)  $\nu$  3207 ( $\equiv$ C–H), 2124 (C $\equiv$ C st) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  1.53 (t, *J* = 7.6 Hz, 3H, 1-CH<sub>2</sub>-CH<sub>3</sub>), 2.73 (s, 3H, 5-CH<sub>3</sub>), 2.85 (t, *J* = 2.4 Hz, 2H, 2 propargyl CH), 3.42 (s, 3H, N-CH<sub>3</sub>), 4.34 (q, *J* = 7.6 Hz, 2H, 1-CH<sub>2</sub>-CH<sub>3</sub>), 4.83 (dd, *J* = 16.0 Hz, *J'* = 2.4 Hz, 2H), 4.91 (dd, *J* = 16.0 Hz, *J'* = 2.4 Hz, 2H) (2 propargyl CH<sub>2</sub>), 5.34 (s, 2H, 4-CH<sub>2</sub>-N); <sup>13</sup>C NMR (100.6 MHz, CDCl<sub>3</sub>)  $\delta$  8.8 (CH<sub>3</sub>, 5-CH<sub>3</sub>), 14.8 (CH<sub>3</sub>, 1-CH<sub>2</sub>-CH<sub>3</sub>), 43.6 (CH<sub>2</sub>, 1-CH<sub>2</sub>-CH<sub>3</sub>), 47.2 (CH<sub>3</sub>, N-CH<sub>3</sub>), 51.8 (2CH<sub>2</sub>, 2 propargyl CH<sub>2</sub>), 55.7 (CH<sub>2</sub>, 4-CH<sub>2</sub>-N), 70.9 (2C, 2 propargyl C), 82.2 (2CH, 2 propargyl CH), 132.5 (C, C5), 136.5 (C, C4); HRMS (ESI), calcd for (C<sub>13</sub>H<sub>19</sub>N<sub>4</sub>) 231.1604, found 231.1613.

#### 4.1.44. *N*-[2-(1-Ethyl-5-methyl-1*H*-1,2,3-triazol-4-yl)ethyl]-*N*-methyl-*N*-propargylamine **52**

It was prepared as described for **31**. From amine **45** (490 mg, 2.91 mmol), Cs<sub>2</sub>CO<sub>3</sub> (952 mg, 2.92 mmol), and propargyl bromide (80% solution in toluene, 0.43 mL, 2.89 mmol), and stirring at 0 °C for 2.5 h, propargylamine **52** (319 mg, 54% yield) was obtained as a yellow oil, without the need of chromatographic purification; *R*<sub>f</sub> 0.59 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 9:1:0.05).

**52**·HCl: yellow sticky solid, IR (ATR)  $\nu$  3500–2300 (max at 3406, 3181, 2981, 2932, 2583, 2518, 2461, 2408, 2366, \*N–H,  $\equiv$ C–H, and C–H), 2123 (C $\equiv$ C) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD)  $\delta$  1.56 (t, *J* = 7.2 Hz, 3H, 1-CH<sub>2</sub>-CH<sub>3</sub>), 2.50 (s, 3H, 5-CH<sub>3</sub>), 3.08 (s, 3H, N-CH<sub>3</sub>), 3.35 (t, *J* = 7.6 Hz, 2H, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 3.45 (t, *J* = 2.8 Hz, 1H, propargyl CH), 3.63 (t, *J* = 7.6 Hz, 2H, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 4.28 (d, *J* = 2.8 Hz, 2H, propargyl CH<sub>2</sub>), 4.51 (q, *J* = 7.2 Hz, 2H, 1-CH<sub>2</sub>-CH<sub>3</sub>), 4.94 (s, \*NH); <sup>13</sup>C NMR (100.6 MHz, CD<sub>3</sub>OD)  $\delta$  8.0 (CH<sub>3</sub>, 5-CH<sub>3</sub>), 14.4 (CH<sub>3</sub>, 1-CH<sub>2</sub>-CH<sub>3</sub>), 20.0 (CH<sub>2</sub>, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 40.7 (CH<sub>3</sub>, N-CH<sub>3</sub>), 46.3 (CH<sub>2</sub>, propargyl CH<sub>2</sub>), 46.4 (CH<sub>2</sub>, 1-CH<sub>2</sub>-CH<sub>3</sub>), 54.0

(CH<sub>2</sub>, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 72.5 (C, propargyl C), 81.9 (CH, propargyl CH), 136.3 (C, C5), 137.8 (C, C4); HRMS (ESI), calcd for (C<sub>11</sub>H<sub>18</sub>N<sub>4</sub> + H<sup>+</sup>) 207.1604, found 207.1609.

#### 4.1.45. *N*-Methyl-*N*-{2-[5-methyl-1-( $\alpha$ -methyl)benzyl-1*H*-1,2,3-triazol-4-yl]ethyl}-*N*-propargylamine **53**

It was prepared as described for **31**. From amine **46** (234 mg, 0.93 mmol), Cs<sub>2</sub>CO<sub>3</sub> (0.30 g, 0.92 mmol), and propargyl bromide (80% solution in toluene, 0.10 mL, 0.67 mmol), and stirring at 0 °C for 30 min and at rt for an additional 3 h, an orange oily residue (263 mg) was obtained and purified through column chromatography (40–60  $\mu$ m silica gel, CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH mixtures, gradient elution). On elution with CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 99.97:0.03:0.2, propargylamine **53** (100 mg, 53% yield) was obtained as a yellow oil; *R*<sub>f</sub> 0.45 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 9:1:0.05).

**53**·HCl: beige sticky solid, IR (ATR)  $\nu$  3400–2300 (max at 3386, 3209, 2936, 2351, \*N–H,  $\equiv$ C–H, and C–H), 2118 (C $\equiv$ C) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD)  $\delta$  2.01 [d, *J* = 6.8 Hz, 3H, 1-CH(CH<sub>3</sub>)-Ph], 2.26 (s, 3H, 5-CH<sub>3</sub>), 3.06 (s, 3H, N-CH<sub>3</sub>), 3.22 (t, *J* = 8.0 Hz, 2H, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 3.42 (t, *J* = 2.4 Hz, 1H, propargyl CH), 3.59 (t, *J* = 8.0 Hz, 2H, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 4.25 (d, *J* = 2.4 Hz, 2H, propargyl CH<sub>2</sub>), 4.89 (s, \*NH), 5.86 [q, *J* = 6.8 Hz, 1H, 1-CH(CH<sub>3</sub>)-Ph], 7.24–7.40 (complex signal, 5H, Ph-CH); <sup>13</sup>C NMR (100.6 MHz, CD<sub>3</sub>OD)  $\delta$  8.1 (CH<sub>3</sub>, 5-CH<sub>3</sub>), 20.5 (CH<sub>2</sub>, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 22.0 [CH<sub>3</sub>, 1-CH(CH<sub>3</sub>)-Ph], 40.7 (CH<sub>3</sub>, N-CH<sub>3</sub>), 46.3 (CH<sub>2</sub>, propargyl CH<sub>2</sub>), 54.7 (CH<sub>2</sub>, 4-CH<sub>2</sub>-CH<sub>2</sub>-N), 61.0 [CH, 1-CH(CH<sub>3</sub>)-Ph], 72.6 (C, propargyl C), 81.7 (CH, propargyl CH), 127.4 (2CH), 129.6 (CH), 130.2 (2CH) (Ph-CH), 134.5 (C, Ph-C1), 139.6 (C, C5), 141.1 (C, C4); HRMS (ESI), calcd for (C<sub>17</sub>H<sub>22</sub>N<sub>4</sub> + H<sup>+</sup>) 283.1917, found 283.1923.

#### 4.1.46. *N*-[(5-Butyl-1-methyl-1*H*-1,2,3-triazol-4-yl)methyl]-*N*-methyl-*N*-propargylamine **54**

It was prepared as described for **31**. From amine **47** (529 mg, 2.90 mmol), Cs<sub>2</sub>CO<sub>3</sub> (946 mg, 2.90 mmol), and propargyl bromide (80% solution in toluene, 0.44 mL, 2.96 mmol), and stirring at rt for 3.5 h, propargylamine **54** (418 mg, 65% yield) was obtained as a yellow oil, without the need of chromatographic purification; *R*<sub>f</sub> 0.29 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 9.5:0.5:0.05).

**54**·HCl: brown sticky solid, IR (ATR)  $\nu$  3500–2400 (max at 3411, 3219, 2955, 2930, 2863, 2491, \*N–H,  $\equiv$ C–H, and C–H), 2121 (C $\equiv$ C) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD)  $\delta$  0.98 (t, *J* = 7.6 Hz, 3H, 5-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>3</sub>), 1.43 (tq, *J* = *J'* = 7.6 Hz, 2H, 5-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>3</sub>), 1.59 (tt, *J* = *J'* = 7.6 Hz, 2H, 5-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>3</sub>), 2.88 (t, *J* = 7.6 Hz, 2H, 5-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>3</sub>), 3.03 (s, 3H, N-CH<sub>3</sub>), 3.47 (t, *J* = 2.4 Hz, 1H, propargyl CH), 4.06 (s, 3H, 1-CH<sub>3</sub>), 4.22 (d, *J* = 2.4 Hz, 2H, propargyl CH<sub>2</sub>), 4.55 (s, 2H, 4-CH<sub>2</sub>-N), 4.92 (s, \*NH); <sup>13</sup>C NMR (100.6 MHz, CD<sub>3</sub>OD)  $\delta$  14.1 (CH<sub>3</sub>, 5-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>3</sub>), 23.0 (CH<sub>2</sub>), 23.4 (CH<sub>2</sub>) (5-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>3</sub>), 31.6 (CH<sub>2</sub>, 5-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>3</sub>), 35.5 (CH<sub>3</sub>, 1-CH<sub>3</sub>), 40.5 (CH<sub>3</sub>, N-CH<sub>3</sub>), 45.6 (CH<sub>2</sub>, propargyl CH<sub>2</sub>), 49.5 (CH<sub>2</sub>, 4-CH<sub>2</sub>-N), 73.2 (C, propargyl C), 81.6 (CH, propargyl CH), 134.9 (C, C5), 140.5 (C, C4); HRMS (ESI), calcd for (C<sub>12</sub>H<sub>20</sub>N<sub>4</sub> + H<sup>+</sup>) 221.1761, found 221.1762.

#### 4.1.47. *N*-Methyl-*N*-[2-(5-ethyl-1-phenyl-1*H*-1,2,3-triazol-4-yl)ethyl]-*N*-propargylamine **55**

It was prepared as described for **31**. From amine **48** (260 mg, 1.13 mmol), Cs<sub>2</sub>CO<sub>3</sub> (0.37 g, 1.14 mmol), and propargyl bromide (80% solution in toluene, 0.13 mL, 0.87 mmol), and stirring at 0 °C for 30 min and at rt for an additional 3 h, an orange oil (333 mg) was obtained and purified through column chromatography (40–60  $\mu$ m silica gel, CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH mixtures, gradient elution). On elution with CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 99.9:0.1:0.2, propargylamine **55** (222 mg, 95% yield) was obtained as a yellow oil; *R*<sub>f</sub> 0.59 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 9:1:0.05).

**55-HCl**: yellow sticky solid, IR (ATR)  $\nu$  3400–2300 (max at 3395, 3193, 3059, 2958, 2925, 2573, 2518, 2459, 2397,  $\nu$  N–H,  $\equiv$ C–H, and C–H), 2123 (C $\equiv$ C)  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  1.06 (t,  $J = 7.6$  Hz, 3H, 5- $\text{CH}_2$ - $\text{CH}_3$ ), 2.81 (q,  $J = 7.6$  Hz, 2H, 5- $\text{CH}_2$ - $\text{CH}_3$ ), 3.11 (s, 3H, N- $\text{CH}_3$ ), 3.27 (t,  $J = 7.6$  Hz, 2H, 4- $\text{CH}_2$ - $\text{CH}_2$ -N), 3.45 (t,  $J = 2.8$  Hz, 1H, propargyl CH), 3.70 (m, 2H, 4- $\text{CH}_2$ - $\text{CH}_2$ -N), 4.31 (d,  $J = 2.8$  Hz, 2H, propargyl  $\text{CH}_2$ ), 4.88 (s,  $^+\text{NH}$ ), 7.53 [ddm,  $J = J' = 7.6$  Hz, 2H, Ph-C2(6)-H], 7.62–7.67 [complex signal, 3H, Ph-C3(5)-H, Ph-C4-H];  $^{13}\text{C}$  NMR (100.6 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  13.4 ( $\text{CH}_3$ , 5- $\text{CH}_2$ - $\text{CH}_3$ ), 16.9 ( $\text{CH}_2$ , 5- $\text{CH}_2$ - $\text{CH}_3$ ), 21.1 ( $\text{CH}_2$ , 4- $\text{CH}_2$ - $\text{CH}_2$ -N), 40.8 ( $\text{CH}_3$ , N- $\text{CH}_3$ ), 46.3 ( $\text{CH}_2$ , propargyl  $\text{CH}_2$ ), 55.3 ( $\text{CH}_2$ , 4- $\text{CH}_2$ - $\text{CH}_2$ -N), 72.7 (C, propargyl C), 81.7 (CH, propargyl CH), 126.7 (2CH), 130.9 (2CH), 131.4 (CH) (Ph-CH), 137.6 (C, Ph-C1), 139.1 (C, C5), 140.2 (C, C4); HRMS (ESI), calcd for ( $\text{C}_{16}\text{H}_{20}\text{N}_4 + \text{H}^+$ ) 269.1761; found 269.1766.

#### 4.1.48. *N*-Methyl-*N*-[2-(1-phenyl-5-propyl-1*H*-1,2,3-triazol-4-yl)ethyl]-*N*-propargylamine **56**

It was prepared as described for **31**. From amine **49** (168 mg, 0.69 mmol),  $\text{Cs}_2\text{CO}_3$  (0.22 g, 0.68 mmol), and propargyl bromide (80% solution in toluene, 0.07 mL, 0.47 mmol), and stirring at 0  $^\circ\text{C}$  for 30 min and at rt for an additional 3 h, an oily residue (278 mg) was obtained and purified through column chromatography (40–60  $\mu\text{m}$  silica gel,  $\text{CH}_2\text{Cl}_2/\text{MeOH}/50\%$  aq  $\text{NH}_4\text{OH}$  mixtures, gradient elution). On elution with  $\text{CH}_2\text{Cl}_2/\text{MeOH}/50\%$  aq  $\text{NH}_4\text{OH}$  98:2:0.2, propargylamine **56** (117 mg, 88% yield) was obtained as a yellow oil;  $R_f$  0.84 ( $\text{CH}_2\text{Cl}_2/\text{MeOH}/50\%$  aq  $\text{NH}_4\text{OH}$  9:1:0.05).

**56-HCl**: orange sticky solid, IR (ATR)  $\nu$  3500–2300 (max at 3400, 3197, 2958, 2930, 2873, 2354,  $\nu$  N–H,  $\equiv$ C–H, and C–H), 2121 (C $\equiv$ C)  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  0.83 (t,  $J = 7.6$  Hz, 3H, 5- $\text{CH}_2$ - $\text{CH}_2$ - $\text{CH}_3$ ), 1.44 (tq,  $J = J' = 7.6$  Hz, 2H, 5- $\text{CH}_2$ - $\text{CH}_2$ - $\text{CH}_3$ ), 2.77 (t,  $J = 7.6$  Hz, 2H, 5- $\text{CH}_2$ - $\text{CH}_2$ - $\text{CH}_3$ ), 3.11 (s, 3H, N- $\text{CH}_3$ ), 3.22 (t,  $J = 7.6$  Hz, 2H, 4- $\text{CH}_2$ - $\text{CH}_2$ -N), 3.45 (t,  $J = 2.4$  Hz, 1H, propargyl CH), 3.70 (m, 2H, 4- $\text{CH}_2$ - $\text{CH}_2$ -N), 4.31 (d,  $J = 2.4$  Hz, 2H, propargyl  $\text{CH}_2$ ), 4.85 (s,  $^+\text{NH}$ ), 7.52 (m, 2H), 7.62–7.66 (complex signal, 3H) (Ph-CH);  $^{13}\text{C}$  NMR (100.6 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  13.9 ( $\text{CH}_3$ , 5- $\text{CH}_2$ - $\text{CH}_2$ - $\text{CH}_3$ ), 21.1 ( $\text{CH}_2$ , 4- $\text{CH}_2$ - $\text{CH}_2$ -N), 22.8 ( $\text{CH}_2$ , 5- $\text{CH}_2$ - $\text{CH}_2$ - $\text{CH}_3$ ), 25.2 ( $\text{CH}_2$ , 5- $\text{CH}_2$ - $\text{CH}_2$ - $\text{CH}_3$ ), 40.9 ( $\text{CH}_3$ , N- $\text{CH}_3$ ), 46.3 ( $\text{CH}_2$ , propargyl  $\text{CH}_2$ ), 55.3 ( $\text{CH}_2$ , 4- $\text{CH}_2$ - $\text{CH}_2$ -N), 72.7 (C, propargyl C), 81.7 (CH, propargyl CH), 126.8 (2CH), 130.9 (2CH), 131.4 (CH) (Ph-CH), 137.6 (C), 137.7 (C) (C5, Ph-C1), 140.7 (C, C4); HRMS (ESI), calcd for ( $\text{C}_{17}\text{H}_{22}\text{N}_4 + \text{H}^+$ ) 283.1917, found 283.1923.

#### 4.1.49. *N*-Methyl-*N*-[2-(5-butyl-1-phenyl-1*H*-1,2,3-triazol-4-yl)ethyl]-*N*-propargylamine **57**

It was prepared as described for **31**. From amine **50** (157 mg, 0.61 mmol),  $\text{Cs}_2\text{CO}_3$  (0.22 g, 0.68 mmol), and propargyl bromide (80% solution in toluene, 0.07 mL, 0.47 mmol), and stirring at 0  $^\circ\text{C}$  for 30 min and at rt for an additional 3 h, an oily residue (172 mg) was obtained and purified through column chromatography (40–60  $\mu\text{m}$  silica gel,  $\text{CH}_2\text{Cl}_2/\text{MeOH}/50\%$  aq  $\text{NH}_4\text{OH}$  mixtures, gradient elution). On elution with  $\text{CH}_2\text{Cl}_2/\text{MeOH}/50\%$  aq  $\text{NH}_4\text{OH}$  100:0:0.2 to 99:1:0.2, propargylamine **57** (164 mg, 91% yield) was obtained as a yellow oil;  $R_f$  0.86 ( $\text{CH}_2\text{Cl}_2/\text{MeOH}/50\%$  aq  $\text{NH}_4\text{OH}$  9:1:0.05).

**57-HCl**: yellow sticky solid, IR (ATR)  $\nu$  3500–2300 (max at 3426, 3209, 2962, 2929, 2869, 2352,  $\nu$  N–H,  $\equiv$ C–H, and C–H), 2120 (C $\equiv$ C)  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  0.80 (t,  $J = 7.6$  Hz, 3H, 5- $\text{CH}_2$ - $\text{CH}_2$ - $\text{CH}_2$ - $\text{CH}_3$ ), 1.23 (tq,  $J = J' = 7.6$  Hz, 2H, 5- $\text{CH}_2$ - $\text{CH}_2$ - $\text{CH}_2$ - $\text{CH}_3$ ), 1.39 (tt,  $J = J' = 7.6$  Hz, 2H, 5- $\text{CH}_2$ - $\text{CH}_2$ - $\text{CH}_2$ - $\text{CH}_3$ ), 2.78 (t,  $J = 7.6$  Hz, 2H, 5- $\text{CH}_2$ - $\text{CH}_2$ - $\text{CH}_2$ - $\text{CH}_3$ ), 3.11 (s, 3H, N- $\text{CH}_3$ ), 3.22 (t,  $J = 7.6$  Hz, 2H, 4- $\text{CH}_2$ - $\text{CH}_2$ -N), 3.46 (t,  $J = 2.4$  Hz, 1H, propargyl CH), 3.69 (m, 2H, 4- $\text{CH}_2$ - $\text{CH}_2$ -N), 4.30 (d,  $J = 2.4$  Hz, 2H, propargyl  $\text{CH}_2$ ), 4.85 (s,  $^+\text{NH}$ ), 7.50 (m, 2H), 7.62–7.66 (complex signal, 2H) (Ph-CH);  $^{13}\text{C}$  NMR (100.6 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  13.8 ( $\text{CH}_3$ , 5- $\text{CH}_2$ - $\text{CH}_2$ - $\text{CH}_2$ - $\text{CH}_3$ ), 21.1 ( $\text{CH}_2$ , 4- $\text{CH}_2$ - $\text{CH}_2$ -N), 23.1 ( $\text{CH}_2$ ), 23.2 ( $\text{CH}_2$ ) (5-

$\text{CH}_2$ - $\text{CH}_2$ - $\text{CH}_2$ - $\text{CH}_3$ ), 31.6 ( $\text{CH}_2$ , 5- $\text{CH}_2$ - $\text{CH}_2$ - $\text{CH}_2$ - $\text{CH}_3$ ), 40.9 ( $\text{CH}_3$ , N- $\text{CH}_3$ ), 46.3 ( $\text{CH}_2$ , propargyl  $\text{CH}_2$ ), 55.3 ( $\text{CH}_2$ , 4- $\text{CH}_2$ - $\text{CH}_2$ -N), 72.7 (C, propargyl C), 81.7 (CH, propargyl CH), 126.8 (2CH), 130.9 (2CH), 131.4 (CH) (Ph-CH), 137.69 (C), 137.72 (C) (C5, Ph-C1), 140.6 (C, C4); HRMS (ESI), calcd for ( $\text{C}_{18}\text{H}_{24}\text{N}_4 + \text{H}^+$ ) 297.2074, found 297.2085.

#### 4.1.50. 3-[3-(Trimethylsilyl)-2-propynyl]benzotrile **61**

A solution of trimethylsilylacetylene (1.59 mL, 1.11 g, 11.3 mmol) in anhydrous THF (22 mL) was cooled to  $-78$   $^\circ\text{C}$ , treated dropwise with *n*-BuLi (2.5 M solution in hexanes, 4.59 mL, 11.5 mmol), and stirred at  $-78$   $^\circ\text{C}$  for 30 min. A solution of  $\text{ZnBr}_2$  (2.59 g, 11.5 mmol) in anhydrous THF (8 mL) was then added and the resulting mixture was warmed to 0  $^\circ\text{C}$ . 3-Bromomethylbenzotrile, **58** (1.50 g, 7.65 mmol), and  $\text{Pd}(\text{PPh}_3)_2\text{Cl}_2$  (290 mg, 0.41 mmol) were added and the reaction mixture was stirred at rt overnight. The reaction mixture was cooled to 0  $^\circ\text{C}$ , treated with 1 N HCl (20 mL), and extracted with EtOAc (2  $\times$  30 mL). The combined organic extracts were washed with satd aq  $\text{NaHCO}_3$  (20 mL), dried over anhydrous  $\text{Na}_2\text{SO}_4$ , and evaporated under reduced pressure to give a residue (2.02 g), which was purified through column chromatography (40–60  $\mu\text{m}$  silica gel, hexane/EtOAc mixtures, gradient elution). On elution with hexane/EtOAc 95:5, compound **61** (1.03 g, 63% yield) was isolated as a colorless oil;  $R_f$  0.73 (hexane/EtOAc 8:2); 2230 (C $\equiv$ N), 2178 (C $\equiv$ C)  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  0.20 [s, 9H, Si( $\text{CH}_3$ ) $_3$ ], 3.68 (s, 2H, 1'- $\text{H}_2$ ), 7.42 (dd,  $J = J' = 7.6$  Hz, 1H, 5-H), 7.53 (d,  $J = 7.6$  Hz, 1H), 7.57 (d,  $J = 7.6$  Hz, 1H) (4-H, 6-H), 7.65 (br s, 1H, 2-H);  $^{13}\text{C}$  NMR (100.6 MHz,  $\text{CDCl}_3$ )  $\delta$  0.2 [3 $\text{CH}_3$ , Si( $\text{CH}_3$ ) $_3$ ], 26.0 ( $\text{CH}_2$ , C1'), 88.6 (C, C3'), 102.4 (C, C2'), 112.7 (C, C1), 118.9 (C, CN), 129.4 (CH), 130.6 (CH), 131.6 (CH), 132.5 (CH) (phenylene CH), 138.1 (C, C3); HRMS (ESI), calcd for ( $\text{C}_{13}\text{H}_{15}\text{NSi} + \text{H}^+$ ) 214.1047, found 214.1048.

#### 4.1.51. 4-[3-(Trimethylsilyl)-2-propynyl]benzotrile **62**

It was prepared as described for **61**. From trimethylsilylacetylene (1.06 mL, 737 mg, 7.50 mmol), *n*-BuLi (2.5 M solution in hexanes, 3.06 mL, 7.65 mmol),  $\text{ZnBr}_2$  (1.72 g, 7.64 mmol), 4-bromomethylbenzotrile, **59** (1.00 g, 5.10 mmol), and  $\text{Pd}(\text{PPh}_3)_2\text{Cl}_2$  (183 mg, 0.26 mmol), a residue (1.38 g) was obtained and purified through column chromatography (40–60  $\mu\text{m}$  silica gel, hexane/EtOAc mixtures, gradient elution). On elution with hexane/EtOAc 90:10, compound **62** (900 mg, 83% yield) was isolated as a colorless oil;  $R_f$  0.77 (hexane/EtOAc 8:2); IR (ATR)  $\nu$  2230 (C $\equiv$ N), 2178 (C $\equiv$ C)  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  0.19 [s, 9H, Si( $\text{CH}_3$ ) $_3$ ], 3.70 (s, 2H, 1'- $\text{H}_2$ ), 7.46 [dm,  $J = 8.4$  Hz, 2H, 3(5)-H], 7.61 [dm,  $J = 8.4$  Hz, 2H, 2(6)-H];  $^{13}\text{C}$  NMR (100.6 MHz,  $\text{CDCl}_3$ )  $\delta$  0.1 [3 $\text{CH}_3$ , Si( $\text{CH}_3$ ) $_3$ ], 26.5 ( $\text{CH}_2$ , C1'), 88.6 (C, C3'), 102.3 (C, C2'), 110.8 (C, C1), 119.0 (C, CN), 128.8 [2CH, C3(5)], 132.5 [2CH, C2(6)], 142.1 (C, C4); HRMS (ESI), calcd for ( $\text{C}_{13}\text{H}_{15}\text{NSi} + \text{H}^+$ ) 214.1047; found 214.1048.

#### 4.1.52. 4-[3-(Trimethylsilyl)-2-propynyl]phenylacetoneitrile **63**

It was prepared as described for **61**. From trimethylsilylacetylene (5.20 mL, 3.61 g, 36.8 mmol), *n*-BuLi (2.5 M solution in hexanes, 15.0 mL, 37.5 mmol),  $\text{ZnBr}_2$  (8.46 g, 37.6 mmol), 4-(bromomethyl)phenylacetoneitrile, **60** (5.26 g, 25.0 mmol), and  $\text{Pd}(\text{PPh}_3)_2\text{Cl}_2$  (940 mg, 1.34 mmol), a residue (7.12 g) was obtained and purified through column chromatography (40–60  $\mu\text{m}$  silica gel, hexane/EtOAc mixtures, gradient elution). On elution with hexane/EtOAc 95:5, compound **63** (2.50 g, 44% yield) was isolated as a yellow oil;  $R_f$  0.50 (hexane/EtOAc 8:2); IR (ATR)  $\nu$  2344 (C $\equiv$ N), 2144 (C $\equiv$ C)  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  0.19 [s, 9H, Si( $\text{CH}_3$ ) $_3$ ], 3.65 (s, 2H, 1'- $\text{H}_2$ ), 3.73 (s, 2H, 1- $\text{CH}_2$ -CN), 7.28 (br d,  $J = 8.4$  Hz, 2H), 7.36 (br d,  $J = 8.4$  Hz, 2H) (Ph-CH);  $^{13}\text{C}$  NMR (100.6 MHz,  $\text{CDCl}_3$ )  $\delta$  0.03 [3 $\text{CH}_3$ , Si( $\text{CH}_3$ ) $_3$ ], 23.3 ( $\text{CH}_2$ , 1- $\text{CH}_2$ -CN), 25.8 ( $\text{CH}_2$ , C1'), 87.3 (C, C3'), 103.6 (C, C2'), 117.8 (C, CN), 128.1

(2CH), 128.6 (2CH) (Ph–CH), 128.2 (C, Ph–C1), 136.5 (C, Ph–C4); HRMS (ESI), calcd for (C<sub>14</sub>H<sub>17</sub>NSi + H<sup>+</sup>) 228.1203; found 228.1203.

#### 4.1.53. 3-(2-Propynyl)benzonitrile 64

To a solution of **61** (1.60 g, 7.51 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (70 mL), a solution of AgOTf (193 mg, 0.75 mmol) in MeOH/H<sub>2</sub>O 11:1 (50 mL) was added. The reaction mixture was stirred at rt for 7 h, treated with an additional amount of AgOTf (386 mg, 1.50 mmol), and stirred at rt overnight. The resulting mixture was diluted with satd aq NH<sub>4</sub>Cl (50 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 50 mL). The combined organic extracts were washed with H<sub>2</sub>O (50 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and evaporated under reduced pressure to give a crude (944 mg), which was purified through column chromatography (40–60 μm silica gel, hexane/EtOAc mixtures, gradient elution). On elution with hexane/EtOAc 95:5, alkyne **64** (690 mg, 65% yield) was isolated as a white solid; *R*<sub>f</sub> 0.72 (hexane/EtOAc 8:2), mp 63–65 °C; IR (ATR) ν 3247 (≡C–H), 2231 (C≡N, C=C) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.26 (t, *J* = 2.8 Hz, 1H, 3'-H), 3.64 (d, *J* = 2.8 Hz, 2H, 1'-H<sub>2</sub>), 7.43 (dd, *J* = *J*' = 8.0 Hz, 1H, 5-H), 7.54 (dm, *J* = 8.0 Hz, 1H), 7.58 (dm, *J* = 8.0 Hz, 1H) (4-H, 6-H), 7.68 (m, 1H, 2-H); <sup>13</sup>C NMR (100.6 MHz, CDCl<sub>3</sub>) δ 24.6 (CH<sub>2</sub>, C1'), 71.9 (CH, C3'), 80.3 (C, C2'), 112.8 (C, C1), 118.8 (C, CN), 129.4 (CH), 130.7 (CH), 131.5 (CH), 132.5 (CH) (phenylene CH), 137.7 (C, C3); HRMS (ESI), calcd for (C<sub>10</sub>H<sub>7</sub>N + H<sup>+</sup>) 142.0651, found 142.0653.

#### 4.1.54. 4-(2-Propynyl)benzonitrile 65

It was prepared as described for **64**. From **62** (642 mg, 3.01 mmol) and AgOTf [(80 mg, 0.31 mmol) × 2], a crude (548 mg) was obtained and purified through column chromatography (40–60 μm silica gel, hexane/EtOAc mixtures, gradient elution). On elution with hexane/EtOAc 80:20, alkyne **65** (346 mg, 81% yield) was isolated as a white solid; *R*<sub>f</sub> 0.76 (hexane/EtOAc 8:2), mp 87–89 °C; IR (ATR) ν 3254 (≡C–H), 2230 (C≡N, C=C) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.25 (t, *J* = 2.8 Hz, 1H, 3'-H), 3.67 (d, *J* = 2.8 Hz, 2H, 1'-H<sub>2</sub>), 7.48 [dm, *J* = 8.8 Hz, 2H, 3(5)-H], 7.62 [dm, *J* = 8.8 Hz, 2H, 2(6)-H]; <sup>13</sup>C NMR (100.6 MHz, CDCl<sub>3</sub>) δ 25.2 (CH<sub>2</sub>, C1'), 71.9 (CH, C3'), 80.2 (C, C2'), 111.0 (C, C1), 118.9 (C, CN), 128.8 [2CH, C3(5)], 132.5 [2CH, C2(6)], 141.7 (C, C4); HRMS (ESI), calcd for (C<sub>10</sub>H<sub>7</sub>N + H<sup>+</sup>) 142.0651, found 142.0647.

#### 4.1.55. 4-(2-Propynyl)phenylacetone 66

It was prepared as described for **64**. From **63** (2.50 g, 11.0 mmol) and AgOTf (280 mg, 1.09 mmol) × 2], a crude (1.79 g) was obtained and purified through column chromatography (40–60 μm silica gel, hexane/EtOAc mixtures, gradient elution). On elution with hexane/EtOAc 95:5, alkyne **66** (1.31 g, 77% yield) was isolated as a white solid; *R*<sub>f</sub> 0.41 (hexane/EtOAc 8:2), mp 58–59 °C; IR (ATR) ν 3262 (≡C–H), 2254 (C≡N, C=C) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.19 (t, *J* = 2.8 Hz, 1H, 3'-H), 3.57 (br s, 2H, 1'-H<sub>2</sub>), 3.69 (s, 2H, 1-CH<sub>2</sub>-CN), 7.27 (br d, *J* = 8.0 Hz, 2H), 7.36 (br d, *J* = 8.0 Hz, 2H) (Ph–CH); <sup>13</sup>C NMR (100.6 MHz, CDCl<sub>3</sub>) δ 23.2 (CH<sub>2</sub>, 1-CH<sub>2</sub>-CN), 24.4 (CH<sub>2</sub>, C1'), 70.8 (CH, C3'), 81.4 (C, C2'), 117.8 (C, CN), 128.1 (2CH), 128.6 (2CH) (Ph–CH), 128.3 (C, Ph–C1), 136.1 (C, Ph–C4); HRMS (ESI), calcd for (C<sub>11</sub>H<sub>9</sub>N + H<sup>+</sup>) 156.0808, found 156.0808.

#### 4.1.56. 3-[(1-Methyl-1H-1,2,3-triazol-4-yl)methyl]benzonitrile 67

It was prepared as described for **9**. From iodomethane (0.30 mL, 0.68 g, 4.82 mmol), NaN<sub>3</sub> (342 mg, 5.26 mmol), Na<sub>2</sub>CO<sub>3</sub> (1.39 g, 13.1 mmol), ascorbic acid (616 mg, 3.50 mmol), CuSO<sub>4</sub>·5H<sub>2</sub>O (436 mg, 1.75 mmol), and alkyne **64** (618 mg, 4.38 mmol), compound **67** (823 mg, 95% yield) was obtained as a yellowish solid; *R*<sub>f</sub> 0.64 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 9.5:0.5:0.05); mp 85–87 °C; IR (ATR) ν 2229 (C≡N) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.05 (s, 3H, 1'-CH<sub>3</sub>), 4.09 (br s, 2H, 3-CH<sub>2</sub>), 7.25 (s, 1H, 5'-H), 7.39 (dd, *J* = *J*' = 8.0 Hz, 1H, 5-H), 7.48–7.53 (complex signal, 3H, 2-H, 4-H, 6-H); <sup>13</sup>C NMR (100.6 MHz, CDCl<sub>3</sub>) δ 31.7 (CH<sub>3</sub>, 3-CH<sub>3</sub>), 36.8 (CH<sub>2</sub>,

1'-CH<sub>2</sub>), 112.7 (C, C1), 118.8 (C, CN), 122.6 (CH, C5'), 129.5 (CH), 130.4 (CH), 132.2 (CH), 133.4 (CH) (phenylene CH), 140.7 (C, C3), 146.1 (C, C4'); HRMS (ESI), calcd for (C<sub>11</sub>H<sub>10</sub>N<sub>4</sub> + H<sup>+</sup>) 199.0978, found 199.0980.

#### 4.1.57. 4-[(1-Methyl-1H-1,2,3-triazol-4-yl)methyl]benzonitrile 68

It was prepared as described for **9**. From iodomethane (0.17 mL, 0.38 g, 2.70 mmol), NaN<sub>3</sub> (191 mg, 2.94 mmol), Na<sub>2</sub>CO<sub>3</sub> (779 mg, 7.35 mmol), ascorbic acid (350 mg, 1.99 mmol), CuSO<sub>4</sub>·5H<sub>2</sub>O (250 mg, 1.00 mmol), and alkyne **65** (346 mg, 2.45 mmol), compound **68** (459 mg, 95% yield) was obtained as a white solid; *R*<sub>f</sub> 0.63 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 9.5:0.5:0.05); mp 116–118 °C; IR (ATR) ν 2227 (C≡N) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.05 (s, 3H, 1'-CH<sub>3</sub>), 4.12 (br s, 2H, 4-CH<sub>2</sub>), 7.23 (s, 1H, 5'-H), 7.36 [dm, *J* = 8.4 Hz, 2H, 3(5)-H], 7.57 [dm, *J* = 8.4 Hz, 2H, 2(6)-H]; <sup>13</sup>C NMR (100.6 MHz, CDCl<sub>3</sub>) δ 32.3 (CH<sub>2</sub>, 4-CH<sub>2</sub>), 36.8 (CH<sub>3</sub>, 1'-CH<sub>3</sub>), 110.6 (C, C1), 118.9 (C, CN), 122.6 (CH, C5'), 129.6 [2CH, C3(5)], 132.5 [2CH, C2(6)], 144.8 (C, C4), 146.1 (C, C4'); HRMS (ESI), calcd for (C<sub>11</sub>H<sub>10</sub>N<sub>4</sub> + H<sup>+</sup>) 199.0978, found 199.0978.

#### 4.1.58. 4-[(1-Methyl-1H-1,2,3-triazol-4-yl)methyl]phenylacetone 69

It was prepared as described for **9**. From iodomethane (0.58 mL, 1.32 g, 9.32 mmol), NaN<sub>3</sub> (660 mg, 10.2 mmol), Na<sub>2</sub>CO<sub>3</sub> (2.69 g, 25.4 mmol), ascorbic acid (1.19 g, 6.76 mmol), CuSO<sub>4</sub>·5H<sub>2</sub>O (840 mg, 3.36 mmol), and alkyne **66** (1.31 g, 8.45 mmol), compound **69** (1.60 g, 89% yield) was obtained as a yellowish solid; *R*<sub>f</sub> 0.93 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 9.5:0.5:0.05); mp 86–88 °C; IR (ATR) ν 2241 (C≡N) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 3.71 (s, 2H, 1-CH<sub>2</sub>-CN), 4.02 (s, 3H, 1'-CH<sub>3</sub>), 4.06 (s, 2H, 4-CH<sub>2</sub>), 7.21 (s, 1H, 5'-H), 7.23–7.30 (complex signal, 4H, Ph–CH); <sup>13</sup>C NMR (100.6 MHz, CDCl<sub>3</sub>) δ 23.1 (CH<sub>2</sub>, 1-CH<sub>2</sub>-CN), 31.6 (CH<sub>2</sub>, 4-CH<sub>2</sub>), 36.4 (CH<sub>3</sub>, 1'-CH<sub>3</sub>), 117.8 (C, CN), 122.3 (CH, C5'), 128.0 (C, Ph–C1), 128.1 (2CH), 129.2 (2CH) (Ph–CH), 139.0 (C, Ph–C4), 147.1 (C, C4'); HRMS (ESI), calcd for (C<sub>12</sub>H<sub>12</sub>N<sub>4</sub> + H<sup>+</sup>) 213.1135, found 213.1135.

#### 4.1.59. 3-[(1-Methyl-1H-1,2,3-triazol-4-yl)methyl]benzylamine 70

A solution of nitrile **67** (739 mg, 3.73 mmol) in anhydrous THF (30 mL) was cooled to 0 °C and treated dropwise with LiAlH<sub>4</sub> (4 M solution in Et<sub>2</sub>O, 2.98 mL, 11.9 mmol). The reaction mixture was stirred under reflux for 2 h, cooled to 0 °C, treated portionwise with 1 N NaOH (100 mL), diluted with H<sub>2</sub>O (100 mL), and extracted with EtOAc (3 × 100 mL). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to afford amine **70** (368 mg, 49% yield) as a yellow oil; *R*<sub>f</sub> 0.28 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 9.5:0.5:0.05).

**70**·HCl: yellowish solid, mp 119–121 °C; IR (ATR) ν 3400–2300 (max at 3303, 3077, 2908, 2870, 2356, 2322, \*N–H and C–H) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 4.14 (s, 2H, 3-CH<sub>2</sub>), 4.296 (s, 3H, 1'-CH<sub>3</sub>), 4.302 (s, 2H, 1-CH<sub>2</sub>-N), 4.95 (s, \*NH<sub>3</sub>), 7.38–7.52 (complex signal, 4H, phenylene CH), 8.39 (s, 1H, 5'-H); <sup>13</sup>C NMR (100.6 MHz, CD<sub>3</sub>OD) δ 30.2 (CH<sub>2</sub>, 3-CH<sub>2</sub>), 39.8 (CH<sub>3</sub>, 1'-CH<sub>3</sub>), 44.1 (CH<sub>2</sub>, 1-CH<sub>2</sub>-N), 129.1 (CH), 129.2 (CH), 130.7 (2CH), 131.0 (CH) (phenylene CH, C5'), 135.3 (C), 138.2 (C) (C1, C3), 144.9 (C, C4'); HRMS (ESI), calcd for (C<sub>11</sub>H<sub>14</sub>N<sub>4</sub> + H<sup>+</sup>) 203.1291, found 203.1297.

#### 4.1.60. 4-[(1-Methyl-1H-1,2,3-triazol-4-yl)methyl]benzylamine 71

It was prepared as described for **70**. From nitrile **68** (310 mg, 1.56 mmol) and LiAlH<sub>4</sub> (4 M solution in Et<sub>2</sub>O, 1.18 mL, 4.72 mmol), amine **71** (254 mg, 81% yield) was obtained as a yellow oil; *R*<sub>f</sub> 0.27 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 9.5:0.5:0.05).

**71**·HCl: yellowish sticky solid, IR (ATR) ν 3400–2500 (max at 3386, 2931, 2810, 2536, \*N–H and C–H) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 4.11 (s, 2H, 4-CH<sub>2</sub>), 4.22 (s, 3H, 1'-CH<sub>3</sub>), 4.90

(s, 1-CH<sub>2</sub>-N, <sup>+</sup>NH<sub>3</sub>), 7.38 (d, *J* = 8.0 Hz, 2H), 7.46 (d, *J* = 8.0 Hz, 2H) (phenylene CH), 8.16 (s, 1H, 5'-H); <sup>13</sup>C NMR (100.6 MHz, CD<sub>3</sub>OD) δ 30.6 (CH<sub>2</sub>, 4-CH<sub>2</sub>), 38.9 (CH<sub>3</sub>, 1'-CH<sub>3</sub>), 43.9 (CH<sub>2</sub>, 1-CH<sub>2</sub>-N), 127.7 (CH, C5'), 130.6 (2CH), 130.7 (2CH) (phenylene CH), 133.4 (C), 139.3 (C) (C1, C4), 145.8 (C, C4'); HRMS (ESI), calcd for (C<sub>11</sub>H<sub>14</sub>N<sub>4</sub> + H<sup>+</sup>) 203.1291, found 203.1292.

#### 4.1.61. 4-[(1-Methyl-1H-1,2,3-triazol-4-yl)methyl]phenethylamine 72

A suspension of nitrile **69** (1.60 g, 7.54 mmol) and Raney-Ni (2.02 g, wet) in 7 N methanolic NH<sub>3</sub> (32 mL) was hydrogenated by bubbling H<sub>2</sub> overnight. The resulting mixture was filtered and the cake was washed with MeOH (2 × 15 mL). The combined filtrates were concentrated under reduced pressure to afford amine **72** (1.70 g, quantitative yield) as an oily residue; *R<sub>f</sub>* 0.17 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 9.5:0.5:0.05).

**72**·HCl: yellow solid, mp 158–160 °C; IR (ATR) ν 3400–2500 (max at 3390, 3331, 3254, 2994, 2970, 2727, 2627, 2573, <sup>+</sup>N–H and C–H) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 2.93 (t, *J* = 7.6 Hz, 2H, 1-CH<sub>2</sub>-CH<sub>2</sub>-N), 3.15 (t, *J* = 7.6 Hz, 2H, 1-CH<sub>2</sub>-CH<sub>2</sub>-N), 4.04 (s, 2H, 4-CH<sub>2</sub>), 4.07 (s, 3H, 1'-CH<sub>3</sub>), 4.86 (s, <sup>+</sup>NH<sub>3</sub>), 7.18–7.27 (complex signal, 4H, Ph-CH), 7.73 (s, 1H, 5'-H); <sup>13</sup>C NMR (100.6 MHz, CD<sub>3</sub>OD) δ 31.9 (CH<sub>2</sub>, 4-CH<sub>2</sub>), 34.1 (CH<sub>2</sub>, 1-CH<sub>2</sub>-CH<sub>2</sub>-N), 37.2 (CH<sub>3</sub>, 1'-CH<sub>3</sub>), 42.0 (CH<sub>2</sub>, 1-CH<sub>2</sub>-CH<sub>2</sub>-N), 125.0 (CH, C5'), 130.1 (2CH), 130.3 (2CH) (Ph-CH), 136.1 (C, Ph-C1), 139.3 (C, Ph-C4), 148.1 (C, C4'); HRMS (ESI), calcd for (C<sub>12</sub>H<sub>16</sub>N<sub>4</sub> + H<sup>+</sup>) 217.1448, found 217.1450.

#### 4.1.62. N-(tert-Butoxycarbonyl)-3-[(1-methyl-1H-1,2,3-triazol-4-yl)methyl]benzylamine 73

To a solution of **70** (352 mg, 1.74 mmol) in anhydrous THF (6 mL), a solution of di-*tert*-butyl dicarbonate (380 mg, 1.74 mmol) in anhydrous THF (2 mL) was added at 0 °C. The reaction mixture was stirred at rt for 3 h and evaporated under reduced pressure. The resulting residue was washed with pentane (3 × 10 mL) and dried under vacuum, to afford **73** (520 mg, quantitative yield) as a yellow oil; *R<sub>f</sub>* 0.85 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 9.5:0.5:0.05); IR (ATR) ν 3341 (N–H), 1697 (C=O) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.55 [s, 9H, C(CH<sub>3</sub>)<sub>3</sub>], 4.12 (s, 3H, 1'-CH<sub>3</sub>), 4.16 (s, 2H, 3-CH<sub>2</sub>), 4.38 (d, *J* = 5.6 Hz, 2H, 1-CH<sub>2</sub>-N), 4.97 (br s, 1H, *NHBoc*), 7.22–7.27 (complex signal, 3H), 7.33–7.38 (overlapped signal, 2H) (phenylene CH, 5'-H); <sup>13</sup>C NMR (100.6 MHz, CDCl<sub>3</sub>) δ 28.5 [3CH<sub>3</sub>, C(CH<sub>3</sub>)<sub>3</sub>], 32.3 (CH<sub>2</sub>, 3-CH<sub>2</sub>), 36.7 (CH<sub>3</sub>, 1'-CH<sub>3</sub>), 44.7 (CH<sub>2</sub>, 1-CH<sub>2</sub>-N), 79.6 [C, C(CH<sub>3</sub>)<sub>3</sub>], 122.6 (CH, C5'), 125.7 (CH), 127.8 (2CH), 129.0 (CH) (phenylene CH), 139.4 (C), 139.6 (C) (C1, C3), 147.8 (C, C4'), 156.0 (C, NCOO); HRMS (ESI), calcd for (C<sub>16</sub>H<sub>22</sub>N<sub>4</sub>O<sub>2</sub> + H<sup>+</sup>) 303.1816, found 303.1812.

#### 4.1.63. N-(tert-Butoxycarbonyl)-4-[(1-methyl-1H-1,2,3-triazol-4-yl)methyl]benzylamine 74

It was prepared as described for **73**. From **71** (90 mg, 0.45 mmol) and di-*tert*-butyl dicarbonate (98 mg, 0.45 mmol), **74** (133 mg, quantitative yield) was obtained as a beige solid; *R<sub>f</sub>* 0.78 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 9.5:0.5:0.05).

The analytical sample of **74** was obtained by filtration of a dichloromethane solution through a PTFE filter (0.2 μm), evaporation of the filtrate under reduced pressure and washing of the resulting solid with pentane (3 × 2 mL); IR (ATR) ν 3382 (N–H), 1690 (C=O) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.44 [s, 9H, C(CH<sub>3</sub>)<sub>3</sub>], 4.00 (s, 3H, 1'-CH<sub>3</sub>), 4.04 (s, 2H, 4-CH<sub>2</sub>), 4.26 (d, *J* = 5.6 Hz, 2H, 1-CH<sub>2</sub>-N), 4.86 (br s, 1H, *NHBoc*), 7.13 (s, 1H, 5'-H), 7.20 (complex signal, 4H, phenylene CH); <sup>13</sup>C NMR (100.6 MHz, CDCl<sub>3</sub>) δ 28.5 [3CH<sub>3</sub>, C(CH<sub>3</sub>)<sub>3</sub>], 32.0 (CH<sub>2</sub>, 4-CH<sub>2</sub>), 36.7 (CH<sub>3</sub>, 1'-CH<sub>3</sub>), 44.4 (CH<sub>2</sub>, 1-CH<sub>2</sub>-N), 79.6 [C, C(CH<sub>3</sub>)<sub>3</sub>], 122.5 (CH, C5'), 127.8 (2CH), 129.0 (2CH) (phenylene CH), 137.3 (C), 138.3 (C) (C1, C4), 148.0 (C, C4'), 156.0 (C, NCOO); HRMS (ESI), calcd for (C<sub>16</sub>H<sub>22</sub>N<sub>4</sub>O<sub>2</sub> + H<sup>+</sup>) 303.1816, found 303.1817.

#### 4.1.64. N-(tert-Butoxycarbonyl)-4-[(1-methyl-1H-1,2,3-triazol-4-yl)methyl]phenethylamine 75

It was prepared as described for **73**. From **72** (1.65 g, 7.63 mmol) and di-*tert*-butyl dicarbonate (1.67 g, 7.65 mmol), **75** (2.34 g, quantitative yield) was obtained as a solid; *R<sub>f</sub>* 0.91 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 9.5:0.5:0.05); mp 92–94 °C; IR (ATR) ν 3358 (N–H), 1677 (C=O) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.42 [s, 9H, C(CH<sub>3</sub>)<sub>3</sub>], 2.76 (t, *J* = 6.8 Hz, 2H, 1-CH<sub>2</sub>-CH<sub>2</sub>-N), 3.35 (dt, *J* = *J*' = 6.8 Hz, 2H, 1-CH<sub>2</sub>-CH<sub>2</sub>-N), 4.02 (s, 3H, 1'-CH<sub>3</sub>), 4.05 (s, 2H, 4-CH<sub>2</sub>), 4.54 (br s, 1H, *NHBoc*), 7.12 (br d, *J* = 8.0 Hz, 2H), 7.19 (br d, *J* = 8.0 Hz, 2H) (Ph-CH), 7.16 (s, 1H, 5'-H); <sup>13</sup>C NMR (100.6 MHz, CDCl<sub>3</sub>) δ 28.4 [3CH<sub>3</sub>, C(CH<sub>3</sub>)<sub>3</sub>], 31.8 (CH<sub>2</sub>, 4-CH<sub>2</sub>), 35.8 (CH<sub>2</sub>, 1-CH<sub>2</sub>-CH<sub>2</sub>-N), 36.5 (CH<sub>3</sub>, 1'-CH<sub>3</sub>), 41.8 (CH<sub>2</sub>, 1-CH<sub>2</sub>-CH<sub>2</sub>-N), 79.2 [C, C(CH<sub>3</sub>)<sub>3</sub>], 122.3 (CH, C5'), 128.9 (2CH), 129.0 (2CH) (Ph-CH), 137.16 (C), 137.23 (C) (Ph-C1, Ph-C4), 147.9 (C, C4'), 155.8 (C, NCOO); HRMS (ESI), calcd for (C<sub>17</sub>H<sub>24</sub>N<sub>4</sub>O<sub>2</sub> + H<sup>+</sup>) 317.1972, found 317.1982.

#### 4.1.65. N-(tert-Butoxycarbonyl)-N-methyl-3-[(1-methyl-1H-1,2,3-triazol-4-yl)methyl]benzylamine 76

It was prepared as described for **17**. From compound **73** (480 mg, 1.59 mmol), NaH (60% suspension in mineral oil, 96 mg, 2.40 mmol), and iodomethane (0.11 mL, 251 mg, 1.77 mmol), stirring at 60 °C for 2 h, treating again with NaH (60% suspension in mineral oil, 96 mg, 2.40 mmol), and iodomethane (0.11 mL, 251 mg, 1.77 mmol) and stirring at 60 °C for an additional 2 h, compound **76** (422 mg, 84% yield) was obtained as an orange oil; *R<sub>f</sub>* 0.85 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 9.5:0.5:0.05); IR (ATR) ν 1686 (C=O) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.48 [br s, 9H, C(CH<sub>3</sub>)<sub>3</sub>], 2.82 (br s, 3H, N-CH<sub>3</sub>), 4.04 (s, 3H, 1'-CH<sub>3</sub>), 4.08 (s, 2H, 3-CH<sub>2</sub>), 4.40 (br s, 2H, 1-CH<sub>2</sub>-N), 7.08–7.19 (complex signal), 7.25–7.30 (complex signal) (5H, phenylene CH, 5'-H); <sup>13</sup>C NMR (100.6 MHz, CDCl<sub>3</sub>) δ 28.6 [3CH<sub>3</sub>, C(CH<sub>3</sub>)<sub>3</sub>], 32.3 (CH<sub>2</sub>, 3-CH<sub>2</sub>), 34.1 (CH<sub>3</sub>, N-CH<sub>3</sub>), 36.7 (CH<sub>3</sub>, 1'-CH<sub>3</sub>), 52.0 (br CH<sub>2</sub>), 52.7 (br CH<sub>2</sub>) (1-CH<sub>2</sub>-N), 79.8 [C, C(CH<sub>3</sub>)<sub>3</sub>], 122.5 (CH, C5'), 125.6 (br CH), 125.8 (br CH), 127.7 (CH), 127.8 (br CH), 128.9 (CH) (phenylene CH), 138.6 (C), 139.5 (C) (C1, C3), 147.9 (br C, C4'), 156.4 (br C, NCOO); HRMS (ESI), calcd for (C<sub>17</sub>H<sub>24</sub>N<sub>4</sub>O<sub>2</sub> + H<sup>+</sup>) 317.1972, found 317.1970.

#### 4.1.66. N-(tert-Butoxycarbonyl)-N-methyl-4-[(1-methyl-1H-1,2,3-triazol-4-yl)methyl]benzylamine 77

It was prepared as described for **17**. From compound **74** (140 mg, 0.46 mmol), NaH (60% suspension in mineral oil, 28 mg, 0.70 mmol), and iodomethane (0.03 mL, 68 mg, 0.48 mmol), stirring at 60 °C for 2 h, treating again with NaH (60% suspension in mineral oil, 28 mg, 0.70 mmol), and iodomethane (0.03 mL, 68 mg, 0.48 mmol) and stirring at 60 °C for an additional 2 h, compound **77** (120 mg, 83% yield) was obtained as a brown oil; *R<sub>f</sub>* 0.56 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 9.5:0.5:0.05); IR (ATR) ν 1686 (C=O) cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.46 [br s, 9H, C(CH<sub>3</sub>)<sub>3</sub>], 2.79 (br s, 3H, N-CH<sub>3</sub>), 4.01 (s, 3H, 1'-CH<sub>3</sub>), 4.05 (s, 2H, 4-CH<sub>2</sub>), 4.37 (br s, 2H, 1-CH<sub>2</sub>-N), 7.14 (d, *J* = 8.0 Hz, 2H), 7.21 (d, *J* = 8.0 Hz, 2H) (phenylene CH), 7.20 (s, 1H, 5'-H); <sup>13</sup>C NMR (100.6 MHz, CDCl<sub>3</sub>) δ 28.6 [3CH<sub>3</sub>, C(CH<sub>3</sub>)<sub>3</sub>], 32.0 (CH<sub>2</sub>, 4-CH<sub>2</sub>), 34.0 (CH<sub>3</sub>, N-CH<sub>3</sub>), 36.7 (CH<sub>3</sub>, 1'-CH<sub>3</sub>), 51.7 (br CH<sub>2</sub>), 52.4 (br CH<sub>2</sub>) (1-CH<sub>2</sub>-N), 79.8 [C, C(CH<sub>3</sub>)<sub>3</sub>], 122.5 (CH, C5'), 127.8 (br CH), 128.0 (br CH), 128.9 (CH), 129.0 (CH) (phenylene CH), 136.4 (C), 138.2 (C) (C1, C4), 148.0 (C, C4'), 155.9 (br C, NCOO); HRMS (ESI), calcd for (C<sub>17</sub>H<sub>24</sub>N<sub>4</sub>O<sub>2</sub> + H<sup>+</sup>) 317.1972, found 317.1965.

#### 4.1.67. N-Methyl-3-[(1-methyl-1H-1,2,3-triazol-4-yl)methyl]benzylamine 79

It was prepared as described for **25**. From **76** (384 mg, 1.21 mmol) and H<sub>3</sub>PO<sub>4</sub> (85% purity, 2.15 mL, 18.6 mmol), amine **79** (242 mg, quantitative yield) was obtained as an orange oil; *R<sub>f</sub>* 0.30 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/50% aq NH<sub>4</sub>OH 9.5:0.5:0.05).

**79**-HCl: sticky solid, IR (ATR)  $\nu$  3400–2400 (max at 3374, 3116, 3074, 2956, 2778, 2699, 2542, 2417,  $^*N-H$  and  $C-H$ )  $cm^{-1}$ ;  $^1H$  NMR (400 MHz,  $CD_3OD$ )  $\delta$  2.73 (s, 3H,  $N-CH_3$ ), 4.21 (s, 2H, 3- $CH_2$ ), 4.32 (s, 3H, 1'- $CH_3$ ), 4.33 (s, 2H, 1- $CH_2-N$ ), 4.99 (s,  $^*NH_2$ ), 7.42–7.52 (complex signal, 3H, 4-H, 5-H, 6-H), 7.55 (br s, 1H, 2-H), 8.47 (s, 1H, 5'-H);  $^{13}C$  NMR (100.6 MHz,  $CD_3OD$ )  $\delta$  30.0 ( $CH_2$ , 3- $CH_2$ ), 33.2 ( $CH_3$ ,  $N-CH_3$ ), 40.0 ( $CH_3$ , 1'- $CH_3$ ), 53.3 ( $CH_2$ , 1- $CH_2-N$ ), 129.5 (CH), 130.3 (CH), 131.1 (CH), 131.2 (CH), 131.5 (CH) (phenylene CH, C5'), 133.6 (C, C1), 138.0 (C, C3), 144.5 (C, C4'); HRMS (ESI), calcd for ( $C_{12}H_{16}N_4 + H^+$ ): 217.1448, found 217.1446.

#### 4.1.68. N-Methyl-4-[(1-methyl-1H-1,2,3-triazol-4-yl)methyl]benzylamine **80**

It was prepared as described for **25**. From **77** (237 mg, 0.75 mmol) and  $H_3PO_4$  (85% purity, 1.29 mL, 11.2 mmol), amine **80** (156 mg, 96% yield) was obtained as an orange oil;  $R_f$  0.24 ( $CH_2Cl_2/MeOH/50\%$  aq  $NH_4OH$  9.5:0.5:0.05).

**80**-HCl: sticky solid, IR (ATR)  $\nu$  3400–2400 (max at 3339, 3085, 2931, 2744, 2708, 2547, 2415,  $^*N-H$  and  $C-H$ )  $cm^{-1}$ ;  $^1H$  NMR (400 MHz,  $CD_3OD$ )  $\delta$  2.71 (s, 3H,  $N-CH_3$ ), 4.19 (s, 2H, 4- $CH_2$ ), 4.23 (s, 3H, 1'- $CH_3$ ), 4.24 (s, 2H, 1- $CH_2-N$ ), 4.90 (s,  $^*NH_2$ ), 7.42 (d,  $J = 8.0$  Hz, 2H), 7.51 (d,  $J = 8.0$  Hz, 2H) (phenylene CH), 8.20 (s, 1H, 5'-H);  $^{13}C$  NMR (100.6 MHz,  $CD_3OD$ )  $\delta$  30.6 ( $CH_2$ , 4- $CH_2$ ), 33.1 ( $CH_3$ ,  $N-CH_3$ ), 39.0 ( $CH_3$ , 1'- $CH_3$ ), 53.1 ( $CH_2$ , 1- $CH_2-N$ ), 127.9 (CH, C5'), 130.7 (2CH), 131.62 (2CH) (phenylene CH), 131.56 (C, C1), 139.7 (C, C4), 145.6 (C, C4'); HRMS (ESI), calcd for ( $C_{12}H_{16}N_4 + H^+$ ) 217.1448, found 217.1448.

#### 4.1.69. N-Methyl-4-[(1-methyl-1H-1,2,3-triazol-4-yl)methyl]phenethylamine **81**

To a suspension of  $LiAlH_4$  (118 mg, 3.11 mmol) in dry THF (4 mL), a solution of **75** (165 mg, 0.52 mmol) in dry THF (4 mL) was added dropwise at 0 °C. The reaction mixture was stirred at reflux for 72 h, cooled to 0 °C, diluted with 1 N NaOH (20 mL), and extracted with  $CH_2Cl_2$  (3  $\times$  15 mL). The combined organic extracts were dried over anhydrous  $Na_2SO_4$ , filtered, and concentrated under reduced pressure to afford an oily residue (169 mg), which was purified through column chromatography (40–60  $\mu m$  silica gel,  $CH_2Cl_2/MeOH/50\%$  aq  $NH_4OH$  mixtures, gradient elution). On elution with  $CH_2Cl_2/MeOH/50\%$  aq  $NH_4OH$  95:5:0.2, amine **81** (53 mg, 44% yield) was isolated as a yellow oil;  $R_f$  0.16 ( $CH_2Cl_2/MeOH/50\%$  aq  $NH_4OH$  9:1:0.05).

**81**-HCl: yellowish solid, mp 149–151 °C; IR (ATR)  $\nu$  3400–2400 (max at 3395, 3118, 2938, 2771, 2450,  $^*N-H$  and  $C-H$ )  $cm^{-1}$ ;  $^1H$  NMR (400 MHz,  $CD_3OD$ )  $\delta$  2.71 (s, 3H,  $N-CH_3$ ), 2.97 (t,  $J = 7.2$  Hz, 2H, 1- $CH_2-CH_2-N$ ), 3.23 (t,  $J = 7.2$  Hz, 2H, 1- $CH_2-CH_2-N$ ), 4.06 (s, 2H, 4- $CH_2$ ), 4.09 (s, 3H, 1'- $CH_3$ ), 4.86 (s,  $^*NH_2$ ), 7.24 (dm,  $J = 8.8$  Hz, 2H), 7.27 (dm,  $J = 8.8$  Hz, 2H) (Ph-CH), 7.81 (s, 1H, 5'-H);  $^{13}C$  NMR (100.6 MHz,  $CD_3OD$ )  $\delta$  31.7 ( $CH_2$ , 4- $CH_2$ ), 32.9 ( $CH_2$ , 1- $CH_2-CH_2-N$ ), 33.7 ( $CH_3$ ,  $N-CH_3$ ), 37.5 ( $CH_3$ , 1'- $CH_3$ ), 51.4 ( $CH_2$ , 1- $CH_2-CH_2-N$ ), 125.5 (CH, C5'), 130.1 (2CH), 130.4 (2CH) (Ph-CH), 136.0 (C), 139.0 (C) (Ph-C1, Ph-C4), 147.7 (C, C4'); HRMS (ESI), calcd for ( $C_{13}H_{18}N_4 + H^+$ ) 231.1604, found 231.1605.

#### 4.1.70. N-Methyl-N-[3-[(1-methyl-1H-1,2,3-triazol-4-yl)methyl]benzyl]-N-propargylamine **82**

It was prepared as described for **31**. From amine **79** (236 mg, 1.09 mmol),  $Cs_2CO_3$  (354 mg, 1.09 mmol), and propargyl bromide (80% solution in toluene, 0.16 mL, 1.08 mmol), and stirring at 0 °C for 30 min and at rt for an additional 3 h, propargylamine **82** (180 mg, 66% yield) was obtained as a yellow oil, without the need of chromatographic purification;  $R_f$  0.66 ( $CH_2Cl_2/MeOH/50\%$  aq  $NH_4OH$  9.5:0.5:0.05).

**82**-HCl: sticky solid; IR (ATR)  $\nu$  3400–2400 (max at 3389, 3191, 3023, 2930, 2491,  $^*N-H$ ,  $\equiv C-H$ , and  $C-H$ ), 2122 ( $C\equiv C$ )  $cm^{-1}$ ;  $^1H$  NMR (400 MHz,  $CD_3OD$ )  $\delta$  2.94 (s, 3H,  $N-CH_3$ ), 3.47 (t,  $J = 2.8$  Hz,

1H, propargyl CH), 4.08 (br s, 2H, propargyl  $CH_2$ ), 4.26 (s, 3H, 1'- $CH_3$ ), 4.30 (s, 2H, 3- $CH_2$ ), 4.47 (br signal, 2H, 1- $CH_2-N$ ), 5.04 (s,  $^*NH$ ), 7.48–7.56 (complex signal, 3H, 4-H, 5-H, 6-H), 7.61 (br s, 1H, 2-H), 8.33 (s, 1H, 5'-H);  $^{13}C$  NMR (100.6 MHz,  $CD_3OD$ )  $\delta$  30.5 ( $CH_2$ , 3- $CH_2$ ), 39.3 ( $CH_3$ , 1'- $CH_3$ ), 40.1 ( $CH_3$ ,  $N-CH_3$ ), 45.4 ( $CH_2$ , propargyl  $CH_2$ ), 59.4 ( $CH_2$ , 1- $CH_2-N$ ), 72.8 (C, propargyl C), 81.9 (CH, propargyl CH), 128.4 (CH, C5'), 131.0 (CH), 131.2 (CH + C), 131.8 (CH), 132.6 (CH) (C1, phenylene CH), 139.2 (C, C3), 145.2 (C, C4'); HRMS (ESI), calcd for ( $C_{15}H_{18}N_4 + H^+$ ) 255.1604, found 255.1600.

#### 4.1.71. N-Methyl-N-[4-[(1-methyl-1H-1,2,3-triazol-4-yl)methyl]benzyl]-N-propargylamine **83**

It was prepared as described for **31**. From amine **80** (131 mg, 0.61 mmol),  $Cs_2CO_3$  (0.20 g, 0.61 mmol), and propargyl bromide (80% solution in toluene, 0.07 mL, 0.47 mmol), and stirring at 0 °C for 3.5 h, an orange oily residue (122 mg) was obtained and purified through column chromatography (40–60  $\mu m$  silica gel,  $CH_2Cl_2/50\%$  aq  $NH_4OH$  100:0.2), to afford propargylamine **83** (48 mg, 40% yield) as a yellow oil;  $R_f$  0.67 ( $CH_2Cl_2/MeOH/50\%$  aq  $NH_4OH$  9:1:0.05).

**83**-HCl: mp 156–158 °C; IR (ATR)  $\nu$  3400–2400 (max at 3178, 3095, 2923, 2692, 2501, 2418,  $^*N-H$ ,  $\equiv C-H$ , and  $C-H$ ), 2120 ( $C\equiv C$ )  $cm^{-1}$ ;  $^1H$  NMR (400 MHz,  $CD_3OD$ )  $\delta$  2.92 (s, 3H,  $N-CH_3$ ), 3.47 (t,  $J = 2.8$  Hz, 1H, propargyl CH), 4.05 (br signal, 2H, propargyl  $CH_2$ ), 4.19 (s, 3H, 1'- $CH_3$ ), 4.22 (s, 2H, 4- $CH_2$ ), 4.41 (br signal, 2H, 1- $CH_2-N$ ), 4.86 (s,  $^*NH$ ), 7.44 (d,  $J = 8.4$  Hz, 2H), 7.52 (d,  $J = 8.4$  Hz, 2H) (phenylene CH), 8.10 (s, 1H, 5'-H);  $^{13}C$  NMR (100.6 MHz,  $CD_3OD$ )  $\delta$  30.6 ( $CH_2$ , 4- $CH_2$ ), 39.0 ( $CH_3$ , 1'- $CH_3$ ), 40.1 ( $CH_3$ ,  $N-CH_3$ ), 45.4 ( $CH_2$ , propargyl  $CH_2$ ), 59.3 ( $CH_2$ , 1- $CH_2-N$ ), 72.8 (C, propargyl C), 81.9 (CH, propargyl CH), 128.0 (CH, C5'), 129.4 (C, C1), 130.9 (2CH), 132.9 (2CH) (phenylene CH), 140.5 (C, C4), 145.5 (C, C4'); HRMS (ESI), calcd for ( $C_{15}H_{18}N_4 + H^+$ ) 255.1604, found 255.1599.

#### 4.1.72. N-Methyl-N-[4-[(1-methyl-1H-1,2,3-triazol-4-yl)methyl]phenethyl]-N-propargylamine **84**

It was prepared as described for **31**. From amine **81** (30 mg, 0.13 mmol),  $Cs_2CO_3$  (42 mg, 0.13 mmol), and propargyl bromide (80% solution in toluene, 0.02 mL, 0.13 mmol), and stirring at 0 °C for 30 min and at rt for an additional 3 h, an oily residue (48 mg) was obtained and purified through column chromatography (40–60  $\mu m$  silica gel,  $CH_2Cl_2$ ), to afford propargylamine **84** (20 mg, 57% yield) as a yellow oil;  $R_f$  0.55 ( $CH_2Cl_2/MeOH/50\%$  aq  $NH_4OH$  9:1:0.05).

**84**-HCl: sticky solid; IR (ATR)  $\nu$  3500–2400 (max at 3413, 3358, 3213, 3068, 2944, 2496,  $^*N-H$ ,  $\equiv C-H$ , and  $C-H$ ), 2144 ( $C\equiv C$ )  $cm^{-1}$ ;  $^1H$  NMR (400 MHz,  $CD_3OD$ )  $\delta$  3.02 (s, 3H,  $N-CH_3$ ), 3.06 (t,  $J = 6.8$  Hz, 2H, 1- $CH_2-CH_2-N$ ), 3.41 (m, 1H, propargyl CH), 3.48 (br signal, 2H, 1- $CH_2-CH_2-N$ ), 4.09 (s, 2H, propargyl  $CH_2$ ), 4.12 (s, 3H, 1'- $CH_3$ ), 4.18 (s, 2H, 4- $CH_2$ ), 4.86 (s,  $^*NH$ ), 7.28 (complex signal, 4H, Ph-CH), 7.89 (s, 1H, 5'-H);  $^{13}C$  NMR (100.6 MHz,  $CD_3OD$ )  $\delta$  31.1 ( $CH_2$ ), 31.4 ( $CH_2$ ) (4- $CH_2$ , 1- $CH_2-CH_2-N$ ), 37.9 ( $CH_3$ , 1'- $CH_3$ ), 40.7 ( $CH_3$ ,  $N-CH_3$ ), 46.3 ( $CH_2$ , propargyl  $CH_2$ ), 57.5 ( $CH_2$ , 1- $CH_2-CH_2-N$ ), 72.8 (C, propargyl C), 81.5 (CH, propargyl CH), 126.1 (CH, C5'), 130.3 (2CH), 130.4 (2CH) (Ph-CH), 135.7 (C), 138.7 (C) (Ph-C1, Ph-C4), 147.3 (C, C4'); HRMS (ESI), calcd for ( $C_{16}H_{20}N_4 + H^+$ ) 269.1761, found 269.1760.

## 4.2. Biological assays

### 4.2.1. Inhibition of hrMAO-A and hrMAO-B

The activity of hrMAO-A and hrMAO-B (Sigma–Aldrich, Madrid, Spain) was determined using Amplex UltraRed fluorometric coupled method.<sup>84</sup> For both MAO isoforms, tyramine hydrochloride was used as substrate and enzymatic assays were performed in 96-well black opaque microplates (OptiPlate-96F, PerkinElmer) in

a final volume of 200  $\mu\text{L}$ . Serial dilutions of each inhibitor were pre-incubated with either 0.36 U/mL *hr*MAO A or 0.0675 U/mL *hr*MAO B for 30 min at 37 °C. Enzymatic reactions were started upon the addition of 100  $\mu\text{L}$  of a mixture solution containing 1 mM tyramine, 0.04 U/mL horseradish peroxidase (HRP) and 25 mM Amplex UltraRed<sup>®</sup> reagent in 0.25 mM sodium phosphate (pH 7.4) as final concentrations. The fluorescence production of resorufin was measured for at least 30 min at 530/590 nm in a spectrophotometric plate reader (FluoStar OPTIMA, BM G Labtech). The enzymatic activity in the absence of compound was used to determine 100% enzyme activity. The potential capacity of the compounds to interfere with the fluorescence generated in the reaction was determined by adding the compounds to solutions in the absence of MAO. From dose–response curves,  $\text{IC}_{50}$  values were accordingly calculated using the GraphPad 'PRISM' software (version 5.0). Data are expressed as mean  $\pm$  SEM of at least three different experiments performed in duplicate. Clorgyline and *R*-deprenyl (Sigma–Aldrich) were used as reference compounds.

#### 4.2.2. Reversibility of *hr*MAO-B inhibition

To study the reversibility of the inhibition of *hr*MAO-B by compound **33**, 100-fold enzyme concentration was inhibited by 200 nM *L*-deprenyl or 50  $\mu\text{M}$  **33** (10-fold  $\text{IC}_{50}$  values) for 1 h at 37 °C. Following pre-incubation times, enzyme solution was rapidly diluted (100-fold) in a mix solution containing 1 mM *p*-tyramine, HRP and Amplex UltraRed<sup>®</sup> reagent in 50 mM phosphate buffer pH 7.4. Next, *hr*MAO-B activity was followed at 530/590 nm for 40 min.

#### 4.2.3. Time-dependent inhibition of *hr*MAO-B

To investigate the time-dependent inhibition of *hr*MAO-B activity by compound **33**, the enzyme was inhibited by 10  $\mu\text{M}$  **33** for at different pre-incubation times (0–360 min). At the end of each pre-incubation, activity was measured as previously described and plotted as percentage of control samples versus pre-incubation time.

#### 4.2.4. Determination of brain permeability: PAMPA-BBB assay

The in vitro permeability ( $P_e$ ) of the novel 1,2,3-triazole-based compounds and fourteen known drugs (Table 2) through lipid extract of porcine brain membrane was determined by using a parallel artificial membrane permeation assay<sup>82</sup> using a mixture PBS/EtOH 70:30. Assay validation was made by comparison of the experimental  $P_e$  values of the known drugs with their reported values, which showed a good correlation:  $P_e(\text{exp}) = 1.003 P_e(\text{lit}) - 0.783$  ( $R^2 = 0.93$ ). From this equation and the limits established by Di et al. for BBB permeation,<sup>82</sup> three ranges of permeability were established: compounds of high BBB permeation (CNS+);  $P_e(10^{-6} - \text{cm s}^{-1}) > 5.18$ ; compounds of low BBB permeation (CNS–);  $P_e(10^{-6} \text{ cm s}^{-1}) < 2.06$ ; compounds of uncertain BBB permeation (CNS $\pm$ ); and  $5.18 > P_e(10^{-6} \text{ cm s}^{-1}) > 2.06$ .

#### 4.3. Docking studies

The binding mode of selected 1,2,3-triazole derivatives was explored by means of docking calculations carried out with Glide, using an empirical scoring function calibrated on the basis of protein–ligand complexes.<sup>85</sup> Docking was performed using the MAO-B X-ray structure of the complex with inhibitor **6** (PDB entry 4CRT)<sup>80</sup> and deprenyl (PDB entry 2BYB),<sup>28</sup> but no significant differences were found for the best ligand poses. The protocol defined in our previous studies was adopted here.<sup>39</sup> Briefly, the docking volume was defined as the space covered by the binding cavity in MAO-B. Suitable restraints were introduced to keep the amine nitrogen of the propargylamine unit close to the position found for the corresponding atom in deprenyl and rasagiline (PDB entry 2BK4)<sup>79</sup> in

**Table 2**

Reported and experimental permeability values ( $P_e 10^{-6} \text{ cm s}^{-1}$ ) of 14 commercial drugs used for the PAMPA-BBB assay validation

Compound	Literature value <sup>a</sup>	Experimental value <sup>b</sup>
Cimetidine	0.0	0.70 $\pm$ 0.03
Lomefloxacin	0.0	0.78 $\pm$ 0.04
Norfloxacin	0.1	0.90 $\pm$ 0.02
Ofloxacin	0.8	0.98 $\pm$ 0.06
Hydrocortisone	1.9	1.40 $\pm$ 0.05
Piroxicam	2.5	1.93 $\pm$ 0.11
Clonidine	5.3	6.50 $\pm$ 0.05
Corticosterone	5.1	6.70 $\pm$ 0.10
Imipramine	13	12.3 $\pm$ 0.1
Promazine	8.8	13.8 $\pm$ 0.3
Progesterone	9.3	16.8 $\pm$ 0.1
Desipramine	12	17.8 $\pm$ 0.1
Testosterone	17	24.0 $\pm$ 1.4
Verapamil	16	28.1 $\pm$ 1.6

<sup>a</sup> Taken from Ref. 82.

<sup>b</sup> Values are expressed as the mean  $\pm$  SD of three independent experiments.

order to mimic the orientation after irreversible linkage with the FAD. Each compound was subjected to 100 docking runs. Whereas the protein was kept rigid, Glide accounts for the conformational flexibility of the ligand around rotatable bonds during docking calculations. The output docking modes were analyzed by visual inspection in conjunction with the docking scores.

#### Acknowledgements

We thank the financial support from Ministerio de Economía y Competitividad (SAF2014-57094-R) and the Generalitat de Catalunya (GC; 2014SGR52 and 2014SGR1189). We are grateful to the Consorci de Serveis Universitaris de Catalunya for computational resources. F.J.L. acknowledges the support from ICREA Academia. Fellowships from GC to O.D.P., N.A., E.V., J.J.-J. and I.S. are gratefully acknowledged.

#### Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.bmc.2016.06.045>.

#### References and notes

- Prince, M.; Wimo, A.; Guerchet, M.; Ali, G.-C.; Wu, Y.-T.; Prina, M. *World Alzheimer Report 2015. The Global Impact of Dementia. An Analysis of Prevalence, Incidence, Cost & Trends*; Alzheimer's Disease International: London, 2015. <http://www.alz.co.uk>.
- Bolea, I.; Gella, A.; Unzeta, M. *J. Neural Transm.* **2013**, *120*, 893.
- Guzior, N.; Wieckowska, A.; Panek, D.; Malawska, B. *Curr. Med. Chem.* **2015**, *22*, 373.
- Perry, E. K.; Perry, R. H.; Blessed, G.; Tomlinson, B. E. *Lancet* **1977**, *1*, 189.
- Coyle, J. T.; Puttfarcken, P. *Science* **1993**, *262*, 689.
- Perry, G.; Raina, A. K.; Nunomura, A.; Wataya, T.; Sayre, L. M.; Smith, M. A. *Free Radical Biol. Med.* **2000**, *28*, 831.
- Gella, A.; Durany, N. *Cell Adhes. Migr.* **2009**, *3*, 88.
- Huang, X.; Moir, R. D.; Tanzi, R. E.; Bush, A. I.; Rogers, J. T. *Ann. N.Y. Acad. Sci.* **2004**, *1012*, 153.
- Mishizen-Eberz, A. J.; Rissman, R. A.; Carter, T. L.; Ikonovic, M. D.; Wolfe, B. B.; Armstrong, D. M. *Neurobiol. Dis.* **2004**, *15*, 80.
- Goedert, M.; Spillantini, M. G.; Jakes, R.; Rutherford, D.; Crowther, R. A. *Neuron* **1989**, *3*, 519.
- Glenner, G. G.; Murphy, M. A. *J. Neurol. Sci.* **1989**, *94*, 1.
- Birks, J.; Harvey, R. *Cochrane Database Syst. Rev.* **2006**, *1* CD001190.
- Birks, J.; Grimley, E. J.; Iakovidou, V.; Tsohaki, M. *Cochrane Database Syst. Rev.* **2000**, *4* CD001191.
- Loy, C.; Schneider, L. *Cochrane Database Syst. Rev.* **2004**, *4* CD001747.
- Areosa, S. A.; McShane, R.; Sheriff, F. *Cochrane Database Syst. Rev.* **2005**, *4* CD003154.
- Chen, X.; Decker, M. *Curr. Med. Chem.* **2013**, *20*, 1673.
- Galdeano, C.; Viayna, E.; Arroyo, P.; Bidon-Chanal, A.; Blas, J. R.; Muñoz-Torrero, D.; Luque, F. J. *Curr. Pharm. Des.* **2010**, *16*, 2818.
- Matinez, A. *Emerging Drugs and Targets for Alzheimer's Disease. Vol. 1. Beta-Amyloid, Tau Protein and Glucose Metabolism*; RSC, 2010.

19. Thomas, T. *Neurobiol. Aging* **2000**, *21*, 343.
20. Riederer, P.; Danyelczyk, W.; Grunblat, E. *Neurotoxicology* **2004**, *25*, 271.
21. Kristal, B. S.; Conway, A. D.; Brown, A. M.; Jain, J. C.; Ulluci, P. A.; Li, S. W.; Burke, W. J. *Free Radical Biol. Med.* **2001**, *30*, 924.
22. Edmondson, D. E.; Binda, C.; Wang, J.; Upadhyay, A. K.; Mattevi, A. *Biochemistry* **2009**, *48*, 4220.
23. Tripton, K. F.; Boyce, S.; O'Sullivan, J.; Davey, G. P.; Healy, J. *Curr. Med. Chem.* **2004**, *11*, 1965.
24. Chen, K.; Holschneider, D. P.; Wu, W.; Rebrin, I.; Shih, J. C. *J. Biol. Chem.* **2004**, *279*, 39645.
25. Binda, C.; Newton-Vinson, P.; Hubálek, F.; Edmonson, D. E.; Mattevi, A. *Nat. Struct. Biol.* **2002**, *9*, 22.
26. Binda, C.; Li, M.; Hubálek, F.; Restelli, N.; Edmonson, D. E.; Mattevi, A. *Proc. Natl. Acad. Sci. U.S.A.* **2003**, *100*, 9750.
27. Binda, C.; Hubálek, F.; Li, M.; Herzig, Y.; Sterling, J.; Edmonson, D. E.; Mattevi, A. *J. Med. Chem.* **2004**, *47*, 1767.
28. De Colibus, L.; Li, M.; Binda, C.; Lustig, A.; Edmonson, D. E.; Mattevi, A. *Proc. Natl. Acad. Sci. U.S.A.* **2005**, *102*, 12684.
29. Son, S. Y.; Ma, J.; Kondou, Y.; Yoshimura, M.; Yamashita, E.; Tsukihara, T. *Proc. Natl. Acad. Sci. U.S.A.* **2008**, *105*, 5739.
30. Juárez-Jiménez, J.; Mendes, E.; Galdeano, C.; Martins, C.; Silva, D. B.; Marco-Contelles, J.; do Carmo Carreiras, M.; Luque, F. J.; Ramsay, R. R. *Biochim. Biophys. Acta* **2014**, *1844*, 389.
31. Song, M. S.; Matveychuk, D.; MacKenzie, E. M.; Duchcherer, M.; Mousseau, D. D.; Baker, G. B. *Prog. Neuropharmacol. Biol. Psychiatry* **2013**, *44*, 118.
32. Burke, W. J.; Li, S. W.; Chung, H. D.; Ruggiero, D. A.; Kristal, B. S.; Johnson, E. M.; Lampe, P.; Kumar, V. B.; Franko, M.; Williams, E. A.; Zahm, D. S. *Neurotoxicology* **2004**, *25*, 101.
33. Naoi, M.; Maruyama, W.; Yi, H.; Akao, Y.; Yamaoka, Y.; Shamoto-Nagai, M. *J. Neural Transm. Suppl.* **2007**, *72*, 121.
34. Weinreb, O.; Amit, T.; Bar-Am, O.; Sagi, Y.; Mandel, S.; Youdim, M. B. J. *Neural Transm. Suppl.* **2006**, *70*, 457.
35. Yáñez, M.; Viña, D. *Curr. Top. Med. Chem.* **2013**, *13*, 1692.
36. Jo, S.; Yarithshkin, O.; Hwang, Y. J.; Chun, Y. E.; Park, M.; Woo, D. H.; Bae, J. Y.; Kim, T.; Lee, J.; Chun, H.; Park, H. J.; Lee, D. Y.; Hong, J.; Kim, H. Y.; Oh, S.-J.; Park, S. J.; Lee, H.; Yoon, B.-E.; Kim, Y. S.; Jeong, Y.; Shim, I.; Bae, Y. C.; Cho, J.; Kowall, N. W.; Ryu, H.; Hwang, E.; Kim, D.; Lee, C. J. *Nat. Med.* **2014**, *20*, 886.
37. Weinreb, O.; Amit, T.; Bar-Am, O.; Youdim, M. B. *Curr. Drug Targets* **2012**, *13*, 483.
38. Sterling, J.; Herzig, Y.; Goren, T.; Finkelstein, N.; Lerner, D.; Goldenberg, W.; Mikolczi, I.; Molnar, S.; Rantal, F.; Tamas, T.; Toth, G.; Zagyva, A.; Zekays, A.; Finberg, J.; Lavian, G.; Gross, A.; Friedman, R.; Razin, M.; Huang, W.; Kraiss, B.; Choren, M.; Youdim, M. B.; Weinstock, M. *J. Med. Chem.* **2002**, *45*, 5260.
39. Bolea, I.; Juárez-Jiménez, J.; de los Ríos, C.; Chioua, M.; Pouplana, R.; Luque, F. J.; Unzeta, M. *J. Med. Chem.* **2011**, *54*, 8251.
40. Bolea, I.; Gella, A.; Monjas, I.; Perez, C.; Rodríguez-Franco, M. I.; Marco-Contelles, J.; Samadi, A.; Unzeta, M. *Curr. Alzheimer Res.* **2013**, *9*, 797.
41. Farina, R.; Pisani, L.; Catto, M.; Nicolotti, O.; Gadaleta, D.; Denora, N.; Soto-Otero, R.; Mendez-Alvarez, E.; Passos, C. S.; Muncipinto, G.; Altomare, C. D.; Nurisso, A.; Carrupt, P.-A.; Carotti, A. *J. Med. Chem.* **2015**, *58*, 5561.
42. Xie, S. S.; Wang, X.; Jiang, N.; Yu, W.; Wang, K. D. G.; Lan, J. S.; Li, Z. R.; Kong, L. Y. *Eur. J. Med. Chem.* **2015**, *95*, 153.
43. Zheng, H.; Youdim, M. B. H.; Fridkin, M. *J. Med. Chem.* **2009**, *52*, 4095.
44. Zheng, H.; Youdim, M. B.; Fridkin, M. *ACS Chem. Biol.* **2010**, *5*, 603.
45. Passos, C. S.; Simões-Pires, C. A.; Nurisso, A.; Soldi, T. C.; Kato, L.; de Oliveira, C. M.; de Faria, E. O.; Marcourt, L.; Gottfried, C.; Carrupt, P.-A.; Henriques, A. T. *Phytochemistry* **2013**, *86*, 8.
46. Pisani, L.; Farina, R.; Soto-Otero, R.; Denora, N.; Mangiatordi, G.; Nicolotti, O.; Mendez-Alvarez, E.; Cosimo, A.; Catto, M.; Carotti, A. *Molecules* **2016**, *21*, 362.
47. Tonelli, M.; Catto, M.; Tasso, B.; Novelli, F.; Canu, C.; Iusco, G.; Pisani, L.; Stradis, A. D.; Denora, N.; Sparatore, A.; Boïdo, V.; Carotti, A.; Sparatore, F. *ChemMedChem* **2015**, *10*, 1040.
48. Domínguez, J. L.; Fernández-Nieto, F.; Castro, M.; Catto, M.; Paleo, M. R.; Porto, S.; Sardina, F. J.; Brea, J. M.; Carotti, A.; Villaverde, M. C.; Sussman, F. J. *Chem. Inf. Model.* **2015**, *55*, 135.
49. Dias, K. S. T.; Viegas, C., Jr. *Curr. Neuropharmacol.* **2014**, *12*, 239.
50. Prati, F.; Uliassi, E.; Bolognesi, M. L. *MedChemComm* **2014**, *5*, 853.
51. Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. *Angew. Chem., Int. Ed.* **2002**, *41*, 2596.
52. Tornøe, C. W.; Christensen, C.; Meldal, M. *J. Org. Chem.* **2002**, *67*, 3057.
53. Struthers, H.; Mindt, T. L.; Schibli, R. *Dalton Trans.* **2010**, *39*, 675.
54. Schulze, B.; Schubert, U. S. *Chem. Soc. Rev.* **2014**, *43*, 2522.
55. Jiaranaikulwanitch, J.; Govitrapong, P.; Fokin, V. V.; Vajragupta, O. *Molecules* **2012**, *17*, 8312.
56. Lenhart, J. A.; Ling, X.; Gandhi, R.; Guo, T. L.; Gerk, P. M.; Brunzell, D. H.; Zhang, S. J. *Med. Chem.* **2010**, *53*, 6198.
57. Ramprasad, J.; Nayak, N.; Dalimba, U.; Yogeewari, P.; Sriram, D. *Bioorg. Med. Chem. Lett.* **2015**, *25*, 4169.
58. Mishra, N. M.; Briers, Y.; Lamberigts, C.; Steenackers, H.; Robijns, S.; Landuyt, B.; Vanderleyden, J.; Schoofs, L.; Lavigne, R.; Luyten, W.; Van der Eycken, E. V. *Org. Biomol. Chem.* **2015**, *13*, 7477.
59. Ma, L.-Y.; Pang, L.-P.; Wang, B.; Zhang, M.; Hu, B.; Xue, D.-Q.; Shao, K.-P.; Zhang, B.-L.; Liu, Y.; Zhang, E.; Liu, H.-M. *Eur. J. Med. Chem.* **2014**, *86*, 368.
60. Fabbrizzi, P.; Bianchini, F.; Menchi, G.; Raspanti, S.; Guarna, A.; Trabocchi, A. *Tetrahedron* **2014**, *70*, 5439.
61. Brabez, N.; Saunders, K.; Nguyen, K. L.; Jayasundera, T.; Weber, C.; Lynch, R. M.; Chassaing, G.; Lavielle, S.; Hruby, V. J. *ACS Med. Chem. Lett.* **2013**, *4*, 98.
62. Liu, K.; Gandhi, R.; Chen, J.; Zhang, S. *ACS Med. Chem. Lett.* **2012**, *3*, 942.
63. Howell, L. A.; Bowater, R. A.; O'Connell, M. A.; Reszka, A. P.; Neidle, S.; Searcey, M. *ChemMedChem* **2012**, *7*, 792.
64. Ouberaï, M.; Brannstrom, K.; Vestling, M.; Olofsson, A.; Dumy, P.; Chierici, S.; Garcia, J. *Org. Biomol. Chem.* **2011**, *9*, 1140.
65. Ronco, C.; Carletti, E.; Colletier, J.-P.; Weik, M.; Nachon, F.; Jean, L.; Renard, P.-Y. *ChemMedChem* **2012**, *7*, 400.
66. Lewis, W. G.; Green, L. K.; Grynszpan, F.; Radić, Z.; Carlier, P. R.; Taylor, P.; Finn, M. G.; Sharpless, K. B. *Angew. Chem., Int. Ed.* **2002**, *41*, 1053.
67. Krasinski, A.; Radić, Z.; Manetsch, R.; Raushel, J.; Taylor, P.; Sharpless, K. B.; Kolb, H. C. *J. Am. Chem. Soc.* **2005**, *127*, 6686.
68. Whiting, M.; Muldoon, J.; Lin, Y.-C.; Silverman, S. M.; Lindstrom, V.; Olson, A. J.; Kolb, H. C.; Finn, M. G.; Sharpless, K. B.; Elder, J. H.; Fokin, V. V. *Angew. Chem., Int. Ed.* **2006**, *45*, 1435.
69. Sharpless, K. B.; Manetsch, R. *Expert Opin. Drug Discov.* **2006**, *1*, 525.
70. Oueis, E.; Santoni, G.; Ronco, C.; Syzgantseva, O.; Tognetti, V.; Joubert, L.; Romieu, A.; Weik, M.; Jean, L.; Sabot, C.; Nachon, F.; Renard, P.-Y. *Org. Biomol. Chem.* **2014**, *12*, 156.
71. Kolb, H. C.; Sharpless, K. B. *Drug Discovery Today* **2003**, *8*, 1128.
72. LogP values estimated with [www.molinspiration.com](http://www.molinspiration.com).
73. Hein, J. E.; Fokin, V. V. *Chem. Soc. Rev.* **2010**, *39*, 1302.
74. Díez-González, S. *Catal. Sci. Technol.* **2011**, *1*, 166.
75. Mendal, M.; Tornøe, C. W. *Chem. Rev.* **2008**, *108*, 2952.
76. Bock, V. D.; Hiemstra, H.; van Maarseveen, J. H. *Eur. J. Org. Chem.* **2006**, *2006*, 51.
77. Shi, Z.-J.; Yu, D.-G. *Compr. Inorg. Chem. II* **2013**, *47*.
78. Orsini, A.; Vitèrisi, A.; Bodlener, A.; Weibel, J.-M.; Pale, P. *Tetrahedron Lett.* **2005**, *46*, 2259.
79. Hubálek, F.; Binda, C.; Khalil, A.; Li, M.; Mattevi, A.; Castagnoli, N.; Edmondson, D. E. *J. Biol. Chem.* **2005**, *280*, 15761.
80. Esteban, G.; Allan, J.; Samadi, A.; Mattevi, A.; Unzeta, M.; Marco-Contelles, J.; Binda, C.; Ramsay, R. R. *Biochim. Biophys. Acta* **2014**, *1844*, 1104.
81. Pérez, V.; Marco, J. L.; Fernández-Alvarez, E.; Unzeta, M. *Br. J. Pharmacol.* **1999**, *127*, 869.
82. Di, L.; Kerns, E. H.; Fan, K.; McConnell, O. J.; Carter, G. T. *Eur. J. Med. Chem.* **2003**, *38*, 223.
83. Li, L.; Zhang, C.-W.; Ge, J.; Qian, L.; Chai, B.-H.; Zhu, Q.; Lee, J.-S.; Lim, K.-L.; Yao, S. Q. *Angew. Chem., Int. Ed.* **2015**, *54*, 10821.
84. Zhou, M.; Panchu-Voloshina, N. *Anal. Biochem.* **1997**, *253*, 169.
85. Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.; Halgren, T. A.; Sanschagrin, P. C.; Mainz, D. T. *J. Med. Chem.* **2006**, *49*, 6177.